var title_f34_59_35760="STRAW staging system for reproductive aging women";
var content_f34_59_35760=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F82933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F82933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 655px\">",
"   <div class=\"ttl\">",
"    The Stages of Reproductive Aging Workshop +10 staging system for reproductive aging in women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 635px; height: 496px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Arrow: elevated.",
"     <br/>",
"     * Blood draw on cycle days 2-5.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Approximate expected level based on assays using current international pituitary standard.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harlow SD, Gass M, Hall JE, et al. Executive Summary of the Stages of Reproductive Aging Workshop + 10: Addressing the Unfinished Agenda of Staging Reproductive Aging. J Clin Endocrinol Metab 2012. Copyright &copy; 2012 The Endocrine Society.",
"     <br/>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35760=[""].join("\n");
var outline_f34_59_35760=null;
var title_f34_59_35761="Calcaneovalgus feet at rest";
var content_f34_59_35761=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Positional calcaneovalgus feet at rest of newborn infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Geraldo Cabrera-Meza, Baylor College of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35761=[""].join("\n");
var outline_f34_59_35761=null;
var title_f34_59_35762="Tobramycin (ophthalmic): Pediatric drug information";
var content_f34_59_35762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tobramycin (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?40/20/41283?source=see_link\">",
"    see \"Tobramycin (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/31/25076?source=see_link\">",
"    see \"Tobramycin (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9600316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Tob&trade;;",
"     </li>",
"     <li>",
"      Tobrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9600317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Tobramycin;",
"     </li>",
"     <li>",
"      Sandoz-Tobramycin;",
"     </li>",
"     <li>",
"      Tobrex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10574226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Aminoglycoside",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10574249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/20/41283?source=see_link\">",
"      see \"Tobramycin (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;\">",
"     Children &ge;2 months and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ointment: Apply 0.5\" ribbon into the affected eye 2-3 times/day; for severe infections, apply ointment every 3-4 hours",
"    </p>",
"    <p style=\"text-indent:2em;\">",
"     Solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Mild to moderate infections: Instill 1-2 drops every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Severe infections: Instill 2 drops every 30-60 minutes initially, then reduce to less frequent intervals",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9600447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tobrex&reg;: 0.3% (3.5 g) [contains chlorobutanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, ophthalmic [drops]: 0.3% (5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AK-Tob&trade;: 0.3% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tobrex&reg;: 0.3% (5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9600319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10574251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid contact of tube or bottle tip with skin or eye; apply finger pressure to lacrimal sac during and for 1-2 minutes after instillation of drops to decrease risk of absorption and systemic effects.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10574227\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Used topically to treat superficial ophthalmic infections caused by susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9600314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tobramycin may be confused with Trobicin&reg;, vancomycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tobrex&reg; may be confused with TobraDex&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F9600342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Rare but important or life-threatening: Conjunctival erythema, lid itching, lid swelling",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10574244\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tobramycin or any component",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9600345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9600321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9749510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed following systemic administration of tobramycin in animal reproduction studies; therefore, tobramycin ophthalmic is classified as pregnancy category B. When administered I.M. or I.V., tobramycin crosses the placenta. Refer to the Tobramycin (Systemic) monograph for details. The amount of tobramycin available systemically following topical application of the ophthalmic drops is undetectable (&lt;0.2 mcg/mL). Systemic absorption would be required in order for tobramycin ophthalmic to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10574246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits cellular initiation of bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, resulting in a defective bacterial cell membrane",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16057 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35762=[""].join("\n");
var outline_f34_59_35762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600316\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600317\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574226\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574249\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600447\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600319\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574251\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574227\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600314\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600342\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574244\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300146\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600345\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9600321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9749510\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10574246\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16057\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16057|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/20/41283?source=related_link\">",
"      Tobramycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/31/25076?source=related_link\">",
"      Tobramycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?13/27/13753?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/45/15061?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?14/54/15209?source=related_link\">",
"      Tobramycin (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_59_35763="Gold sodium thiomalate: Pediatric drug information";
var content_f34_59_35763=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"13\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Gold sodium thiomalate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?40/15/41204?source=see_link\">",
"    see \"Gold sodium thiomalate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/11/34996?source=see_link\">",
"    see \"Gold sodium thiomalate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708895\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176984\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Myochrysine&reg; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176985\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Myochrysine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Gold Compound",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/15/41204?source=see_link\">",
"      see \"Gold sodium thiomalate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: Initial: Test dose of 10 mg I.M. is recommended, followed by 1 mg/kg I.M. weekly for 20 weeks (maximum dose: 50 mg); maintenance: 1 mg/kg/dose at 2- to 4-week intervals thereafter for as long as therapy is clinically beneficial and toxicity does not develop. Administration for 2-4 months is usually required before clinical improvement is observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 10 mg first week; 25 mg second week; then 25-50 mg/week until clinical improvement or a 1 g cumulative dose has been given. If improvement occurs without adverse reactions, give 25-50 mg every 2 weeks for 2-20 weeks; if continues stable, give 25-50 mg every 3-4 weeks indefinitely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     50-80 mL/minute: Administer 50% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;50 mL/minute: Avoid use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F176969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Myochrysine&reg;: 50 mg/mL (1 mL [DSC], 10 mL [DSC]) [contains benzyl alcohol]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F176954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059031\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Administer I.M. only, preferably intragluteally; addition of 0.1 mL of 1% lidocaine to each injection may reduce the discomfort associated with I.M. administration; patients should be recumbent during injection and for 10 minutes afterwards; observe closely for 15 minutes after injection",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of progressive rheumatoid arthritis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F177003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Bradycardia, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Confusion, fever, Guillain-Barr&eacute; syndrome, hallucinations, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, angioedema, dermatitis, nail shedding, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, abdominal cramps, diarrhea, dysphagia, enterocolitis (ulcerative), gingivitis, glossitis, nausea, stomatitis, taste disturbance (metallic), thick tongue, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, aplastic anemia, eosinophilia, leukopenia, purpura, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestasis, hepatitis, hepatotoxicity, jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis, corneal ulcers, gold deposits in ocular tissues, iritis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, gold bronchitis, interstitial pneumonitis, pulmonary fibrosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Glomerulitis, hematuria, nephrotic syndrome, proteinuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reaction, anaphylaxis, nitritoid reaction",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to gold compounds, any component, systemic lupus erythematosus; avoid concomitant use of antimalarials, immunosuppressive agents, penicillamine, or phenylbutazone; severe toxicity from previous exposure or from other heavy metals; severe debilitation",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequent monitoring of patients for signs and symptoms of toxicity will prevent serious adverse reactions; NSAIDs and corticosteroids may be discontinued after initiating gold therapy; must not be injected I.V. Use with caution in patients with a history of blood dyscrasia; allergy or hypersensitivity to drugs, skin rash, history of hepatic or renal disease, marked hypertension, or compromised cerebral or cardiovascular circulation; ensure that CHF and diabetes are well controlled prior to starting therapy.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use may be associated with significant toxicity involving dermatologic, GI, hematologic, pulmonary, renal, and hepatic systems; patient education is required",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Signs of gold toxicity include decrease in hemoglobin, leukocytes, granulocytes and platelets, proteinuria, hematuria, or persistent diarrhea, rash, metallic taste; dermatitis (urticaria or eczema) and lesions of the mucous membranes are common and may be serious; pruritus may precede the early development of a skin reaction; advise patient to report any symptoms of toxicity; prior to each injection, the patient should be fully evaluated for any signs of adverse reactions.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Injection contains benzyl alcohol which may cause allergic reactions in susceptible individuals; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use of gold sodium thiomalate in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F176963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: May enhance the adverse/toxic effect of Gold Sodium Thiomalate. An increased risk of nitritoid reactions has been appreciated.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F176965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1059026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential, platelets, hemoglobin, urinalysis for protein, white cells, red cells, and casts at baseline and prior to each injection.  Skin and oral mucosa should be inspected for skin rash, bruising, or oral ulceration/stomatitis.  Treatment should be withheld in patients with significant GI, renal, dermatologic, or hematologic effects (eg, platelets &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     , WBC &lt;4000, granulocytes &lt;1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1059029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gold: Normal: 0-0.1 mcg/mL (SI: 0-0.0064 micromoles/L); Therapeutic: 1-3 mcg/mL (SI: 0.06-0.18 micromoles/L); Urine &lt;0.1 mcg/24 hours",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Unknown, may decrease prostaglandin synthesis or may alter cellular mechanisms by inhibiting sulfhydryl systems",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F5224439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Delayed; may require up to 3 months of therapy",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059033\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Breast milk to plasma ratio: 0.02-0.3",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 5 days (range: 3-27 days); may lengthen with multiple doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Majority (50% to 90%) excreted in urine with smaller amounts (10% to 50%) excreted in feces (via bile)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13340 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-1D72A0B336-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35763=[""].join("\n");
var outline_f34_59_35763=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708895\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176984\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176985\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059027\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059022\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176969\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176954\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059031\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059030\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F177003\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059034\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059021\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059020\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299416\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176963\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176965\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293360\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059026\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059029\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059019\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5224439\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059033\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/15/41204?source=related_link\">",
"      Gold sodium thiomalate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?34/11/34996?source=related_link\">",
"      Gold sodium thiomalate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_59_35764="Facial atopic dermatitis";
var content_f34_59_35764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56815&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Atopic dermatitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slightly lichenified dermatitic plaques are present on the face. Erythema is subtle in this dark-skinned patient.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35764=[""].join("\n");
var outline_f34_59_35764=null;
var title_f34_59_35765="Meshed skin graft";
var content_f34_59_35765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F70840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F70840&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Meshed skin graft",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Traditional widely meshed skin grafts leave hypertrophic interstices long after the wounds are mature.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Mulholland MW, Maier RV, et al. Greenfield's Surgery Scientific Principles and Practice, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35765=[""].join("\n");
var outline_f34_59_35765=null;
var title_f34_59_35766="CF atelectasis1";
var content_f34_59_35766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53555%7EPEDS%2F66266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53555%7EPEDS%2F66266&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right upper lobe atelectasis in a newborn with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest radiograph of a newborn male with cystic fibrosis and&nbsp;right upper lobe&nbsp;atelectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan D Finder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right sided atelectasis in a newborn with cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 389px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGFAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKANjQs/PjqDmu209dyjsa5PwvGGR2xyGx+grtbRQqgY574oA1LOPjkHPat/R7r7LLiYboW4Ye1ZNqOAR0rRiGFzg0AeheHBJbyrNZypLayH+992vQtJeWGbfMC0Z/hIzxXiOj3sljLwcxt95f616v4U1y3eNIZd7rjgselAHewWlv8A69oI9hGSQcVQ8VQC400BVCiTGfqDUiTncFjI8vupPWnanGWtYo15VXzj1FAHM/2LbpbxSsArKMMSagmgjjG6CQsB1UnqPaty+hSW2KoWXHPIrnpLOdZgV+dDxkUAbWnRwpEkjtgnt1NXDdQJlfJHJyG74rn33xPsLZC9N1Pa6cthgGUjAI/xoA2DNAZA6odwPHsatpO00yPtBdVII6VzSyNwVJx0IxW9p9vuh8yQkA8e5oAXzkmDGNSrKc8dantQzoPkORV+3WFJQNsZ4xuxzUN7q9pZ7gWXOenegCaO3YcyNgHr60XFzDbphnAAHQ1zV74lMp/c4XPc1mSXryHczFs+/SgDY1bVgvEZ496w31WQgAls+nvTLlg8QUtz37/rWeV25OCccYNAGranzRmRyTn1rodPLomBv2dMGuQs5UV8TNg+ua6zTnh2CTzNw6YoAnn8wuBnPPatOBRNGCy9uayroqCHhk49zU2l6lH5hRmADdjQBHe2ObeRVViVbzFOOgPX+lZuo2gNvtZlVucha259ThjbbI4xnb9M8VwWt+IEdnjTO5Wxn1oAtW96trDsZshTxkdazLu6Ooy7UyEY8HNYsly1y4RSB35OK0NLtySvmnC9zQBbtNDku7hBGV27uST2q7faKIxtz271LDq9pp7MAyrjqSarat4vsJjiIb3TnpxQBzGt2ght2dApKnGcda5Z7ox468nnmuh1nWorjcUQjI9K5C7mDSFsDFAEs18GUgkj/Gsi9uRg5bB9KWcn8etZV10OfXNAFS+uFye59q5vULjbuJ4+laN/Oo3BcE1hXIMjZY8D0NAHPXkjSzsSMDsKr1s3NurKQR2rKljaNsHpQBHRRRQAUV0/gHwNr3jzV/7P8O2ZmdRulmc7YoV9Xbt9Op7CvpDw9+yhpyWqt4h8Q3UtyeqWUaog9stkn68UAfJFFfW3iP8AZQsGtXbw54huo7kcql7GrofbKgEfka+cPHvgfXvAurnT/EVm0DnJilU7oph6o3f+ftQBzFFFFABRRRQAUUUUAFFFFABRRSgE9KAOk8JH5ZB/tf4V3FouVGc59K898MS7Ll07EA16Fp+GVcdfY0AatsSOOxrViAxwc8VmRYzxxVyBvVfxoA0U4wB3roNBu2t5IzkZBAxXPJIM8A9utXbRi0v7rr157UAey6fegwRuW68HPWntqrrcfIeMjk1yFhrEcemqHIMijBPai2mm1K6BY7IgR37UAek219bzCTzCFbGD9Kc0dvMAYXVeMZX+tcTe74VkaOT5VXv1JqpBr0lpj94owPzoA7mawgkjAlwxxgEdKoS6RPHHiOPMeOoIzWRaeOLJSguFI7FgO9bcWuLcxeZZN5iN1JNAFe2thADJMyoc8A9RT7rxDa2tnL5Z3soxgc5NY/iCOW/hZ43CyL/Cp4J9K4zUZGt4UtiuJCct7etAHUx+Jbm7mCqwjQc47mqNzes8hBbknqTmud06YibOMlRkcVYMxdj6dfrQBqpOVRTuzg881L9qIC7jgdSOazBIcBjjjjA4qTeMEnn2oA0xcjqTnH8qe9x8ny555rJ8zIb5utBuWJxkY9u1AA8xMpEhKrngCtewnlgRghYo2M4PNYN6Dv8AMBGM49xWlpsgljxHJg8cNwaAOot7lpotpOM8Co9PspX1INt+XBOQeaotd/ZocKu9+gArV0i/jCKqt85wCSf5UAM1ixItWIdlLkbST3rn9V0PdqUrqrMrYbnoMjP+NdNq+oo8ap8rCPng96q6jqKGyt5MgBkK9eeCaAOIv7N7CVZEGQp59CKt/akFsXVtwIyPXFUtb1VZyyrhlA6j1rDtpJGkA3Hb6A8UAXLqK8vptwRiDwoFalt4emW1R3GyTHzCrOi20ku1y+wDnpXR3eoRQWgDOhROWJ6mgDhrzShHG5dlf0AFcdqarFdypxgc/Xiu81fWrFkdlIyR13V5vrt+kkhMXJB6igCrdTiMZZuPrXP3ty8mQpwtTzFnJLHJ9KqyDIPbNAGbKmegqtJHnIPStJ48dM1BJGOeOaAM6SEEHGeaqTW+4FWArVKH0qNkB4I4oA5y4sWBzH+VR6fp9zqGoW1jaxl7m5lWGNfVmIAH5muieEHpXV/Bi1hb4ueFfOVSn21Tg9CQDj9cUAfZ3wu8E2HgHwfZ6PYxp5qqHupwPmnlI+Zif0HoAK6O7uY4AjXEyQRscBncLzViUZX27/SvKPHjzTeJZ4p2PlQhRFGegBA5A+tAHqMFwskZaFlnReNyMGz+Xeub+JngvTvH/hC70jUI13upe3mx80Mo+6wP6H1GRWH8N5J01Ce0STbaNGXZf9roCPTrXpCjg8Y5oA/LjV9PuNJ1W8069TZdWsrQyr6Mpwf5VTr1j9o7TY0+MfiM22AHkRyAONxjUmvKpI2jbawwaAGUUtJQAUUUUAKAScDk05VO4ZX8DTauWW9nC/eXrxQBIlpFImTuRv0qRNMkAJjZXB9ODWjEqlMA4PoauJbbVyQR+tAGPBbyW0iOFIYdzXa6HdrIq8jPQisYRnAAIYehqa2HlSKyLtbvigDuIWGBj0/KrMR+TnoDWBYXqFgCenUGtaGUN1PTpQBoCTDcnntitO0uURdoI3t1NYYcEn07UeZ6DOaAOwtrxEZdwyPzrZ0u8Yy7iAI48njv6V5/azTq4Zzth9W5/KuosbuJoE8pisK8sTQBu6nqMjWpxnMjYUnrgVzM3mFtzFiGNTSXhnuM4+QDCj29aiALRfNzzigBiS8Dk+lamk6vPYzB42Ow9VzxWEzFDjGWPQ5qW1zJKE6Z70Aev6ZJHd2a3URByM7TXC+LoDFfm56iQ4JA4zV/wxqQW4FvkbFHTPetLX7YXVrJGcZPKnFAHF6fIVZzjBK44qa3kBX7wyOuRUFrGYrspLu4BBAPP4UkIKuVA5B9OaANIOrcEcY/WpBgnj7uMYqBEZucEDPU1KdqdZQKAHb1UEDnFQhck7Sc/Wq95f2lsgZmyPQnrWDf+KgoxbKsf+0aAOtRV8s+cVAHqaqNci0kbyGz7iuKfXCzB3kaVh1pJdXnmC7DtXPUdaAO+h1I7cvMEUjJyf0qre6w3lMtlIRjgsvXHtXH28Ms8ys+5t3I3HpW/pqIt2EYAEgcUASy3955LETsfmx05p11Jfz6XbFndisjKw9OBiuli0yJ4GPAIIO4dKmbTsabjzQFaYY+X2/+tQBwDwTbCWznryMUmmXeZJInUBh79a6+7sIlDbiD2/GuC1WN4L3dC/Ocggd6AN19ZntY2Ak7ZxWDBc32rSyCWV2jzwoqxDaG+Cq+QT1IrtPDPhuCxi3uGYHufWgDz2706SNgdrenHNY97ZNEN2a9g1S0jUMYwhB7VxWu2yeQSNqsD0B6igDhnTaMHrUDp1zitGaLnkdO9V5Ige1AGe0fynOcZ/OoGi/CtEx9R71HLH360AZjIaiaPj/GtiGwnuTtjj49T0rUt9CiQbrgl29OgoA48RNI2EUsfYVpaLDf6fqtlqdouyezmSeMn1Ug/wBK6tLaGFcRIi+5FU7q5giBEkh68Be9AH2v4c1m08Q6HaanYSB4LmMMMHlT3U+4OR+FLquj2Op+Wb2He8YwrjhselfIPgT4p6h4GvHWwi+16bKQ0tpK2AT/AHlP8Lfzr37w/wDHXwRqsCtdX8mmT4y0V3ERg+zLkGgD0XTtOttOgMdlCqBjknufqadq2oW2k6Zc39/KsVrbxmSR2PAArgNa+N3gXTIGdNXF9IBxFaRM7H8cAD86+d/iv8WdW8dubKFDYaGrblt1bLyHsZD3+g4oA4Tx3qsniLxXqmsycNeTtKB6LnCj8ABXJXEAeTOAPc1tiAy8Z69al/s2MD5kJJoA5lbUFDgL071G1rkYAAyOeK6N9OQcISPY1UeBkO0qQRQBz0ls6DPUVCQQcHrXSPb5B4GTVG5tN3bj6UAZFSQO6Sq0RIYdKjrR0e0NxMHcfu1PX1NAG5pbMyq8yBjjjtW7AYHBDDBPc1XtbY7OBWjHaD0HFADDZROPl/MVCLJlPBPHY1aMDKOMr+lLucD72T70AVWjMb5ORjuKvW1yBgM4+tKXPSRMjHrVGYJHIQVYA9O9AHQwzhgGD/XkVbSQAEmVR+NciroOVcqTUgnYDHm5+tAHUyXUS5+ZnzxgCmw6hKJVA4iPVB/P61yzXcw+7ICfrVmzubkkHfz25oA9GtYndFcHPfip1WWJcgZOckYrntA1G+KeWJlBTp9K05rm+2n96ig+1AElxIEOXibnvU9nNBBHJLI23sM1yOrzXi4D3GST0FZ9xPKqLCJC34UAeh6Tq9lbXySNOp/wrvF1axnhVkkJGOK+dw0y/NGTXQ6Dq90VEJfgDA7kUAej6vcwl/PghzIhywJ61zmp+IYon8wMihh27VWYXM5BaZiOmB3po8LLfKQMrK3Iz0NAFObxYPupuY/XiqFx4hu5yQmUB4pLvwxf2UhWS2cgdwMj9KrrZTLIFaNgR2I6UARSzTz8ux3Y61XkhbHzEmthbJ1QEKfU1HPEBwRj04oAzUhbHy5xU0bSRJgE8HOau2m5pccBcZ56VeurSMW7lMK2O1ADdI1HzAFlGAPWt+CUGVXDdOM9fwri4o5NwRMZY9Qa6rQrN5FADLkHHWgDroNYhihZSDkAAk1ZfVozpbtkf65cA/Q1CdFP2YvGNzEc5qLULFItIHmoRmcDp7f/AF6AMu+1NpFZVKhfbk1zN1L51wABgD8zXSS2QC4iXt371l6hZbYxLzuAoA0tFeFGQ7lBFdhHqUC2zr5qjIwQTmvOLa4VU+YEdOtb3hzSDqM8u9G2EcZoAz9Yu5LmdtkwYAnaAeBXPX0s5BXPBH4V6JdeEihdVbBz1/8ArVmP4ZjxukmcjHYCgDzvyXKk9O5JqBlyQAMn0r0afw7aJwAzelRW2hxxBmWBQc9KAOBi0+5lOUjKr6mtWy0WEKGuDvb0ruYbFcHcNo+lZ2pzW2nyKThhnoO3vQBmx2oiQBEG1eSx4xWVqmpW8GUiIdx1wOhq9f3E2qqyxZSL+6veuavbCW3zvX5fUUAULy+uJj12jsKzmUnryfU81pSQjHv7VG0WOe1AGdJHkZI5AqFowO2eK1TCMYqD7MxIwCaAM4x+gFPSFnOF61opZMx+bj2q5DZbB04HWgCpa2YBGfqTU7Q91HFadtb/ACnOOe1JNFHGrbm6dc0AYcsasCQPaqk0AcED7w5Bq3dXEW4rFlveoPMLHgc0AZjR84qF4SQTt5rV2c9KYwwegoA4O3haeZY16k/lXZ6PZBVVVGFHH/16ytBsiih2Hzv+grtNMtvlAHQ0AWLS2VVDEc9hVzyNo461ct4giDGcipIkx6ZxyPSgCi9rlBkH6VSlhAbgA9q3nA5btVK4RGPoSKAM8xYjUgGqd/FmLcRjbWu6Dyxg4/GqV4n+jP3oAxgOMYpDyT0FWRFnApkkTHHGTigCBVJbHFa1jB0JHTtVays5pJQBGfTmultdOnRctGQPpQBb8O2jNMTj5QOTXRGOJrVxkbh3A71TsVa3h285Y1LKT5Uiqp453YoAkbT7eYjzlG4DJPvWDcaMrTuyEYz0HXFX57qRLMvzuc45rOiupBISnDHqe9AEqaIHYDYASccVNb6FMkwaNCqj2xmp7W6uR90Y79a1UnuZFAGecHOaALWmQFWWN4uRxknrW9HCRHyAMe9cfIbgMWwxwfXFaWj3F08wjxuHUnPSgDfuIZbmLEeRJ3x0rJutJaKXfNliQOev6V2lkIo0AAXkcnPWuf8AEN9HDM0MABkIyB0oA52eyCgcAd8etVbixhKf6vHOCOtLcvcTEtLI49BnFVTFMASGkx16mgCP7DDFKxVScjgVn61P9ntyioeD39K1bdm2jzDnA57Vn6rGLhZCikqGAAoAzdDuo5bpVmjYg54FejaDsGFSJFbvkda87sbT/Sl2hhj04r0/QoysMZI+8RzjNAG2jeXHgkkE8c9qdqDj7DAMKVLM2PyqnqMEuFaNTjvk1S1BJ/Ltk8xwFjyc+pJoAJJAxZdoGTxWNrKZUxrjBGeO1XUtZHY7pSV9KS805iCUIIA70AU9I01ZCu4LzxzXoGmW8drCCgVWA6461y+lkIg38HpjFdNb3CCA7iXwOlADL2/VW5CsTwAaw55hy6qAp68VHqupLGzs6gdhnmuN1XXZ3do422J2GeTQB1U+oW8MZMhRGx68VjXWvwDAikDNnv0rl2eaT55RkdeTmoUdXcxsOegx3oA6hLqS8YHzmK+imm31iJYydnzdOayLOGeF1khBz0wOhFdzFZtLaK2xslfyoA4GzY285j9DjGK3f9HuEC3EYAIxuHf61n6tatHqRDIwGPSrln8w2sPpQBnaj4VM0Zm02RCD/DmucutLuYGKyDkdRivQUt5EyYmKnPapCPM2pe26Sj+8O1AHmsVm7MBghqsPpzbCxyGx3r0B9MtZlPkFRnsRVe20INLsc8MfWgDiIdPOeegOc1K9kQMjJ56Gu7m0MRo3lgE5Gaq3GlmEn5R9fSgDjpMQLl+AByQK53UbhrljjhAeldH4jVg5hGBgZOO9c0YmxgDigCls+bgdqkEWMEdal8r5wAMYqdYzgYxQBWMRpkkXUkYrR8gkZUEkU77FM44XgetAGFYwEbcda62whKRqMZrBt0AIxtAHNdBBJ+7Azx6UAXS2wBSMnFKG6FhjsOaiLkckZJ70xZEHzuNqjpzxQBNNLtUHAAFZk9yC5ycDNVdT1WLlIGLH17ViGR5XyznNAHRPNlFwBnFU7qQthF5x1pqZEaguT9aXaM9RmgCOON3bA4X1rQt7RcEtwSMjFPgiUQoPXrU+wqrMuemAR1oAt6NaB35YhjyP/rV11jYtn76l+4Ncbpy4aMIjFs4BJ6V3lg5hjjZnLOR8w9BQBFqFmIwJFA3L2rFu55vLxHkKeAK6fUHR7V2z8zDoawLVVaTJPC5Jz60AZupMVVYmwVC5JrPVN5yAAR0rSvJElnZgvB6cdqjKoDxHmgBtvlTk54PA96vW08iSAr07+oplpE0jKiRlj6V0mnaSTgyICfpQBTtlnuBtCl93A4rtdE8Nz21mskg2luWJGa0/D+mw2+yW5RcKOAeg9zWpr3ia3sNPkCfvpmGFxwB75oA5PU0aHMcUjg9SR2qFtNhniik8tmIHOawr3XruV2KKibucgZpZb+9a3iDTyL3bnHagDfGnr1EYWM9RjFMuLSBBgbc46Y61g/aZCFy75I/vGltp7jzgWlJXqQeeKAJLrTwELKu3jAIFVYLPy2OEAUjJ71sPdC4BRhtxgexp0eBGwZRnGOnegCpbabFM4zEFPc4/rXTaPYAnCk/LxtqhbZii3KFLdea6HR5w0G8jYcnOO9AF2TT9pVSAc8AmqOracwupjF8wGEH0AxWyl0s0ybsLsy2e3AzWVLqEf/PQbiT1560AZZtiAVMaqwHzZFVZRtQjAbHrV251OKNWzIhbtk1zeta3ECdjDPOaAIJLjyrh1Ujk9MVuaG0s6t5wwuOp7muZtLhZAHJDMeTW1b3flQjBCk0AU/EFlGGJKNjPAB61ycsI3sFh5Hc9xWhr+uyq7Im4kHk5zisFbmaSVdzEg/Nx1oA1ra1V1JYHHcVdi0y1LdMEgDcO1ZEeoiNGVTuPWm/2pLIxO7Yp4AFAHU2GirCwIuE8v3HJFdfZzWSxBPNRcDBBrzez1BdgAJJzwSelN1XXUhQxxHMz/pQB2F3HZ3F2TFcQvjj73NTWunxMQCAQa8sguSr7ixJPJPc12Hh7Vpdw+cnH8JP8qAOon0UlCYWCMOAOxrAvPNtnKyL83v8AzruNPmF1brIpBB4/Gs3xFYC4tmYcSKMjA6+1AHDmUByV3Rv0JFS211KrjcSyDkeopjhgVY9PpSRF95AI2980AdD9pDRrKinLc9Oc0+4XzoyTnPXpUGnyJtCyjdzxirlwwjXy8+3rQB5lrkDG4lZk6sea5qeMh8Acetei6xbLKWxz61xmp2+wk4oAyNmM+vrU8ERdwq9TSgc1d05QGZ8cUAWYbdUUAAH3p7qdmAMVJEu4k8nP86lKcjOdvegDiNpwOp7/AFreslKwqTycYzWXDDhc4yTUt3qcVlaKCQ0hHCj1oAv313FaxlpSR2ArmLzU5LyXbnbF2UHFZ1xdy3UrSTsSM8DPFLB8xBxzQBZIz+FLCMyDpTiPl6U61AMoz0oA0R97HSnqeOtIwpB1oA0bVw0e3PI4q7BK6EFgGHvWGCQ2VOCOauR3MqgdCfU0Ab9jcMt0GXCsx64HFdRa/KCXJI7sa4SzuZDcRkbR74rrLeR5lBkfKgUAT3l1ulGz7q8Gn3Eaw2HmKMPJwDnsf/rUyG1M21UBLMcmr+rwMtuiMuFVcj86AOYEfqBzzVu1s3uJlSNSSTgUGPBwBzjnNej+BvD4eyW5dAZH5x7UAU9G0JII1Lpg96fqGpwafIYYVDy4xnstdB4nEunWapEP9IlB2gdh61w6abNIS0vByeMZoAuf2rK/zSysfYdB+FZWpXbXLYZtwIwTWimmqMck57GpRpsZJxGPQ0Ac7BH58qjgAdfapnJknJQDYDgc11A01La32oEEjelR29mobHlKfbigDASMMCQBkenPNW4YsI7KPmxxxXRR2wUgrHF05HBpJAqyAPsUYxQBzDRylskNjPUitGzUvtQ8989enar88KbSCQB1yKZamNJMqQQo4oAe6mNcMMZ6VqWThIlXPXGQKzGuklbaQo9eeeKmt5YzOETg45PUGgDfdwtjM2SGf92Mdu/8hXJXwYzMqlsAckcV2MsH+iRJn7q+Y34//WArEmtt249yOPSgDk5bPztwBc461ianZhizjcemOa6m4trpYmEoUBjj5aytQjcbUI+XgZPNAHP2dybYgyE46DJrTgvk2lt2QB/niua12J0d9gbrxxVvwraTSzyLMzcr0JoAoavLiZiQctzWYl9hWyeenFdPrmmiOQAAknqoHSsKSxgJ2hckHB+tAEEdx355GPrUqzgtgcnoBWhb6dHx8oJ/pUqaekcgdgucdxQBQN0yAhA2faqbudzOxyxNddbRKHVHeNw2MD0pz6XGzncEKnspFAHHrNjGOK2dEuJjcKIc5PfPet2DwzDcOAz7E7kAV1elaTY6ft8qJN4HUigDovC9o6WCmUjceTx3qXUiyq3cYI47Vb0uSOMbiBs28U+8giuY2aPGTxxQB5hcRhpX9CeKZGNr9OK6fWfD80KNNAMqvVR1x61zgUA4/TFAGhaDgkd60Zx5tuknG7gNj1rOtDtXGQKmExiyARjGMZoAy7+MAsrde1cbrY+cgj8RXZapMhAJHzEc9sGuI1WTzbhs4yOBQBk7Tn1HWr9if9FyeueapP0PHfpmpbSQLvQ9DzQBppnGCMc8Yq3Fggnris2KcDr1B9a0LaQeXyeaAPOde1uHToSkZ3TNwAD/AJ4rm9OupL0O8zZcH9KwZ5pJ5WklYs56k1e0WUJK6H+IZFAG2MAYHNSRNgjn8qrhhk9etSocdMCgDSDZSp7DBk3fhWfG/wC6yTj3rQ008ZP/AOugC+2M55ox3pOpPc1JjpQA1PvVYiQk5PApscQBBNTqfmwPrxQBZthyWrrbBSYFxz71zECsVUAY9a6zTlIhUL+tAHSeE4xJfuZBuAj6EVa8VLGkESr1IPbmjwjHma4dl/hAzT/EgzNGp5wpJz9aAOQQY4PIFeyaSQuhWcMI2hlDEqOvFedaDosl4yyFRsJ4969BW7h0/T03sqCP5cE8/lQA7WE80J5mGKDGfauS1G/tIGb5tzA42qKh17XZ71yIm8uPoADzXPFc/ezQBfm1d3yIoguOCTyaSCe6dmdpCEUZGKqrC5PCEk88CtA20yRJFHGwzzQBWeSaWQM7sc9DntTwrE/eyuMDmp1s3CgshHXpQkD7QfLPHtQAxAcbgef51m3Rc7ijlSOetbLxOkTfKeP51jaiCONuB7CgDPXV7qJyHYyJ6Z5FbUd+DEjgn5hnr0rnmj3SEDHXnIrR2bEwDzjA4oAEv3a6LAMQWOOavaTqzS6pGjKMM231xWfDF+7cqcFR+GagtlaLz7jJBVdqn/aPH8s0AegDXkmkmw4G44Gey9AKy7nWli53qSOMisfT45JFJ6DjnpmodQsZF2vtfBHzYoAs3mux7QNw+b1Fc/quuIFCliSDxgVJcWu9NzLnA45NV7vRo5Y1kKncAOKAKqXH2x4jkgAdTXRWyw2MDsrfMemPWuTjUWkv8QAOOe1a5uUaNcHOP5UARarrIjVgApkzgE9hWD9qLbiyLvzuyOKbfLiRmKliTnnpjtWYJnMhGRjuKAOhi1NY1DEcgdOtVJ9UZmUrlcDnvzWU0mD8o/E1AZGZcHIAP50AbK3bkEl2I9BVtZdwBxljXPLKy5bIGKm+2MQdrfMRj6UAdTpl35UyiR9o571srrIi3bJGdz0weBXnaTs7jc5OD61t2jrLEGzge1AHStr1+xBa6lCZ4CjOfrXX6B4mlW48udVkjIzg8MK4S0dJjtdlXHQY61u6Zb7pUlQYkbjrQB67YzwXUIZOjDBU1wnijTxY6mfKULC/IHvXZ+HrbybEA/NnnJ/lXP8AjNw+BnlTgUAc9AoCg4onOHDHoKSIdE7ntnrRNkjAGMdKAMbVHIV88GuMujuYn3612Gv5ijOPw5rj5RliRk0AU2yQTzgVXdipJBq04IB45qrN1JNAEE9zIoypwTVrTtUZcJMfoaz5cHOapscZGeaAPNamtX8udG7ZweahooA6KKQHPPzVKp7+lZNncZQr/EPfrWgknPFAFmSTZEozwfWtjTm/d+2O9czcybpY0By3pXTaWuIAW6jFAGhCSc1YVgMEjJqshI4Wp4xlhnvQBMhZs+noatW0eXAPTvTI0ya0LWPHzEE/0oAtW8e6ZeBjOa6iyT5sngdDiuesFJnU54HNdPbKQpJAOR1HagDqvCCAJcseASAPerkunvqWsrEozGqjcfQc8U3wfGfschA+UtjmvQNCsI7aCW6lHBAP19qAMC4ht9HsORtCqTwK4XULmbUZjJglR0TsK9I1rbqViY1QId+TgdV9K586fDC6YC+mPSgDlrfSnlw02RmrqabGh5UEj2rRvb23tWKs3zD+EDmsmbV2Y7YI1UdyeTQBq2dr84+X5QMmptitKWLr6DNYkV5cNG8hkOe2aiMrsA245HWgDoGWLIG9eT3pYYoy4COuOpz7VhoZCxO84wOKmgZxyD0754oA2p4sJ8uz8KxrqFmY5UY/vAZqC6kkK4+bGOOayh5rHCSSJj0Y8GgDVSyjlXDRRlj1yKZf6QpA+QL647Ci2ubqPKmTeq4OCev41pC5FyozgEjGRzQBmJp8Qttm0Z649ap6hoyGC3iWQLubzWXv6D+tbUmGk28HJ2cVm6rqFsl8w3AqpCDvwOBQBoaXpL+SM9M5yO9Sy2mHZSw4+XGKtaXeosKOxOwDAH+NVL+/Q3Rdm2jsMdKAMLVtNuFQLCY8MeSOoFU5B9ntggID45rS1K7XygA7ZA5PrzWNqV5BHbGRiGY9vSgDmdSBMjsF4bqKq6OXvbvYkfHQZrUeZNQlby4/l/LNdHoVglrKJgi7sY5HAoA5/UtIeKIrIOSK5eSxdJP3aAr3JNeka+BcSlVcRKOWY8AVykgi2SgurqDgY5zQBiR6a83zMTgdgKc1kynaiE57elbSPbRQqquQzds5qlLqkcbgIA2OCQetACW+lBuGRC7dABmp5dHaNeYUcn+FRjIqt/a9zkeVhB245q1FqV1KB5lxIW9j0oAiGmPkn7CwA6cVds9HcOpS0k56io/7QmjkB86UkerGtWz1m5RuLhvzzQBs2PhQ3JVpCIB3yc12OkaFaWZBRjI/ALGuLt9ZueP3gkHuK1LbxPHBIqXEQAPUq3+NAHo9upWJ0QhzjiuH8Su3miM5yDk5rZ0fXbSZlW3ly3TaeK0tR0uPUICWH7zHBHagDg7U7lJzx2zSNlmKseD6VYuLV7aZ42GCvoOtViQWXPPH5UAY/iFVFqMEdq5OVcNnt2rrtfJNvtweDXKXAyeR04+lAGfOQDnHFZ8rZJBFX7jlvbrg1QuDtz0oApTnOR0xVRzkE/pU1wwG7PWqc0g24HXFAHntFFFADkYo2VODWhYkylQ2SB71m1JDK0ThlJ+gNAGnHIh1JVABGcDFdahKwpjjPb1ridGUvqMXc5zXcI24gAYI4oAuwjKgjFXIVyOgqtACBjj1rQhQYAAzmgCeGPJAPPPNakUYEY4PNVLVAScZ64rUhj5IP4UAWdNizLkdAK6GNcxhcdf1rH05drg4G0VsxNu6cg9AOKAO28JqE03p8u7GPSu+mbfYxIucAA8VyHgqzafTVOP3Zbn3rqru4js4W8xhhQAeaAKF06W8TM2Nnqe1cNrmtM7slqcJkgt3o8Ra4bqVkif92OMDvWVb2k1wQxBAPbpQBTU5JJIJPr3qSNdpwvJJ61rQ6RtZWfPPFaEGmou0KgJNAGSkBW0QYOWJyVoSFscKRn2rrDaKFQHAAGeegpNkWMEoQOM5oA5dIzkAozHGMCpREUAJiPHPSuiZrfedrKTjqBTZTGync6FyO/egDkp1Y5IQ/THWksbcu7fKR0x611SxRbM7VPbj3qSGJoxnaAD/ABBe1AHPXESxBQM+/rUdv9xgCBjLcmupuoklTDgMxPbisy8tQFGxAVPfHUUAYAuJVmlk/giUsD6nGB+prlpVBmDFsnrjPOa7u7sQdMd4h80jhSPUD/65FcpfWLCQAAhuox0NAF/TDPJGIycD3rZfSzMytISxB7GodGSRF8t0w2Bz610dqmBtIy3UelAHO3uhqsAdQwY5Arlr/SPNikimYrIegz1r0+S2uH+VcAbsnPpWJqlhEZW3Abx3oA4TT7D7MmAY2YdauTXTuu0HYnTAp2qKLWXdHjcOx9ayYZWnnlWIHcx/KgDK8Q30zSMik7E7Z6/Wuca4Yv8Ae+Q8HFbWtxSmRxyWGcH1rmnV9wQr82eaAJJZmJIBwB39ahEw3ZHLZqX7LKzDpnFIlmxYgAnv8ooAkicuwZjtxWhBcKFKgjce4qtFYqhxNu9/m6VYMNlCg5Yt9eKAHmZXIUtn0JqU3KQkAuAuPxqsYoZHAjcrxjrzUR0luSZT9c0AaB1xlULAPoTUSXEskwmmfcfrSW+lMVDbsgDPIpzafcs4KnKA/nQB0Gh3zi5jcMwIIwa9u8NXpubON3xz8p7814JpkFxHLkxHAr3HwfE0Wkw+b9/OW46UAM8X2qrPHKq8MMEiuNmUZ9/513fiZxLaruwQDxXF3qZBYYBFAHOa25KMvUg8e9cvdtg9Qa6PXWPyOucZwRXJ3744oAglb5RjvWfdPzwKleY7azLmbJIzxQBXuZCSexrNmlxnNWZ2yCawdRuwkm1SKAOeooooAKKKKANHQSF1BWPZSa7Gx+eXPNcZooBvcnspNdrpq4j3EY5oA1IhjH1rTth3B475rNi6/T9a0bY9Ae9AGpbLzkHnFaEBwMnqKp268KDjnrV2FBjnOB+lAFuCUocrjk9K39JX7bcRQRpmRuAPSsOCEs+BnHavVvhfoMSD+0LzBboinp9aAO50Owj0vSoU2KNq81wXi+7nvrxreEERdWNen3TC4t5AF+VVJGO9cINHmM0ks+xBnJY0Ac3Y6QqldwGfU1pMIreMFiFA96tXKKAyQSZPdsZrGuNGuZmJW5yTzhhQBLLqUCMDGCxA4ycCq41aSRgEO3LYwBVK40y6tuXQsnTcOaW1TEqYHA5wDQBcmuXkmO9mLAckmnJMRwMbc9T3qKUAlhjA7YpY0J4XnjGKAJPObJI457CknLlBuc49acEHPXHfimTuS+1jgD9DQBHEG3bULde9WhJNGMLIwGP71MgiXLY6/wCe1Xo7bO3cBkDjFADLe9nRwGCvjruXk1ceUShQFA49OlEVvwWG3cDikkiDTYUANuxn8aAKl6vkiKPkbV3HnuTn/CmxxRyKpKqxHtU97OtxcOD/AAkgEe3FZ6tNHIzqw/CgDo7OxjCKXiGD7dqimmitZmSPHHJHrUVlJNPADvJfvnrS3NlNMdwcDjmgCpd6qI0DMSG7Y71yupauruxdjjkcCujvtLaeNt55HA+XFcrq2gTxIzMwwT1oAxJSuouWUspBxz2rW0LRERvOmZghGFx1z70zR9OWCM+Zjk881tvdLFAkUUfnEnB9hQByniHT0iZ5lTJxhe9cbLF/pEu5SDjgV0njLUAk3kxpJgL/AN8muFnuZI5Ny5lPQ5PSgDVfyxGu0YK9SaqXN1FD91snHrg1kTXszMR3NVZ2JIb+KgDQk1JQw4dh3BNNXVMA4gjz23EnisxWYtknJ7VOnzHGMjvxQBe/teRRtVIl9wvWpbfU7h+X8tgO22q0FkjnHzADuatrpzs+1HUD3oAvw664Ub4UZPXpWvpurWc0yIRJGzY4xkVm2WiLIcSS5Uc4Arq9GsLazIMcShu7EZNAHbeGdFjZluJtjDqo7n6139tBGY9qqBkdPSvNbS6eEApJgr0ArpfD/iNZbhYZ2BYHGc4NAB4lWaEAEYXPWuXkmB46Y4Oa9Mu7eK/gbIyMY5rzXVrZrS8eFgcDp7igDk/EjYbC4YA8etcfek5OTjIrr/EiOyeYBtC9ea469fILE9OKAM6VsK2ax7hznOTir9255x1rKuTnAHFAGZq140ELbep4Fc1LK0hBY81c1eYyT7Oy1n0AFFFFABRRRQBqaCAblwT/AA/1rtrRNsSjjJrjvC8Xm6hjBxjBrutuW244FAFmFTx82DWnagHr0rPgHHNadmhxhvXrQBqW4ztxjpmtC2QE4OTVO3wDn264rRtlO/gHJ4GKANPSoRJcqgGN2B0/Cvc/D1iRa2sbDaigcdM4rz7wFoZadZ51y/BA9K9Qe8jtDHGpBkPAHvQBp30sOn2UskhVFA5JwBXlGveLIZZmitkZ489cferofGc099pskaNlSwyexrkLHw+gALjdjoTzQAy11u4lYeXbryOvJrXsb25Ln7RAu09cdaljs4oFUkKMU5ruCL5N25j6evrQBs2MMF2gAOG9D/KkufDluHMsUfzgcqBWAuqmNt0CgODxnnFdVpGrteQFmcBwNpFAGL/Z0RLfuxnd1PSpPs8SDAVc1W1hhbXTAsxVzuUdazGuGfPB56c0AbY8kMCdgx2qNo4mbKqmD371g3FwxUgkgDDdKLQyScjcADk59KAOphs4wnKLgHPHOatCGIEZTnA4rBhuJUK5YkdPatKC9flTg+o/woA01s4yjHavNVF05PtCtzhcufwqxb3a4GVx/umpY7iF0mbfg7TnjnrQBy9zZ+UJGUk552+tZ3lFXJ/hzziumkVZtxP6CqTaeS4KkA5xn1oAsaSq7R8vJ6+laUluFXcoAGeQTSabZlF+bHH4g1pTPGgCsQD+lAGNOkmXKKCMccdK56+3NBjAIIwQRXV31zGkZwRkj8q5zU7mJwdwBx7UAcdfFLY53YGO/aqVpqcM1yRG3zquMg9aNZYNvWMsWJrF0LSrgaj5gGEJ5oAd4lsTdEyxDGV7jqa4OaxdJfnYAe9eqakigmFmXaOvNc/PpdvPLmQFTuzxxmgDz67sMNuU8D9ap/YJi4yWAPTiu+u9PgtdxKgkHrWFfzqD8pUegHagDGGmAHJZge/FXba0iU4DsfUlaYt/FuxK52+qrzVqO9slXP7wk9DwKAJI7QswEUgOO2K17HR7ljxjGM5/+vVSzvLYHcIG28HLNmtmx123hYoIpfwNAEtnZSQAbxk56VqJbyctEmePxFRQ63ZNy4ZQOcsO1PfXLabKW0qDPBY/L+FADL3UHtE2sp8zpxziqWjahL9vjYlh82fpWlFZrMAxKuCeoNael6LFcXKKE5yOaAPSLG4ZIopgSSygnH0rmfHqlQlzHgA8HArrbSyMVoVXoBxXL+MP3mnOrDBU8cYoA8w1EvNGys2Qe3TNcle4KsvcV2F4uAcn8a5bVIysp44Izx3oA5m6YqWBJx0rEvLgRq2T0rYvcgkHFcvrOdj8Z47UAY10we4dlOQTmoaKKACiiigAooooA6nwRDummlP8Irq0G5zgnBNZPhSDyNER2HzSsW/DtW7bKeOO/NAFu2TIAxz3rXtU+UZ61Ttl+YDgjFa1ug2Y6cUATxx/MCFx9K63wzpxkkjmdck8IP61i6PZm7uVQn5RyxHpXqnhPTQ8vnEfu4/lUHoTQB0OmxjS7EcDzWFQw83SSSctIeM/wirVyFC/OQSe1c5f6vFa36ZYPICMKBwtAHTa15MWnu0pUIuDk1xF5rqLuW2XA6BjWrq7y39lMMkkjIArlbfT5pAMoc570ASG+knbLuxGcimq7bfn6da0LbRyoy75AH51dh0yLoc+vrQBkREbR1APrW94XbbdyJj7y5+tPWxjDZRBgDqe5ra8P2JEzSADhcHigDN8RrxC2zOCQfYfWsVI23blRtvTpXb6rApRASmRzzWaYov4SmPTNAHNm2c43JgDtViJdihcYFbyRoW+bbt6DnpUn2eNgQqL2PNAGAuOxH0zUi4xg8Y6YFbJsbfdgoAfUcUDS0kx5blc8kHuKAKSA+RhTxxSxZW3nbcA2AOvv3rQbTJFiIVlzjio2spltZflDfMvegCnE26NeuO/f8atLOg47D0GapTW8iId2OBgCoCCvQYbp1oA6ixngeNNu4n0NR30ZkkJ2nBHbvVTRggbk5681tbwByBQBz11bShRhfoaybqwlkVgsXBzXbuY1jyy9/zrPuJgwcoMDuaAPNJNLK3J8xCQDzzV4W0UEH3RnnGBWyIw07s4wMd6q3qocJ0BOelAHCa5ffZ5SFjDOx4OO1cjf6s7TNkbADxiuy8V2isuYWwV5FcA6CaQkgAjsKAJL/VFeHYQTJjmuU1FCX/dsxBGeRWy8LibLcknGCKq6jbNEvyjIJJGKAMQN5eQDlvWnRyA4zjPrSywTNztJP0qIRPhSEbr6UAasErBVG7aAO9XIbhIm5OT7c1gb3UkMH+hFWoJnXqpPPpQBpzXDyPiRvl64BpYVYnCtg+lV0DyNuVDzz0rQhjkLoEX5uvTrQBetbq5gcGCUjnoDXp/gPVJJFMt0owOFb1rzbStOubq8EbRsAOWbHQV6ZpaR28CRou0KNvSgD1LS7mGaIcj5qwPGemfaLWQR8MemKyLHUjbToFPynGVNdG1z5rhT8yHpmgDxO/jKNJG+VZeCK5rVELp6kdK9Q8daaILkXEY+V+D9a861KMhSccfzoA4PUxhicYFcrqo+R/pXbavD95h0PtXH6mo2tnFAHM0UUUAFFFFABSgZOB1pKtaXH52pWsf96VR+tAHosEQgsrW3AIMcYBFaNsoyCenrVJ23XZUgYrQhB3BR0oA07VScADGeMVsW6nHes20G0EHmug0a3NxdxRHJHUk+lAHW+GdPZYEAX97JyWI6CvTrGKKz09QCAiDr6muX8P24Zg2MDge1dDcYkOxiRBH8xA7kUAZutX0kVu7xDdMR8gx90etcrpumSSu0t1Ixc8/jXU3aGeB5ThST29Kotd22n2/7xhvPOAeTQB0+iQRPaIVTBAwQetZ17bm0uWU4VScqTWFpnigx3Ij4EDnBPpXQXKJqMK7yWHVXz0oAom+tojwCcdTio5NWw2IlX15qC40S5BxE4fPvinW2hXMjfv2VEzj1P40ALHfXNzIsSNlyeNo4FdVaE29uEZiXA+YnvVLT9Phs1JjALYyXIqrqd40gaKENj+Nvb0FAFXUL17i6Z/m2LwOf1qp5rlC3T196cIn7RsQec4p6wvkAxnr1NABG77TlmDe1SRzTKc89Op4pixmNtzcY6cUq7sjB4xzQBejvZlA757VpW94uB5gwR6ViKx3Z5/HvVpXUBgBg/WgDo4JRIgKOrVK2DbuuMcjkfjWFA25CeQvHfpV6Kd/s0y7iwGD1oAqXaByU3YA61Sa2fqoJ54qwrNLMxbtV6LC4DHAz3oAi0m1IIOwgZ9ea2lg2/fH4Z6VHbKCMqy8d+1RahKwYbCSMY5NAEkwjVPm9cgVmXksTKQGwewqC6klxgs30rFvXkbhN/H3QeaAC+lSAHJ/DrmsuOSW4nLYYAHjNRguZSGZt/HUVpWwXYM8t9elAGX4k0p1tWYAEsOn1ryPxFotzBdF7cnaeSK941GeNrTbNz2NcLrSW4WSVAcehFAHFx6cWs45XkBfaMdz71kXKqk5DkEdAMYrXnnCSMkTYUE7fpWLqLswO3qT09KAK3mRxsd6nrxxxUZuogTtBJHUGqN01wxJaQsRxVVmYx/If3me9AGwJ0lOSic8DFSh41BDFDjnFc95syqBu5HbGKQyPIQM8+nvQB0yXMXUuAcVuaXEk0iO5CrnrXHWVnudWPLdeelb1t5gU7WIPbJoA9S0hYvs4EIQgDrnJroLe3TC8Db6V5Np+oSxOqdTwTz1ro28QNaQE+YR2AzQB02owK1zlcnGK7LT7Lz7CKRG+YLg143ZeLpTKTLhwScbq9e8E61BfWKA/KxyMGgDM8Z2Zk011dTxyDXj+ooWQ8dOK+jdYtY7i2dCAwYc4rwzxdo8mmys+GaBjxg9KAPOtRTJZWBxXGaxb7GP6Gu81FAQcelczqcXnRMvcfpQB5zcJsmdfeoqu6pGY7khqpUAFFFFABWl4dH/ABOrU/3W3fkDWbWn4eO2/wB3ohoA7yJy10S3GTmtS0O6TANZFq+UVj90/pW5p6qcdvWgDYswCyk9K7TwxERE82PmJ2LxXI2kfygry1es+CdK81YN6ny4hkkj86AOn0iD7DpaM4HnEYxS3kyRWymYgA/MfenXdyimSaTiFPlUE+lcB4g11727kVT+5Q7R70AX9b195EeO1ISPOM461z8rSPwzMc9cmltraS6lUAYQnHPFb1tpyhgp5A67qAMm1t5Hz8jc9+ldJpct5bMqbhsHVTzxVqC2VMAqM9qsKY0yxYBvSgDWtbqFox58bK3qDV37ZBgiOMntzXOG8UY8vOB09/Wg3UjDj5fXFAG9LcvMApIVcYIAqJUjA5K/nzWOsj4PzE/ianiU/wAWOmMGgDVLwgk8Z9KaGhxwDn2qmD8owcdzShgOXJAH4UAXA8TD5gMdOf50020LcAKfccVTaRRnecfQ0onAGPmGO5HNAFk2EY4VyAexqI2EwwVO4Djg1JBeAL8xOO9Wo7kHaFC4xQBVhjljUh1bB4xUsUm5JYwCN0ZwPpz/AErTgkQjLrtyelTLDEJVbYvPGcevFAHMxuVPTk9aeSxJPXjNX7qEKzKoJ2kgCqvlvHjeO2KAL+mkOApOcHkZq/KoyuCP8Ky9KRi27JI7jtWw0TMvQ9OlAFZrdWXPTtVO5s40PJIOM4+lXpY22qM4wc5zVO4VQQ7ZI7c0Ac9OsY34T5icDHNVgCG2pgEjkA1cu02Slz0bPSspyfNO1xknuaAG61JshzIducY71xt9ObmN0jJ3dx611etRGeJSMg4ripj9nuC8i/KRjPrQBwev+ZDPkFhzg4rLScu3zOeO3rXZapYNdRlwpJAyOOtcmbaMXGwgKSOmaAIZiuzjAc1QnGJCcccdK6BNLR0Iy49z3qpHp0IXDbtw9TQBkcMRkj3BpyqoIK9OmM81u/ZLLZygL+5qxZ28Kks0cYA6ECgDPtCTwFbB74rWtbe4bB8tzjnGOtSR3MafLkK3Xgdq07XUFk2qG5x6UAUX82Mj90ykde1Zeo3css2CrBVGAMV0mpXVtGg8xm3NweKrW8VvJGNjg46YPNAGBbzshACkHPQivW/C1y1lYwxkjeqjn61gaHptvdXiGRRtX5jkV2P2KEr8o68dcUAdFpXiISR+RPINx4Df0qtq1vBqkE1tIq+Yy5APeuOvoHgl+SQrmtW2num022uGP76B9rMO4oA8q160exvZ7WXhozjOOo7Vyl+uGPoTzXqvxLt0l8q/VcN9x8foa8uv1BBIoA4vxFbbozIB8ynNc3XaakgaNge4rkLiMxSlSOOo+lAEVFFFABWnoIH2iQn+5j9azK19DQ+XM49QKAOv09meFSM8dq6PTXUqA/GO+K5jStzR4HBFdPp42ou4fjQB1Wg27XOp28CjO9vXiveNNgWx0vap2l/lH9a8o+F9j9o1GW7xlYhsXJ7mvS/El6LWzwh+cLtQdOTQBzWv6ibm5a3hyYl44P3jWFZWAY75+pOdvYCty2swkJdhmRgeMVHAAseWGD/KgCzZwhXX2HAq6JEViWIGOPesoX4DEJg8dM1WR3dmLtuJ59aANb7cxwqYAx19aQSM+d3f3qnEV+uOuatJypx0JoAmj2qw5+uasq4BynzMRnFV442c8cjqRViNMcoAO3AoAmDHacY56H0pyyuCfnIOaRV5zjr+NPVGZRgsx9MdKAAOwfPzDAqVRuGXHHXvT0tpmGWGCe/Spfscu1csOD3oArABwCQAo7GlKkZYkYNW/sTnuM/zoFjNz0OeMZoAroAoxk4x26VIjEEnJB9qc8EiYDIcfSkUZxkUAXrWeSLaCQfr39qtLdpkYyp6kdhWWrNtGOSM8VOQDCeR17c0AXrqXzJd/wDDIM/5/GrEEZaMl+RjjPeqCHdZ5BG6I/jg/wD16ab1wf4gMcYNAG3bRFCCFHJyB6U69m8l++3HaqFjO0sa5LE5yakuE8wjcxwO4oAq3WoZDADj/PNZNzenyyQMZHc1otZAZB3HB61C+mCQZdePegDnYpnuWJcYQHOPWmLCJGzCFCeladxYxRyNhSqgc4PWqxcQthQMHOSaAHyxI1psG3gYOTXJ6xbbchk4HTjpWveTBQ7DLKB1HGfrXCa1fyby7SMSc4X0oAsTqEjk3DAxjP8AKvO7ySNJnMhHmBjjjrXRXV7PhtxAHdfauH1O5Vr192QOv40AWxqpiBYyfN0qtPqIcmQnvzzWRJMC43dKCFZTg7ie3pQBoz6kgHQ59RTY9UYAjkZrLeVHTZzkCq28oec0AdFJcmT7hG6ltr+aOXdkZHesFJeRyQT71MbkbduTz3oA6F9U+1SkzKPTIqSOUM4CtjnjFcxFKC2Pet6zhCqJc89fpQB2miXdxYwYMhKk5JPP4V01n4i5HmLu56rxivNormVThiSp565q/b3UmyRgeANvNAHb3WuWs04jL4ZjwGOK6bw64ms5ULKQxAHvXhF9el5yTxjg11/gfxDNZLsmYvCzdzyPpQB3fjTSRcadPHAMNtzjsTXht6jKxSUYYcHNfRbXEWqaaHhO7A59RXkvi7R/Mmn8tAJlORgdaAPLb0YZlrltUQDnPIrsdQjwxyMEda5jWIcRsy80AYlFFFABXQaGAtnnuXJrn66PRhmyiHqSf1oA6HTkO4EH3rqbHJX71c7paEkcDPTNdfo9us9/boBxkEg9xQB698PrX7BocIcYkdi7fjV3XJfOuk3EsBnj9Ks6VCyRKCAEiGTWZeyqbpndiABknPGKAJdypCHdgq9Oa5u9vmkkdVJ2gnHPNJqepi5fbHkRJwo9fes6AB8tnk9eaANOzzIpJBzVyEcLgZOBkVDbJtthkAselX7WIt26UATxLtYjuKvW8TNwp688VJaWLOAX4HXitiCCOEDCDOPxoAo29lKzAvgCtGKwQD5zuPTHSrChB3BzQ0oHOMg+lAD1toVQYAPpUuxU5HB6Yqq0jbeuPehWx3PvQBZ8wcAcgn8qN52jIyMVErA/iOhHAp4wD8+4emB1oAUO24YOQPSnxzPzwdp7Y60xuDz396jZyCQe36UAX0mQ7c8Z6VIEifqgYk5rJDHIP8OcVPE7Bv1HtigC+9nC4DIOeny+tC6eqrgE4PX2qGK7IOWUgDuKuxXCuAQwPqTxmgCnBAIZjvPyEEHA6iqstqY5ShI3ZxWtOQW3BQe3/wBepPs/nxKxAyvByO3Y0AZOmylJWiYcevetJyzEhOp9e1JHaRrPuTt1NWZAqbcYIbNAFWAuZAGXjv2zTbuba4A+5jmm3lygUbXUMPQ1i3t9sTJcdeBmgCC/uBvc55OeDWHPepEDubJPTHalvtQWSRgMMT+OKxbuBp2ViTtx0HWgBb24aW2JRGwSc56/pXD6xMIpAJBk88V6bpunSSaefkZWPQ9OO1c7rPhOS4kYMAH65HpQB56SZFcvgMTxXH+Ibd0vsINw9q9ntvB0cBUys0hJ71W1zwzYxyoyIMjk+tAHiDWt3JjZDJx3AqcaTfEqzRSAnvjrXsD2FnG4Aj4PBzRLbRPDgRgqvABOKAPKYvD13N/yzYHqal/4Re4DjeQufU16ike1R8qqMYyO1RvHbPAVHzMOhzQB5wvhjIGXBHqO9L/wjigAEPk812d0AhCBQq/w1ENxwUAwBzmgDm7fwqsnzjfgdeelX08NTIpCSuvfmuksi+7jA9cVooxIPmDI+tAHEyaJfKuFIbB64rOu0urSA70I3MTkV6ObiNXI2857+tZOrQx3NyFTaQF+6BQB5oZtxJY5J61vaRIY0jGcDqRVy70ASuFRBkntUdzpk9pkoCR0/CgDrNF8Qy6ftk3Ex7vmHtW/q32fUbP7fbMGUfeArzJ7grbLnIYdQa2fBesNFe/ZJGzDOdjA9AT3oA5nxhYi2vmkjH7qTmuK1SHdbyDFexeMtME2mTFBloCcH2ryu7T5evGKAOGooooAK6bRc/Zof0/OuZrodAObcAHkE8UAdhpgPy8cV6B4JtjPqUYAycgf1rgdL3KFHavWPhbA0jy3O0EJwvuTQB6VKwttPKjJZsD61xXia7KyLbIPmcbnI9PSuq1WfGyMYxGu5hXBamZJrgztzkkHHb0oAqqHY4TPHrV22jwxwhyeaitxnqvFbelWTSuGlGFz0x1oAt2tq7lFX5cdT6Vu2VosajaGL+pNMVUGFxtAx2xVuNwiZ9uBQBaiUgAZNSeYicZz7GqQmJU5JIPWpSQDlcfl1oAneTcACCPQFacrEZJA4/WqwY7VJ9OM1PGGcBiePQUASL1w2D7joKUHBJAJOaZEhwMknvUiq20ccjNACk7jyc+lICQOCcZ/SpFBBAHTHU1LHHzkqSMADPFAEa5HPUnrkUIC3A55qwkRI3NnHr1p2zAXkA+lADFQDAB4z1p0cQ27iM9cZqZUGRg9f0pQgIOSC3tQBCIiVAI5pQrA4U4wKmVQQB3xnmpFHygEA4NACwv8/wA2WP06CrcN2IW5+YHg57iqYO3nORjnmpQhk6c4oA0VdSQEXKtyD7VR1Aucpj2Bq7YAKojkyCTkegNWpIVddrAbgaAOPNk8rNgnd2IqjcaVMzMMsPY4612ws0DDgg9cUsscYLFEJz39aAPMV8OSG7Em45x3HBrWttJjiCtJGNw5BIz+VdNcod7dlIxxVeVUVB04HagCGPaiYCjj2rF1S8XBVFAYcE+prWeRAG2DIHWufvot0jbcqW4IoAo3FzlgnyevFc5r0xkkGw9eM+tbUkbq2DnHTgdTWff26tJnHIoA5+RJHYAv+IHFNktZFQ4YnnHWtxbZSoAA4HWkNvtiIwTz3oA55bUqd7AgehohtN0rJjDEdq3XhJwW5I9e1CQDfvPQcUAc9LZnd5bZYDOD6VTNhJuLpnGfSuuurbB9vYVAbYlSTye2KAMW1iZVByM4x06VaVFOc/eHbtVswADHy5/PFRSW4IYnqB+dAGfOQDknBGeM1iSlll8wggk5rbntzMCR1HpxVSaA7ck8Ac4oArWMpM4OeB1rWa3SQbhghj1NUbe3eGEvtzu9qs2cpLkNx6jtQBg+JdKCWoaIYAboP6Vytk721yrEnrkNXp2otFNbBCMEg8HqK5LUNMAbKYweMYoA62QpduM423EQY59cV4/qluYLq4gxjYxWvVArW1lZPknag5rgfGUezW5WX7rgMKAPIaKKKACt/wANsNrLjkHrWBWloMvl3uCMqRzQB6JYD92D1A7V7l8O7YWegW4fgvmRvxrxTQYDcywQqeJHC59K9vSYWmmHZyANgoANUviyTyZ4dgg+lZblJcKQMH9Kiv5cJDGOccn2qzptqZzudo1QYIAoANKsSzsZASoPQV1NhGM/LwAKqQRDOFOcd6uCUIj/AN4HigCaSQK5Ax0pVdgRjoe1UVdmYnPIHAPpVpOxGfU4oAuRybXBThhxyKkwSAcEn+dQx5bJ9uuetWIiOnPp7UASqBtHIJ7e1SLEM5Gc98HGaSNQuRk4IqxEowCcGgBqpjIOcnpipFQ8AZz/ACqVEO7I+nNSxwksMjcDznFAEaIxTgfTHepUQjg5HerUVqSPXtnpVpLZY9pAAyexoAz1RyfUfSpfs7txitERqD8x+nNAUDjBOO3rQBQW3l28KuD0B6U9bSQ8cAgdauqyghcEZ607z4hk+lAFdLJj/ERnmp0sAOWck/SgXcYQMFYkgDpUkd6vIKkD1zQBXltxH0II60+3ULIR6fpUsk0bBiSR65qOIhnz0GegNAE6wuZA7DA71qLHlATgHFQwDdtHBwKt0ARPGv8AhVOVlxyp/pVqYOwJQEkdvX6VQlSRwQRgd6AKdyqrjaetZdym+QhM57D0rRntZfMUnOw0qWyjIAIPr9aAM61079y+T7msbVrJ1LNt+70967m1hVFxkc96ztRty2dwO3rntQBwMaE/fAYng/Wp309Zh0GD0J4Oa3ZYtmSuCM+lQyuiFQzYPHagDAGgMOUYr+GamOiylCflY9+DW/HPCvf6ihrmLoXXb0GRQByM+lujE+WSc8+lQeQVBOw+4xXXTyRlj5m3pxzVCUR7SBjntigDnriEtDu29Oc1R8raeVJ5711pRFj9Qe2Kz50QucgZHagDnZIxuLKOT2x0qNovlJBwO9b81rG5BCgnFV5bAgfuyQD0zzmgDmposZ25H05qubZmIXbuz1zWzPbPESHGR/KnWVtvlJycL3I/SgDNktztUbcCqU0IXtzXUTQrtPzHPfisy5hUxnHFAHJasx+QqxOOaitLpZyI35fOAPX/AOvVjVoB5vy5IxVbTbNnu1kOTtIx7GgDsn0pjpao6AjHA7jivKfHds8WoAPwwX9K9z0mX7XEYW/1qjj3rzn4s6WSkdwineo5oA+aKKnhtmkTeSqJ/ebv9KvQRxQLuwv/AF0f19hQA7RNGk1I7idiZwD61ujwlJayrJDcbvYjrVzw+8cemrcRnfyeWOMVbj8Zx/2jHaXEUbQE7Sy/w0AdL8PLOT+2oVnU/uvm9jXpGtzFEtoehb5yK1PAHhGKbRTdPMqST5aEkZJXHFYXiEMuvSxN1hAjwDnmgBkiPcXUar07muhto9kaqpCjoDWfBbmOFT/GTk57VbafyUAX77cLj+dAGg04i+RcZzy3pUkL5hLHOccd6y4zkgnJOPzrSjHyKoyM/hQBLGoBySSKvRqQeM7TzxVRAcEY/KrkY2g/N3zigCzEoz15+vFWoVYH/Z74OarQjcw/vZ5xWhChIHO4dMkYoAVEztGPerUUbtwevPNS21sO+c8nFXoYxt55HuKAIYrfoTg49quBQB0GR2pu7bznA6UxpMk46/pQBOGIIx9aTcxOBwO2KiJJbIHShc45JyeaAJMgHnOR2FEkn/AT1z600BhyOT+dKEDMw/kOlAEe4kncTzT1UHHc+lOUEAsBx2pQpXPy80AIq85K8ew61IE3gHGQKcinHUn/ABqRhlti4K4oArSfeAGMdc5qSMFQpAyKJFAJKgk9OBQGIIYDJFAF60dvM5wPfoa00Oaxo3I2hcZ4/wD11p25Y/SgCxTTGpOcc+tOooAgkiQnkcDrTGiTHsKtVDKxUAZxj2oAqSLt7989Ky76V/nTdwelaUhZycc8/nVG6iG/G3kDAPpQBiyKcnt9TVeSIMVJGa12h45G7HSmmJQwPWgDJNuVBHHXpmq8kRwQ4wfWtmRRzkcelV5E+UknrxwKAMKaMg8kn0OP51Vk3KxAB575rbkiBOMjFVbmLByE/HPWgDLMjoozkkgcU1wrYYZBOcg9jU08RP8ADxjgEVCYiORznn1oAWMjByORS+cMHp6dKiwRnI6GoXb5iM4xzQBO6I7cgUn2dfKbbwOtVfO2uCCcfWrUV2ittcgZ9TQBQuInQENgqKyXYbiR0NdFcSISRxg881k3lqrhnj4x1PSgDldQUGZ8DI9aNGiPmHaTgEnIqze20hdiQdvY1d0C0iSOZn5/GgC/bXP2e2MoyJEbdx7DiqPjbZqelCaMgFo8svoauTuv2SQxq3Py9Olc/eXMkV08M4ykkY49CBQB8vSzhipHJAwPQfhUDuznLkk+9NooAlWeVYzGsrhP7oY4/KpdNTfexDGRnNVavaKM36CgD6E8AfEa403RorG5tTO9sm2GTfjjtmrunXkmpai93c4LuxYnHevNdG+VsDqRgV6Dov7qMDpjqaAOx85JICOhHJJ9KpRytNIXY5XPGOwqjNOwjCd36n2q3YoCBj8aANS3G8oAcegrR6uADzgE4qnYpulBPQD0qzHy5YgZoAtQ4I4OeOtXIsEK2Cf8aq20bvJtU8j0FbdnbrHjI5POBQBPaW+4hmGD1NaUUSomSMfjUMagBSAMnrU/mADOPwNAFlTgnpR5oYE8H9RVYyMwPTpwtSRr0C5APb2oAkUsw3HpnoecU9BkY4B9cU1E6gnpUqjOOOKAADAye/SnKp78dvrSgYPPOeamVRnDN1PegBiqdpHtzT1QYPXNOUcEHJBFPRcnA69eaAI1XADHjHapFUs3Q/jUqwllHAPr2qwsG1cE8+1AFbIAAUcew6Uiw5c7c1cWFQR19uelSAKijkKM0AUxbnAJ7U1ohxnp/Wr26NiRu4qFgof5SOtAESWxIyD+PpWlAhSMButRW4AIBOD6VZoAQsB9aj84DqKkIzUbwhx1waAAzKPX2qORlk4xtOOD/SnJAVz8x5pywKDn9KACOEBAGHIqrc2+DkcjtV+mSLkcDJFAGM1s/QL1qLySDg9eorWIGeDkioJUweM4PpQBkNGR1GM9Peqkqj159K3ZI1YDcv0qlPaKfuE7h0oAxpFGSADt9M1WmUdMdOlaklq6joc9fpVKVO5UjHHTtQBnuu44xx64qJo8sTtBIxjFXXCjG7p7VWlYAADJ7GgClIgbOePas66QA5ODxz71emfcxBzgHsKoXEoR9jgEn2oAy2L8hMjmo5pmQAMCD+tXxG5Lvt4x1Iqm0ca/NKSzeh9KAIYrptoZj8mcc1pWlxAeCQ3GK527kdtwX5V6ZpLCV423Z+bsAaANfUV3q20AZ7+tU7Kza1ZlPzbhmr0MiyuiyHHqTUk00SlgOT2agCo0rRKyY+RuMe/Y1wPjC8kS5Lg42Y6dzXc6hcxi1ZjhSvJFeU+J7wXE5Vc7R1J70AeH0UUUAFanh5A19nuBxWXW94YQGR275xQB3+hxZlQ4HFdvYjH0NcrocDFFOQM+tdZa7lYZ7fhQBbibzLpzj0GK2rYHrg+h4rD08g5JH51uWrZAIz7UAbFocQu2fy6GrNujOdowd1QW6lrcJjDGtmzhCAdPagC3YwiLJxz1PfNaMfB3dx2PAqrE4VQ2c4608OXJ29M80AWvM9M/zqSMksGJ/WoEXABzx6VYiPy+v60ATx5Ayo46DIqxHzwRjNRRgkgYGDyRU0WSeg470ATIFHHPTp1p4XIBHf2pijk9TUseM7QSB60APUBhwDgU9QOB39aWJCwwuMdSRVuKPaowOaAI4IjgEjG6p1VRnaMAU/AAPXNLwv0NAC/Kv1prNj2PamMx3DqT7U3HPUketACs5J6nPXJpOcg8/wCNOxzz3p21s4zxQBGQOTTtuPu85p4XODzg9vSnBRu9R70ALag+YCe3rVyqijBPJ65qypyOOlADqKKKACiijPGaACmyMAvr7Ux5Bu4PSkk3EKaAKc7fOSucelVw5yOfrirTjnPbrkdqaUV+OA/5A/4GgCuzkscOSR2JphfaAHw2TzinyBhlGzu6c9TVY5f5eRjofWgBskyHBBOarSfMMHBHapZF3HBQDFRtGAKAM+e1BwQMZ645/SqclqwLMSCo6Y4rWZwrYAOOlUp5AwKpgYHOOtAHPXP7tiQcHPJHrVGWRd3zjLH0x1rWu495KJtb+YrJvIWiUkdumaAKOoXZWPaWwp44PNZUrggkMemaS4YkkNgn1IqpNOM7FGW60AHmb5VRumORVuOJBuA698Cs1mwwOc4NadqfM5AG0gUARzKUYkEnI7mmxXIdtr8kdDmpLsEZx0Pesq6Oxyf1oAnu3BVlbJBHNebeIbfyZncfcJNdzJdBhtcgehrD1aBZInDYOflxnoaAPnmiiigArpvCqERM/HLVzNdh4YTbaoR1PNAHfaS+1VOe3pXSWcoEfJBHTpXJ2BwAO3St+1cggD60AbVkOmex4xW5Zg+YAOp645rEsc84OeOK6fS4tjpuAye9AG3DEqIgPUflWhCQi7iSB0zVPIzk8EDv0pVk8wrn7o4/CgC55rSZPAB7e1W4htXLYA9KpRLkAkZ9avQrnqBn0oAtp2A6VbgXnjJBqrboGALf41ch4HHT1oAmi6Z6Hp61YA9R+FRpwOPXiphyvJ79O2KAHoOR6evrVqFCwJbgnoKbbRdGbOKuLlTzQAsSCNSRgHpxT8/MPQUwEknB+WnKMklvxoAkXhckCmE7nxxQzgnAAwD+dOCEg7QaAGqvzc4GPepAMg89+1KYzgY4GacEJGR65oAjAB65+op4Gc9/xqQJwMn86cka84PNAEQBIxtp+3HQHg1MEAxQwB60ANUAkZyfepAMdKQADpS0AI2cfL1qMswzzz6YqWjA9KAIHdwcAcimEu/XrntVrHNIQD2oAgij+fLAcVORx70tFAFfywMjI69qheNRnBzz3qzKOCe9RFcrnnrQBDKQUBPOOneqNyjgBkUFOmc/zrRkTKnv+NRjfHnaBk9Qec0AYxLHIB56Gq0pYAt26GtK5iJb5R17Cqcg5IxyDyKAM2VsQk7sY7etZtxLsAYEBR+tWr2JzJmMnHU1n3O6YFNrDuOOlAFMXKvLyRjuSelVbt0chWOVzVa9zEcNyR2x92s2W5PQEZ7kn9aAHanCgi3x5L9iK5os6thwQfbvXTLMJEwxHIziqE1qrZJ5z68UAZgIVD155xWnZsNoXgD0qldRbOAcgVasFPLNjJHegCe4OAemKy7wAAEZ9K1bgHaASKzLsDbz9OOxoA5zUQMHGc9eKzjd+dG0ZOZVGB/tCtDUiQPlznk/Subdik4cNjBz/wDWoA8VooooAK7jw+gS2iHtXEoAXUHua7vRV/dJ06UAdVY9s/nWzb4LDnisezxjJ6dq2bJS7oCcetAHSaShJD4+Xtmup08AuN3THGO1c7p5X5QCMDit6GTyISc7SeKAL7y5Zlxjnr61PESR6EdQBWZAcjLAjPStWD7iluvp1oAvwEfLkk+1X4MBjg5HXGKowEH5guAK0LfOAAOKALcGCv17VcjB4I69hVWLK55znjHpVqLc2MAZPBFAFlRk9MHPPvV6GPvxkVBBGFIDfePpVtCqKQATnqRQBKpCqP5d6XcSyAE49ajJyflznHPNSxxkgZPTtQA5VZn46evpUzAgYpciMbVHNNG5ge+PWgB6lRyRmpd3Xjp2qJQfoD171KMduKAAMe2RSgnsaULz3yB0qVFxyaAGopI6+1SKMCl6Uh56daAAn060nU0uO9HTmgAUYGKWgUUAFFFFABRRRQAUUUUAQMSWOOR1oVyD1/SpG5JIPIqJulADywIzjBz+dRyKjH9OabyVAP1pjFlII5oAhuoypBxnnANVHlSTImGCB98dfx9avPKM7j0rO1CMeXmMgHoKAMPVibZg7EbT0IPDVz89/kSMAflPHua6K6tjLaXCOSV3KQPSuWvlMO4YG0EcHvQBk6hcZlYsufXHasi5Hmfd4U9PetS7/hIBG4duMis+VQUw2fz5oAp5eN8uMqDVu3kRigONveom5XJGENNiXBzgk0AWzZiaU7kO3pnNSNZGFNyA7egqW1BHJcZ9PWtZIwsWCAwxnmgDnZmIXBUkVh6lLIpCkYHqOldNqcHlliFOD2x0rAvkDAhhuU8fhQBzF90yPzrnbxiHJwK6a8iaMFOSvY1zuoR4JIBoA8TooooAkgGZkH+0K7zSv9XHj6UUUAdLbfdB7Z6Vs2JzjPeiigDpNOkwqce1b6uTAOOgoooAtWZyFzyeua14hja2W5HrRRQBpQ8EHjt29qvW2doPGckf5/OiigC9bjcQckFhWhbLhXfPIx+tFFAF6MnHuDinyNgn9f50UUAWLdcruzzwelWF4yB6ZoooAauTlu4qUDg5570UUASAbW+oqVBubGaKKAJlG3iloooAQ9OpoxzyTRRQAuKKKKACiiigAooooAKKKKACiiigAIz1pjDrz92iigCI9KYQOlFFAFW6GwZHT0rJuJmXPHG3pRRQBTeZxIXB6jBU9CPSuX8SOruCkax+u3PNFFAHLSyuBsJyD09qRCGU7xnOKKKAGogdipJqVIQSoJyD60UUAS22JJgpAwOlasLnysHkUUUAU7p8jgAA8EVzOpIMtjgAZxRRQBzmoDJJ6YNYF0pMpBbPBPSiigD/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Follow up radiographs one day later. The condition has progressed to complete right-sided atelectasis, with mediastinal shift toward the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan D Finder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35766=[""].join("\n");
var outline_f34_59_35766=null;
var title_f34_59_35767="Iloperidone: Drug information";
var content_f34_59_35767=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iloperidone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/40/32389?source=see_link\">",
"    see \"Iloperidone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9770228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7731166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Fanapt&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7742696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsychotic Agent, Atypical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9770291\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Schizophrenia:",
"     </b>",
"     Oral: Initial: 1 mg twice daily; titrate to the recommended dosage range with dosage adjustments not to exceed 2 mg twice daily (4 mg daily) every 24 hours; recommended dosage range: 6-12 mg twice daily (maximum: 24 mg daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Titrate dose to effect (to avoid orthostatic hypotensive effects); treatment &gt;6 weeks has not been evaluated; when reinitiating treatment after discontinuation (&gt;3 days), the initial titration schedule should be followed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment in patients receiving strong CYP2D6 inhibitors (eg, paroxetine, fluoxetine, quinidine):",
"     </i>",
"     Decrease iloperidone dose by 50%; when the CYP2D6 inhibitor is discontinued, return to previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment in patients receiving strong CYP3A4 inhibitors (eg, ketoconazole, clarithromycin):",
"     </i>",
"     Decrease iloperidone dose by 50%; when the CYP3A4 inhibitor is discontinued, return to previous dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Dosage adjustment in poor metabolizers of CYP2D6:",
"     </i>",
"     Decrease iloperidone dose by 50%.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9770292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15897602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; however, pharmacokinetics of iloperidone do not appear to be altered by renal impairment due to extensive hepatic metabolism.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F9770293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is not recommended in patients with hepatic impairment (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9770297\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fanapt&reg;: 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, 12 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral [combination package (each titration pack contains)]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fanapt&reg;: 1 mg (2s), 2 mg (2s), 4 mg (2s), and 6 mg (2s)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9770230\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9770479\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7742697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acute treatment of schizophrenia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9770229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fanapt&reg; may be confused with Xanax&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Iloperidone may be confused with domperidone",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9770270\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Tachycardia (3% to 12%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (10% to 20%; dose related), somnolence (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Orthostatic hypotension (3% to 5%), hypotension (&lt;1% to 3%; dose related), palpitations (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Fatigue (4% to 6%), extrapyramidal symptoms (4% to 5%), tremor (3%), lethargy (1% to 3%), akathisia (2%), aggression (&ge;1%), delusion (&ge;1%), restlessness (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (&le;10%), xerostomia (8% to 10%), weight gain (1% to 9%; dose related), diarrhea (5% to 7%), abdominal discomfort (&le;3%; dose related), weight loss (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Ejaculation failure (2%), erectile dysfunction (&ge;1%), urinary incontinence (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (3%), stiffness (1% to 3%; dose related), dyskinesia (&lt;2%), muscle spasm (&ge;1%), myalgia (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Blurred vision (&le;3%), conjunctivitis (&ge;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Nasal congestion (5% to 8%), nasopharyngitis (&le;4%), upper respiratory tract infection (2% to 3%), dyspnea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, amenorrhea, amnesia, anemia, anorgasmia, aphthous stomatitis, appetite increased, arrhythmia, asthma, AV block (first degree), blepharitis, bradykinesia, breast pain, bulimia nervosa, cataract, catatonia, cholelithiasis, confusion, dehydration, delirium, difficulty walking, dry eye, duodenal ulcer, dystonia, dysuria, edema, enuresis, epistaxis, esophageal reflux, eyelid edema, eye swelling, fecal incontinence, fluid retention, gastric acid secretion increased, gastritis, gynecomastia, heart failure, hematocrit/hemoglobin decreased, hiatal hernia, hostility, hyperemia, hyperthermia, hypokalemia, hypothyroidism, impulse control disorder, lenticular opacities, leukopenia, libido decreased, major depression, mania, menorrhagia, menstrual irregularities, metrorrhagia, mood swings, mouth ulceration, nasal dryness, nephrolithiasis, neutrophils increased, nystagmus, obsessive compulsive disorder, panic attack, paraesthesia, paranoia, parkinsonism, pollakiuria, polydipsia psychogenic, postmenopausal hemorrhage, prostatitis, pruritus, psychomotor hyperactivity, QT",
"     <sub>",
"      c",
"     </sub>",
"     interval prolongation, restless leg syndrome, retrograde ejaculation, rhinorrhea, salivation, sinus congestion, sleep apnea syndrome, stomatitis, testicular pain, thirst, tinnitus, torticollis, urinary retention, urticaria, vertigo",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9770234\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iloperidone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9770235\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Altered cardiac conduction: May alter cardiac conduction and prolong the QT",
"     <sub>",
"      c",
"     </sub>",
"     interval; life-threatening arrhythmias have occurred with therapeutic doses of antipsychotics. Risks may be increased by conditions or concomitant medications which cause bradycardia, hypokalemia, and/or hypomagnesemia. Avoid use in combination with QT",
"     <sub>",
"      c",
"     </sub>",
"     -prolonging drugs. Avoid use in patients with congenital long QT syndrome, history of cardiac arrhythmia, recent MI, or uncompensated heart failure. Discontinue in patients found to have persistent QT",
"     <sub>",
"      c",
"     </sub>",
"     intervals &gt;500 msec. Patients with symptoms of dizziness, palpitations, or syncope should receive further cardiac evaluation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anticholinergic effects: May cause anticholinergic effects (confusion, agitation, constipation, xerostomia, blurred vision, urinary retention); use with caution in patients with decreased gastrointestinal motility, urinary retention, BPH, xerostomia, or visual problems.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Blood dyscrasias: Leukopenia, neutropenia, and agranulocytosis (sometimes fatal) have been reported in clinical trials and postmarketing reports of antipsychotics; presence of risk factors (eg, pre-existing low WBC or history of drug-induced leuko-/neutropenia) should prompt periodic blood count assessment and discontinuation at first signs of blood dyscrasias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Cerebrovascular effects: An increased incidence of cerebrovascular effects (eg, transient ischemic attack, stroke), including fatalities, has been reported in placebo-controlled trials of antipsychotics for the unapproved use in elderly patients with dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dyslipidemia: Has been reported with atypical antipsychotics; risk profile may differ between agents. In clinical trials,  changes in triglyceride and total cholesterol levels observed with iloperidone were similar to those observed with placebo or were  clinically insignificant. Small reductions in cholesterol and triglycerides have been observed in longer term iloperidone trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Esophageal dysmotility/aspiration: Antipsychotic use has been associated with esophageal dysmotility and aspiration; use with caution in patients at risk of aspiration pneumonia (eg, Alzheimer's disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Extrapyramidal symptoms (EPS): May cause EPS, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions is generally much lower relative to typical/conventional antipsychotics). Risk of dystonia (and probably other EPS) may be greater with increased doses, use of conventional antipsychotics, males, and younger patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperglycemia: Atypical antipsychotics have been associated with development of hyperglycemia; in some cases, may be extreme and associated with ketoacidosis, hyperosmolar coma, or death. Use with caution in patients with diabetes or other disorders of glucose regulation; monitor for worsening of glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hyperprolactinemia: Use is associated with increased prolactin levels; clinical significance of hyperprolactinemia in patients with breast cancer or other prolactin-dependent tumors is unknown.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Neuroleptic malignant syndrome (NMS): Use may be associated with NMS; monitor for mental status changes, fever, muscle rigidity and/or autonomic instability (risk may be increased in patients with Parkinson's disease or Lewy body dementia).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Orthostatic hypotension: May cause orthostatic hypotension associated with dizziness, tachycardia, and syncope; use with caution in patients at risk of this effect (eg, concurrent medication use which may predispose to hypotension/bradycardia or presence of hypovolemia) or in those who would not tolerate transient hypotensive episodes. Use caution with history of cerebrovascular or cardiovascular disease (MI, heart failure, conduction abnormalities, or ischemic disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Priapism: Rare cases of priapism have been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sedation: May cause sedation, use with caution in disorders where CNS depression is a feature; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Suicidal ideation: The possibility of a suicide attempt is inherent in psychotic illness; use with caution in high-risk patients during initiation of therapy. Prescriptions should be written for the smallest quantity consistent with good patient care.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Temperature regulation: Impaired core body temperature regulation may occur; caution with strenuous exercise, heat exposure, dehydration, and concomitant medication possessing anticholinergic effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Weight gain: Significant weight gain has been observed with antipsychotic therapy; incidence varies with product. Monitor waist circumference and BMI.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death compared to placebo.",
"     </b>",
"     Most deaths appeared to be either cardiovascular (eg, heart failure, sudden death) or infectious (eg, pneumonia) in nature. Iloperidone is not approved for the treatment of dementia-related psychosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hepatic impairment: Use is not recommended in patients with hepatic impairment due to lack of data in this patient population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Seizures: Use with caution in patients at risk of seizures, including those with a history of seizures, head trauma, brain damage, alcoholism, or concurrent therapy with medications which may lower seizure threshold. Elderly patients may be at increased risk of seizures due to an increased prevalence of predisposing factors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; High potential for interactions: Use with caution in patients taking strong CYP2D6 inhibitors or strong CYP3A4 inhibitors; dosage adjustment recommended for iloperidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; CYP2D6 poor metabolizers: Use with caution in patients known to be poor metabolizers of CYP2D6; dosage adjustment recommended for iloperidone.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Elderly: Use in patients with dementia is associated with an increased risk of mortality and cerebrovascular accidents; avoid antipsychotic use for behavioral problems associated with dementia unless alternative nonpharmacologic therapies have failed and patient may harm self or others. In addition, use may cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion or hyponatremia; monitor sodium closely with initiation or dosage adjustments in older adults (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Long-term use: Continued use for &gt;6 weeks has not been evaluated.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9774916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9774915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): May enhance the neurotoxic (central) effect of Antipsychotics. Severe extrapyramidal symptoms have occurred in some patients.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Antipsychotics may diminish the stimulatory effect of Amphetamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anti-Parkinson's Agents (Dopamine Agonist): Antipsychotics (Atypical) may diminish the therapeutic effect of Anti-Parkinson's Agents (Dopamine Agonist).  Management: Consider using an alternative antipsychotic agent when possible in patients with Parkinson's disease.  If an atypical antipsychotic is necessary, consider using clozapine or quetiapine, which may convey the lowest interaction risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Management: Reduce iloperidone dose by half when administered with a strong CYP2D6 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone. Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Eplerenone.  Management: When used concomitantly with moderate inhibitors of CYP3A4, eplerenone dosing recommendations may vary depending on international labeling. Consult appropriate labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of other Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium formulations: May enhance the neurotoxic effect of Antipsychotics. Lithium formulations may decrease the serum concentration of Antipsychotics. Specifically noted with chlorpromazine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Antipsychotics may enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents. Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinagolide: Antipsychotics may diminish the therapeutic effect of Quinagolide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: Antipsychotics may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetrabenazine: May enhance the adverse/toxic effect of Antipsychotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9770282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease serum levels of iloperidone). Avoid kava kava, gotu kola, valerian, St John's wort (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9770231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9770232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal studies have shown  an increased risk of developmental toxicity and fetal mortality. Antipsychotic use during the third trimester of pregnancy has a risk for abnormal muscle movements (extrapyramidal symptoms [EPS]) and withdrawal symptoms in newborns following delivery. Symptoms in the newborn may include agitation, feeding disorder, hypertonia, hypotonia, respiratory distress, somnolence, and tremor; these effects may be self-limiting or require hospitalization.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9770233\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9770294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be given with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fanapt Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     12 mg (60): $836.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fanapt Titration Pack Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 &amp; 2 &amp; 4 &amp; 6 mg (8): $111.50",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9770295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Vital signs; fasting blood glucose/Hgb A",
"     <sub>",
"      1c",
"     </sub>",
"     (prior to treatment and periodically during treatment); signs and symptoms of hyperglycemia; signs and symptoms of cardiac arrhythmia; CBC (frequently during first few months of therapy); serum potassium and magnesium levels (prior to treatment and periodically during treatment); orthostatic blood pressure changes; assess weight prior to and periodically during treatment;",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9770305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iloperidone is a piperidinyl-benzisoxazole atypical antipsychotic with mixed D",
"     <sub>",
"      2",
"     </sub>",
"     /5-HT",
"     <sub>",
"      2",
"     </sub>",
"     antagonist activity. It exhibits high affinity for 5-HT",
"     <sub>",
"      2A",
"     </sub>",
"     , D",
"     <sub>",
"      2",
"     </sub>",
"     , and D",
"     <sub>",
"      3",
"     </sub>",
"     receptors, low to moderate affinity for D",
"     <sub>",
"      1",
"     </sub>",
"     , D",
"     <sub>",
"      4",
"     </sub>",
"     , H",
"     <sub>",
"      1",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      1A",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      6",
"     </sub>",
"     , 5-HT",
"     <sub>",
"      7",
"     </sub>",
"     , and NE",
"     <sub>",
"      &alpha;1",
"     </sub>",
"     receptors, and no affinity for muscarinic receptors. The addition of serotonin antagonism to dopamine antagonism (classic neuroleptic mechanism) is thought to improve negative symptoms of psychoses and reduce the incidence of extrapyramidal side effects. Iloperidone&rsquo;s low affinity for histamine H",
"     <sub>",
"      1",
"     </sub>",
"     receptors may decrease the risk for weight gain and somnolence while its affinity for NE",
"     <sub>",
"      &alpha;1/&alpha;2C",
"     </sub>",
"     may provide antidepressant and anxiolytic activity and improved cognitive function.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9770314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1340-2800 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: ~95% (iloperidone and active metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via carbonyl reduction, hydroxylation (CYP2D6) and  O-demethylation (CYP3A4); forms active metabolites (P88 and P95)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: Oral: Tablet (relative to solution): 96%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extensive metabolizers: Iloperidone: 18 hours; P88: 26 hours; P95: 23 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Poor metabolizers: Iloperidone: 33 hours; P88: 37 hours; P95: 31 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (58% extensive metabolizers, 45% poor metabolizers); feces (20% extensive metabolizers, 22% poor metabolizers)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/59/35767/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cutler AJ, Kalali AH, Weiden PJ, et al, &ldquo;Four-Week, Double-Blind, Placebo and Ziprazidone-Controlled Trial of Iloperidone in Patients With Acute Exacerbations of Schizophrenia,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2008;28(2 Suppl 1):20-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/59/35767/abstract-text/18334909/pubmed\" id=\"18334909\" target=\"_blank\">",
"        18334909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dixon L, Perkins D, and Calmes C,",
"      <i>",
"       Guideline Watch (September 2009): Practice Guideline for the Treatment of Schizophrenia",
"      </i>",
"      , Arlington, Va: American Psychiatric Association, 2009. Available at file://www.psychiatryonline.com/content.aspx?aid=501001",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kane JM, Lauriello J, Laska E, et al, &ldquo;Long-Term Efficacy and Safety of Iloperidone: Results From 3 Clinical Trials for the Treatment of Schizophrenia,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2008, 28(2 Suppl 1):29-35.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/59/35767/abstract-text/18334910/pubmed\" id=\"18334910\" target=\"_blank\">",
"        18334910",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moore TA, &ldquo;Schizophrenia Treatment Guidelines in the United States,&rdquo;",
"      <i>",
"       Clin Schizophr Relat Psychoses",
"      </i>",
"      , 2011, 5(1):40-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/59/35767/abstract-text/21459738/pubmed\" id=\"21459738\" target=\"_blank\">",
"        21459738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Potkin SG, Litman RE, Torres R, et al, &ldquo;Efficacy of iloperidone in the Treatment of Schizophrenia: Initial Phase 3 Studies,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2008, 28(2 Suppl 1):4-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/59/35767/abstract-text/18334911/pubmed\" id=\"18334911\" target=\"_blank\">",
"        18334911",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiden PJ, Cutler AJ, Polymeropoulos MH, et al, &ldquo;Safety Profile of iloperidone: A Pooled Analysis of 6-Week Acute-Phase pivotal Trials,&rdquo;",
"      <i>",
"       J Clin Psychopharmacol",
"      </i>",
"      , 2008, 28(2 Suppl 1):12-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/59/35767/abstract-text/18334908/pubmed\" id=\"18334908\" target=\"_blank\">",
"        18334908",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9087 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-41275854C3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35767=[""].join("\n");
var outline_f34_59_35767=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770228\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7731166\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7742696\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770291\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770292\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15897602\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770293\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770297\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770230\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770479\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7742697\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770229\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770270\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770234\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770235\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9774916\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9774915\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770282\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770231\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770232\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770233\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770294\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321958\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770295\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770305\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9770314\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/40/32389?source=related_link\">",
"      Iloperidone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_59_35768="Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection";
var content_f34_59_35768=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35768/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35768/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35768/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35768/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35768/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35768/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/59/35768/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hepatitis C virus (HCV) infection usually have evidence of chronic hepatitis, a slowly progressive liver disease. Cirrhosis occurs in 25 to 50 percent of chronically infected patients, some of whom develop hepatocellular carcinoma. In addition, extrahepatic manifestations such as mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and thyroid disease may occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=see_link\">",
"     \"Extrahepatic manifestations of hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The trials demonstrating the efficacy of standard interferon in the treatment of chronic HCV infection will be reviewed here. However, standard interferon has generally been supplanted by peginterferon plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for treatment of chronic HCV. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferons comprise a group of related proteins whose effects include antiviral activity, growth regulatory properties, inhibition of angiogenesis, regulation of cell differentiation, enhancement of major histocompatibility complex antigen expression, and a wide variety of immunomodulatory activities. They were originally classified according to their source and have subsequently been renamed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alpha interferon (formerly known as leukocyte interferon)",
"     </li>",
"     <li>",
"      Beta interferon (formerly known as fibroblast interferon)",
"     </li>",
"     <li>",
"      Gamma interferon (formerly known as immune interferon)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At least 18 distinct genes (including four pseudogenes) are known for the human alpha interferons; in comparison, there is only one gene for beta interferon and one for gamma interferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alpha interferons have been extensively studied in the treatment of patients with chronic hepatitis, including hepatitis B, C, and D. The mechanism of action of alpha interferon in these infections is unknown. Alpha interferon is directly antiviral to all of these viruses; it also appears to stimulate a cellular immune response to the hepatitis B virus, but such an effect has not yet been observed in patients with HCV.",
"   </p>",
"   <p>",
"    Interferons are also multifunctional immunomodulatory cytokines which may have effects upon the cytokine cascade, including several antiinflammatory properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/3\">",
"     3",
"    </a>",
"    ]. It is possible that these functions are critical to the observed antiviral and immunostimulatory effects of the drug.",
"   </p>",
"   <p>",
"    Four types of alpha interferon have been evaluated in large clinical trials of patients with chronic HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       Interferon alfa-2b",
"      </a>",
"      (Intron A, Merck &amp; Co.) is produced by recombinant DNA techniques. It is approved in the United States for patients with HCV infection at a dose of 3 million units (MU) subcutaneously three times weekly for up to 24 months. It is also approved in many other countries; in the European Union, the recommended dose is 3 MU subcutaneously three times weekly for 12 months, although this may be extended to 18 months in some patients.",
"     </li>",
"     <li>",
"      Interferon alfa-2a (Roferon, Genentech) is also a recombinant alpha interferon. It differs from",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      by a single amino acid. However, it is possible that other differences result from the manufacturing process since a high proportion of treated patients develop neutralizing antibodies to interferon alfa-2a, but not alfa-2b. The majority of people produce interferon alfa-2b, which probably explains the high rate of antibody formation when interferon alfa-2a is given.",
"      <br/>",
"      <br/>",
"      Interferon alfa-2a is approved for use in the United States in patients with HCV infection at a dose of 3 MU subcutaneously three times weekly for 12 months. The dose approved by the European Union is 3 to 6 MU subcutaneously or intramuscularly three times weekly for six months, followed by 3 MU three times weekly for six months. This regimen was approved based upon studies that suggested responses were improved with a higher dose induction. Dose equivalence to 3 MU of interferon alfa-2b has not been shown.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24822?source=see_link\">",
"       Interferon alfacon-1",
"      </a>",
"      or consensus interferon (Infergen, Three Rivers Pharmaceuticals) is a non-natural recombinant interferon which was developed by scanning subtypes of alpha interferon and assigning the most frequently observed amino acid at each position to form a consensus molecule. It is approved for use in the United States at a dose of 9 mcg subcutaneously three times per week for six months (this dose is roughly equivalent to 3 MU of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      ). Patients who tolerated previous interferon therapy and did not respond or relapsed following its discontinuation may be subsequently treated with 15 mcg three times per week for six months, although this dose is not recommended as initial therapy. Trials have also looked at the use of daily doses of consensus interferon for patients who have failed to respond to prior attempts at treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Interferon alfacon-1 (consensus interferon)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Interferon alfa-n1 (Wellferon, Glaxo-Wellcome) is a mixture of nine interferon subtypes produced from a human B lymphoblastoid cell line [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/5\">",
"       5",
"      </a>",
"      ]. It has never been marketed in the United States.",
"     </li>",
"     <li>",
"      Interferon covalently bound to polyethylene glycol (pegylated interferon) has the advantage of permitting once weekly dosing while sustaining more uniform interferon concentrations compared with standard preparations. The latter effect may have therapeutic advantages based upon viral kinetic studies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are differences in specific activities among the interferons. Treatment outcomes generally are thought to be similar with the different preparations, although the dose and duration of therapy may vary, and only a few of the interferons have been compared head-to-head at their approved regimens. Health care providers should be aware that changes in interferon brand may require adjustments in dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a change in the route of administration. Pharmacists should not substitute interferon preparations without consultation with the prescribing clinician. Patients should be warned not to change brands of interferon without medical consultation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several uncontrolled studies and more than 70 randomized controlled trials have documented the efficacy of interferon for the treatment of chronic HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/6\">",
"     6",
"    </a>",
"    ]. At the relatively low doses listed above, interferon improves liver tests, reduces the level of HCV RNA, and decreases hepatic inflammation on liver biopsy in many patients with chronic hepatitis due to HCV. Approximately 40 percent of patients respond during treatment, with early normalization of the serum alanine aminotransferase (ALT) concentration and loss of detectable HCV RNA, usually within the first 8 to 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results of many of the studies using interferon for chronic HCV have been pooled in several meta-analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/6,8-10\">",
"     6,8-10",
"    </a>",
"    ]. The following conclusions were reached in a meta-analysis from Cochrane Collaboration (containing the most recent controlled trials), which focused on 54 studies that included a total of 6545 patients who had never before been treated for HCV (ie, treatment-na&iuml;ve) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to no treatment, interferon given at a dose of 3 MU three times weekly for 12 months increased the probability of a virologic sustained response (OR 4.6, 95% CI 1.53 to 13.85). The overall rate of virologic SR at this dose and duration was 17 percent (95% CI 10 to 28 percent).",
"     </li>",
"     <li>",
"      A dose of 6 MU was more effective than the 3 MU dose, as was a duration of treatment of 12 months or greater versus six months. However, adverse events were more common with higher doses and prolonged duration of treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to realize when comparing the results of different trials that the study groups and definitions of response may be different. To address these potential differences, it has been recommended that study groups be stratified by factors that can strongly influence response (eg,",
"    <span class=\"nowrap\">",
"     fibrosis/cirrhosis,",
"    </span>",
"    viral levels, and viral genotype) and that uniform definitions of response be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accordingly, the NIH Consensus Development Conference on the Management of Hepatitis C suggested standard response definitions as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An end-of-treatment response (ETR) is defined as a normal serum ALT concentration (biochemical response) or the absence of detectable HCV RNA (virologic response) at the end of treatment and on another occasion at least one month earlier in the treatment.",
"     </li>",
"     <li>",
"      A sustained response (SR) is defined as a biochemical or virologic response at the end of treatment and throughout an observation period of at least six months following the discontinuation of interferon therapy. Although the length of follow-up varies in different studies, patients who have a persistently normal serum ALT with undetectable HCV RNA for at least six months are unlikely to relapse with longer follow-up.",
"     </li>",
"     <li>",
"      A histologic response has not been well defined since the time at which posttreatment liver biopsies have been performed has varied from study to study. Regardless of when the posttreatment liver biopsy is obtained, it is compared to a pretreatment biopsy obtained within the 12 months before treatment. Most studies have defined histologic response as a two-point or greater reduction in the histology activity index score (Knodell histological score for inflammatory components only) (",
"      <a class=\"graphic graphic_table graphicRef56831 \" href=\"mobipreview.htm?5/34/5677\">",
"       table 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Interferon alfa-2b",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of clinical trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    in chronic HCV infection examined 20 studies comparing interferon to placebo, and 12 studies comparing different doses, durations, or treatment strategies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/12\">",
"     12",
"    </a>",
"    ]. The following benefits were noted in patients treated with interferon alfa-2b compared with controls who were either untreated or received a placebo:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater likelihood of a biochemical ETR (47 versus 4 percent) that was more likely to be sustained for at least six months (23 versus 2 percent)",
"     </li>",
"     <li>",
"      A greater likelihood of a virologic ETR (29 versus 5 percent); a six-month virologic SR was uncommon in both groups (8 versus 1 percent)",
"     </li>",
"     <li>",
"      A greater likelihood of a histologic response (73 versus 38 percent), although only four studies had histologic data that could be evaluated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A treatment course of at least 12 months reduces relapse and increases the SR compared with six-month regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The first study to show that a longer duration of treatment increased the durability of the initial response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    evaluated 303 patients, all of whom were treated for six months at a standard dose of 3 MU of interferon alfa-2b three times each week [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/13\">",
"     13",
"    </a>",
"    ]. At the end of six months, patients were assigned to the same treatment for an additional 12 months (group 1), dose reduction to 1 MU three times each week for an additional 12 months (group 2), or no further treatment (group 3). The following results were observed with the longer duration of treatment (group 1):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A greater likelihood of a biochemical ETR at 18 months (45 versus 27 and 30 percent in groups 2 and 3, respectively)",
"     </li>",
"     <li>",
"      A greater likelihood of a biochemical SR (22 versus 10 and 8 percent)",
"     </li>",
"     <li>",
"      A greater likelihood of improved liver histology (70 versus 48 and 39 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above results have been confirmed by others and reviewed in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/12\">",
"     12",
"    </a>",
"    ]. These studies have all demonstrated that extending the duration of interferon treatment for an additional 12 to 24 months does not increase ETR, but reduces relapse in those initial responders when compared with only six months of treatment (27 versus 14 percent). Thus, treatment for at least 12 months is now considered the standard of care for patients who respond to interferon within the first 12 weeks of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Interferon alfa-2a",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alfa-2a has similar effects as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    in the treatment of chronic HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/14\">",
"     14",
"    </a>",
"    ]. Studies have included the evaluation of fixed dose regimens for varying lengths of time, escalating dose regimens, and deescalating dose regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Fixed doses of 3 MU of interferon alfa-2a three times weekly for at least six months demonstrated biochemical ETR rates of 15 to 70 percent, although studies outside of Italy all had biochemical ETRs of 33 percent or less. Biochemical SRs in these latter studies ranged from 4 percent for a six-month course to 12 percent for a 12-month course. Doses lower than 3 MU were not effective.",
"   </p>",
"   <p>",
"    Doses of 4.5 to 6 MU three times per week had biochemical ETR rates similar to those previously reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    . However, there is no published head-to-head comparison of interferon alfa-2a and alfa-2b at their approved doses.",
"   </p>",
"   <p>",
"    Several studies have suggested that initiating interferon alfa-2a at a higher dose (6 MU) for one to six months and then decreasing to 3 MU three times weekly increases the biochemical ETR and SR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/14\">",
"     14",
"    </a>",
"    ]. This regimen may be of particular benefit in patients with genotype 1b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/16\">",
"     16",
"    </a>",
"    ]. An escalating dose regimen has also been evaluated in several reports that have not demonstrated a consistent benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Interferon alfacon-1 (consensus interferon)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized controlled study of 704 patients with chronic HCV infection compared treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/15/24822?source=see_link\">",
"     interferon alfacon-1",
"    </a>",
"    (9 mcg subcutaneously three times weekly for 24 weeks) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    (3 MU subcutaneously three times weekly for 24 weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. The sustained virological response (SVR) rates were similar (12 versus 11 percent).",
"   </p>",
"   <p>",
"    Preliminary data suggested a potential role of consensus interferon combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in patients who failed to respond to standard interferon plus ribavirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/19,20\">",
"     19,20",
"    </a>",
"    ] and provided the rationale for a multicenter randomized controlled trial. The study (referred to as the DIRECT trial) evaluated two doses of daily therapy with consensus interferon (9 or 15 mcg daily) plus ribavirin in 487 patients who failed to respond to peginterferon plus ribavirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/21\">",
"     21",
"    </a>",
"    ]. On intention-to-treat analysis, the SVR was only 11 percent in the group assigned to receive the most effective dose (15 mcg daily). On post-hoc analyses, SVR rates were higher among patients who had achieved more than 2 log(10) decrease of HCV RNA during previous peginterferon and ribavirin treatment (23 percent in the 15 mcg group). The highest rate of SVR (32 percent) was seen in patients who had lower baseline fibrosis scores (F0 to F3) and had achieved more than a 2 log(10) decrease in HCV RNA while on previous peginterferon and ribavirin treatment and were treated with the 15 mcg dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Interferon alfa-n1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two reviews of trials of interferon alfa-n1 in patients with chronic HCV infection showed that it had similar efficacy to the recombinant interferons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Studies comparing six-month courses of interferon alfa-n1 to either interferon alfa-2a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/24\">",
"     24",
"    </a>",
"    ] or alfa-2b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/5\">",
"     5",
"    </a>",
"    ] showed the ETR to be nearly identical, although the sustained response may be improved with interferon alfa-n1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/5\">",
"     5",
"    </a>",
"    ]. Similar to the other interferons, 12 months of therapy with interferon alfa-n1 is superior to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/25\">",
"     25",
"    </a>",
"    ]. The drug is not used commonly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     LONG-TERM EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sustained response in most of the above reports was typically in the 6- to 12-month range. The virological response in such patients appears to be durable after long-term follow-up and is accompanied by continued histologic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/26-33\">",
"     26-33",
"    </a>",
"    ]. An illustrative study included 150 patients who achieved a sustained virologic response to interferon-based therapy and were followed for at least five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No patient developed a virologic relapse.",
"     </li>",
"     <li>",
"      In 49 patients who had a follow-up biopsy, 82 percent had improvement in fibrosis and 92 percent had improvement in at least one component of inflammation. However, only a minority had normal liver histology.",
"     </li>",
"     <li>",
"      Two patients who had pretreatment cirrhosis developed hepatocellular cancer, suggesting that a sustained virologic response does not fully protect against progression, a conclusion also reached in other reports (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     HUMAN IMMUNODEFICIENCY VIRUS COINFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with treatment of HIV and HCV coinfected patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=see_link\">",
"     \"Evaluation of the HIV-infected patient with chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PREVENTION OF HEPATOCELLULAR CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have demonstrated that a sustained virologic response to interferon is associated with a reduced risk of developing hepatocellular carcinoma (HCC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]. As an example, in a study of 1022 patients with chronic HCV infection, the seven-year cumulative incidences of hepatocellular carcinoma in sustained, transient, and nonresponders were estimated to be 4.3, 4.7, and 26.1 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients who develop HCC despite a sustained virologic response tend to be older, male, and more often have advanced-stage histologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/42\">",
"     42",
"    </a>",
"    ]. One study suggested that such patients should be followed carefully for &gt;10 years after completing interferon therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Interferon may also be protective in responders who already have compensated cirrhosis at the onset of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In one study, 21 of 232 patients (9.1 percent) with chronic HCV infection and Child's class A cirrhosis (",
"    <a class=\"graphic graphic_table graphicRef78401 \" href=\"mobipreview.htm?8/21/8540\">",
"     table 2",
"    </a>",
"    ) who were treated with interferon alfa developed hepatocellular carcinoma during at least three years of follow-up; this value was approximately one-half that seen in 259 untreated patients (18.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/38\">",
"     38",
"    </a>",
"    ]. The benefit was greatest among patients who were not coinfected with hepatitis B.",
"   </p>",
"   <p>",
"    A meta-analysis of 20 studies (4 randomized controlled trials, 10 retrospective studies, and 6 prospective studies) with 4700 cirrhotic patients found that patients who received interferon therapy (with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) had a significantly lower risk of HCC compared with untreated patients (RR 0.43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/43\">",
"     43",
"    </a>",
"    ]. In that analysis, 14 studies with 2778 patients reported results based upon whether a sustained virologic response was achieved. The analysis found that patients who achieved a sustained virologic response had a significant reduction in the occurrence of HCC compared with nonresponders (RR 0.35) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/43\">",
"     43",
"    </a>",
"    ]. This reduction was greatest in patients who attained a sustained virologic response after treatment with both ribavirin and interferon (RR 0.25 compared with nonresponders).",
"   </p>",
"   <p>",
"    It remains uncertain whether interferon treatment can reduce the risk of developing hepatocellular carcinoma among patients who do not have a sustained response following treatment. The potential for this effect is supported by the observations that interferon may have a benefit on liver histology even among patients who do not have a sustained virologic or biochemical response, and that interferon may have an antiproliferative effect that is independent of its effect on viral replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/3,44-46\">",
"     3,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have demonstrated that the risk reduction associated with interferon is not confined to sustained responders, or (in studies that did not stratify patients by interferon response) that treatment with interferon was a protective factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/35,37,38,47,48\">",
"     35,37,38,47,48",
"    </a>",
"    ]. However, not all studies have confirmed these observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/49\">",
"     49",
"    </a>",
"    ], and a meta-analysis of four studies with 1152 nonresponders did not find a statistically significant decrease in the risk of HCC among nonresponders who were maintained on low-dose interferon compared with those who did not receive maintenance therapy (RR 0.58; 95% CI, 0.33-1.03) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35768/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects associated with interferon are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=see_link\">",
"     \"Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Multiple trials have evaluated various formulations of standard interferon in the treatment of chronic HCV. However, standard interferon has generally been supplanted by peginterferon plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      . Standard interferon may still have a role in settings where peginterferon is not available and is used in some countries for treatment of acute HCV. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"       \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"       \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Four types of alpha interferon have been evaluated in large clinical trials of patients with chronic HCV infection. There are differences in specific activities among the interferons. Treatment outcomes generally are thought to be similar with the different preparations, although the dose and duration of therapy may vary, and only a few of the interferons have been compared head-to-head at their approved regimens. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Types of interferon'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Health care providers should be aware that changes in interferon brand may require adjustments in dose",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a change in the route of administration. Pharmacists should not substitute interferon preparations without consultation with the prescribing clinician. Patients should be warned not to change brands of interferon without medical consultation.",
"     </li>",
"     <li>",
"      A number of studies have demonstrated that a sustained virologic response to interferon is associated with a reduced risk of developing hepatocellular carcinoma. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prevention of hepatocellular carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Lodish H, Baltimore D, Berk A, et al. Molecular cell biology. Scientific American Books, 3rd ed, Oxford Press, New York 1995. p.916.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/2\">",
"      Kirchner H. Interferons, a group of multiple lymphokines. Springer Semin Immunopathol 1984; 7:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/3\">",
"      Tilg H. New insights into the mechanisms of interferon alfa: an immunoregulatory and anti-inflammatory cytokine. Gastroenterology 1997; 112:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/4\">",
"      Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26:71S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/5\">",
"      Farrell GC, Bacon BR, Goldin RD. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study. Hepatology 1998; 27:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/6\">",
"      Camm&agrave; C, Giunta M, Pinzello G, et al. Chronic hepatitis C and interferon alpha: conventional and cumulative meta-analyses of randomized controlled trials. Am J Gastroenterol 1999; 94:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/7\">",
"      Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 1989; 321:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/8\">",
"      Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/9\">",
"      Niederau C, Heintges T, H&auml;ussinger D. Treatment of chronic hepatitis C with a-interferon: an analysis of the literature. Hepatogastroenterology 1996; 43:1544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/10\">",
"      Myers RP, Regimbeau C, Thevenot T, et al. Interferon for interferon naive patients with chronic hepatitis C. Cochrane Database Syst Rev 2002; :CD000370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/11\">",
"      Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/12\">",
"      Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26:83S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/13\">",
"      Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med 1995; 332:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/14\">",
"      Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology 1997; 26:89S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/15\">",
"      Ryff JC. Usefulness of interferon for treatment of hepatitis C. J Hepatol 1995; 22:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/16\">",
"      Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology 1995; 22:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/17\">",
"      Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/18\">",
"      Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology 1997; 26:101S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/19\">",
"      Kaiser S, Hass HG, Gregor M, et al. Successful retreatment of chronic hepatitis C patients with a nonresponse to standard interferon/ribavirin using daily consensus interferon and ribavirin (abstract). Hepatology 2004; 40 (Suppl):240A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/20\">",
"      Cornberg M, Hadem J, Herrmann E, et al. Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 2006; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/21\">",
"      Bacon BR, Shiffman ML, Mendes F, et al. Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology 2009; 49:1838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/22\">",
"      Bardelli F, Messori A, Rampazzo R, et al. Effect of recombinant or lymphoblastoid interferon-alfa on alanine aminotransferase in patients with chronic hepatitis C or chronic non-A non-B hepatitis. A meta-analysis. Clin Drug Invest 1995; 9:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/23\">",
"      Farrell GC. Therapy of hepatitis C: interferon alfa-n1 trials. Hepatology 1997; 26:96S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/24\">",
"      Rumi M, Del Ninno E, Parravicini ML, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology 1996; 24:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/25\">",
"      Benhamou JP, Hopf U, Rizzetto M, et al. A randomised, double-blind, controlled, multicentre trial of human lymphoblastoid interferon alpha in the treatment of adults with chronic hepatitis non-A, non-B (C). J Hepatol 1995; 21:173A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/26\">",
"      Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med 1997; 127:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/27\">",
"      Reichard O, Glaumann H, Fryd&eacute;n A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferon. J Hepatol 1999; 30:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/28\">",
"      Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferon-based anti-viral therapy. Aliment Pharmacol Ther 2006; 23:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/29\">",
"      Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/30\">",
"      Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/31\">",
"      Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/32\">",
"      Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/33\">",
"      George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/34\">",
"      Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998; 129:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/35\">",
"      Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27:1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/36\">",
"      Bruno S, Borzio M, Battezzati PM. Interferon-alpha in chronic hepatitis C. Ann Intern Med 1998; 128:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/37\">",
"      Serfaty L, Auma&icirc;tre H, Chazouill&egrave;res O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27:1435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/38\">",
"      Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. International Interferon-alpha Hepatocellular Carcinoma Study Group. Lancet 1998; 351:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/39\">",
"      Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999; 30:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/40\">",
"      Camm&agrave; C, Giunta M, Andreone P, Crax&igrave; A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 34:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/41\">",
"      Imazeki F, Yokosuka O, Fukai K, Saisho H. Favorable prognosis of chronic hepatitis C after interferon therapy by long-term cohort study. Hepatology 2003; 38:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/42\">",
"      Makiyama A, Itoh Y, Kasahara A, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004; 101:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/43\">",
"      Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/44\">",
"      Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/45\">",
"      Bonis PA, Ioannidis JP, Cappelleri JC, et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997; 26:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/46\">",
"      Yano H, Iemura A, Haramaki M, et al. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999; 29:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/47\">",
"      Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999; 131:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/48\">",
"      Shiratori Y, Ito Y, Yokosuka O, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005; 142:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35768/abstract/49\">",
"      Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112:463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3671 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-DEDEA7E9BD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35768=[""].join("\n");
var outline_f34_59_35768=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Interferon alfa-2b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Interferon alfa-2a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Interferon alfacon-1 (consensus interferon)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Interferon alfa-n1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      LONG-TERM EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HUMAN IMMUNODEFICIENCY VIRUS COINFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PREVENTION OF HEPATOCELLULAR CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3671\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3671|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?5/34/5677\" title=\"table 1\">",
"      Knodell score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/21/8540\" title=\"table 2\">",
"      Child Pugh classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/36/11848?source=related_link\">",
"      Evaluation of the HIV-infected patient with chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/8/15498?source=related_link\">",
"      Extrahepatic manifestations of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/9/16538?source=related_link\">",
"      Management of the side effects of peginterferon and ribavirin being used for treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_59_35769="Overview of hyperkyphosis in older persons";
var content_f34_59_35769=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of hyperkyphosis in older persons",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35769/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35769/contributors\">",
"     Deborah M Kado, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35769/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35769/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35769/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35769/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/59/35769/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkyphosis is excessive curvature of the thoracic spine, commonly known as the \"dowager's hump.\" Although it is also referred to as kyphosis, the term kyphosis is meant to describe the sagittal convexity, or forward curvature, of the normal thoracic spine which can range from normal to abnormal. Kyphosis tends to progress with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and treatment of hyperkyphosis is challenging due to the lack of standardized diagnostic criteria and evidence-based treatment options. Within the last several years, exercise programs, spinal orthotics, and other interventions have been studied that may help delay the progression of age-related kyphosis. However, stronger evidence of efficacy with improved clinical outcomes is needed prior to widespread use of many of these interventions.",
"   </p>",
"   <p>",
"    This topic will focus on the etiology, evaluation, and management of hyperkyphosis in older adults. Hyperkyphosis in children and adolescents is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=see_link\">",
"     \"Back pain in children and adolescents: Overview of causes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no widely-accepted definition of hyperkyphosis, and therefore the prevalence of hyperkyphosis in older persons is not precisely known. However, current estimates range between 20 and 40 percent among community-dwelling subjects aged &ge;60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of hyperkyphosis increases with age, with the greatest change in the angle of kyphosis occurring among women age 50 to 59 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vertebral bodies and intervertebral discs are the major anatomical structures that contribute to spinal contour (",
"    <a class=\"graphic graphic_figure graphicRef65574 \" href=\"mobipreview.htm?15/29/15826\">",
"     figure 1",
"    </a>",
"    ). Thus, any process that affects either supporting structure can lead to hyperkyphosis. Deformities that result in anterior wedge shaped vertebra will accentuate the angle of kyphosis. As with other age-related conditions, hyperkyphosis occurs as a result of multiple contributing factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vertebral fractures",
"      </strong>",
"      &mdash; Vertebral bodies account for the majority of height in the spinal column, and it is commonly believed that age-associated hyperkyphosis mainly results from vertebral fractures. Patients with vertebral fractures have worse kyphosis compared to those without vertebral fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/6-8\">",
"       6-8",
"      </a>",
"      ]. However, only 36 to 38 percent of older persons with the worst degrees of kyphosis have underlying vertebral fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/6,9\">",
"       6,9",
"      </a>",
"      ]. Nonetheless, large observational studies report that with each vertebral fracture, kyphosis increases by about 3.7 to 3.8 degrees [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/10,11\">",
"       10,11",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is important for the clinician to note that, unlike limb fractures, vertebral fractures represent a continuum of deformity. There is no set cut-point that distinguishes a vertebral fracture from another deformity that is not due to osteoporosis. In fact, achieving an acceptable level of radiologic agreement in defining a vertebral fracture is challenging. Vertebral compression fractures are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=see_link\">",
"       \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Short vertebral height",
"      </strong>",
"      &mdash; There are other causes of vertebral deformity, not due to fractures or osteoporosis, that are collectively called \"non-fracture\" deformities. These deformities may be the result of developmental abnormalities with or without degenerative changes. The most common type of developmental hyperkyphosis is Scheuermann's disease, which is an inherited kyphotic deformity of the spine that usually occurs in early adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/12-14\">",
"       12-14",
"      </a>",
"      ]. As Scheuermann's disease has an estimated population prevalence of 8.3 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/15\">",
"       15",
"      </a>",
"      ], it cannot account for the large prevalence of age-associated hyperkyphosis seen in older adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=see_link&amp;anchor=H9#H9\">",
"       \"Back pain in children and adolescents: Overview of causes\", section on 'Scheuermann (juvenile) kyphosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Degenerative disc disease",
"      </strong>",
"      &mdash; In the thoracic spine, the intervertebral discs range in size between 1 and 2 centimeters in thickness. However, with age, the discs can desiccate, lose height, and anterior wedging may occur. There is a significant association between degenerative disc disease and degree of kyphosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/6,11,16\">",
"       6,11,16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Postural changes",
"      </strong>",
"      &mdash; The postural configuration of the cervical, lumbar, and sacral spinal areas may also influence thoracic curvature. Subjects with thoracic hyperkyphosis are more likely to have cervical or lumbar lordosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Postural flexibility, which decreases with age, also likely contributes to hyperkyphosis. Compared to younger women, women age 66 years and older had greater flexicurve kyphosis and were less able to actively correct their usual relaxed posture to an erect position [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Muscle weakness",
"      </strong>",
"      &mdash; It is unclear whether hyperkyphosis precedes or results from muscle weakness. Most [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/20-26\">",
"       20-26",
"      </a>",
"      ], but not all [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/27-29\">",
"       27-29",
"      </a>",
"      ], studies report an inverse correlation between muscle strength and hyperkyphosis. In one study of 189 women age 50 to 80 years, those with weaker back extensor muscles were more likely to have significantly greater kyphosis (58 versus 51 degrees by goniometer) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/20\">",
"       20",
"      </a>",
"      ]. Another large study of 1172 older men and women aged 70 to 79 years assessed spinal extensor muscle cross-sectional area and density via lateral scout computed tomography scans and found that lower spinal muscle density was associated with hyperkyphosis (defined as &gt;40 degrees) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Intervertebral ligaments",
"      </strong>",
"      &mdash; With aging, intervertebral ligaments that provide stability to the spine are susceptible to loss of elastic tissue, calcification, and ossification [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/31\">",
"       31",
"      </a>",
"      ]. In theory, any of these changes might predispose an aging individual to hyperkyphosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Genetic/metabolic",
"       </strong>",
"      </span>",
"      conditions",
"      &mdash; Early onset hyperkyphosis is often observed in inherited genetic conditions including osteogenesis imperfecta, Ehlers Danlos Syndrome, Marfan syndrome, cystic fibrosis, mucopolysaccharidoses, spondylo-epiphyseal dysplasia, and Scheuermann's disease.",
"      <br/>",
"      <br/>",
"      Age-associated hyperkyphosis is most likely a complex inherited trait. In a population-based cohort, investigators found that those who reported a family history of dowager's hump were more likely to have greater kyphosis, independent of a family history of osteoporosis, bone mineral density, or vertebral fractures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Mouse knock-out and transgenic models suggest that hyperkyphosis may be a common physiologic phenotype that results from mutations involving genes important for DNA repair and delaying senescence. These knock-out mice develop early senescence and often suffer from pronounced hyperkyphosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/34-37\">",
"       34-37",
"      </a>",
"      ]. In humans, it is commonly believed that poor posture can worsen kyphosis, but kyphotic mice demonstrate that gravitational forces may play a minor role in the development of hyperkyphosis, as mice spend their lives in a prone position.",
"     </li>",
"     <li>",
"      <strong>",
"       Other causes",
"      </strong>",
"      &mdash; Other causes of hyperkyphosis that arise in childhood include congenital kyphosis and neurofibromatosis. Later-onset causes can include spondylolisthesis, ankylosing spondylitis, spinal tuberculosis, post laminectomy syndrome, and inappropriate surgical procedures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ASSOCIATED HEALTH CONSEQUENCES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The health conditions associated with hyperkyphosis are varied. The most important conditions include impairment of lung function, decreased functional capacity, and increased mortality.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Impaired pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have shown that increasing kyphosis leads to modest, but predictable, declines in forced vital capacity, as well as other measures of pulmonary function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/38-42\">",
"     38-42",
"    </a>",
"    ]. In a study of 323 community-dwelling adults age 65 and older, those with hyperkyphosis were more likely to have restrictive ventilatory dysfunction (OR 2.3, 95% CI 1.1-4.8), obstructive ventilatory dysfunction (OR 3.3, CI 1.7-6.5), and self-reported dyspnea (OR 2.5, CI 1.1-5.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/43\">",
"     43",
"    </a>",
"    ]. Another study of 56 patients found that, in addition to worse forced vital capacity and forced expiratory volume, those with a kyphotic angle &ge;40 degrees had worse duration of exercise than those patients with &lt;40 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=see_link&amp;anchor=H22#H22\">",
"     \"Diseases of the chest wall\", section on 'Kyphoscoliosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diminished physical function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple observational studies suggest that hyperkyphosis is associated with poor physical function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/3,21-23,25,27,28,45-51\">",
"     3,21-23,25,27,28,45-51",
"    </a>",
"    ]. In studies that have examined muscle strength directly, most have demonstrated a significant negative correlation between kyphosis and back extensor strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/20,22,23,27\">",
"     20,22,23,27",
"    </a>",
"    ] or grip strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/49\">",
"     49",
"    </a>",
"    ]. Hyperkyphosis is also associated with worse physical performance functional measurements, including walking speed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/3,47,48,50\">",
"     3,47,48,50",
"    </a>",
"    ], the timed get up and go test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/48,51\">",
"     48,51",
"    </a>",
"    ], and the standing from a chair test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. Problems with daily functioning such as dressing oneself, cooking, and bathing have also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/45-47,49\">",
"     45-47,49",
"    </a>",
"    ]. One prospective study of kyphosis and mobility changes over a mean of 4.4 years reported that women who suffered from increasing kyphosis were more likely to decline in the timed get up and go test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Falls",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been hypothesized that hyperkyphosis fundamentally alters balance, thus increasing fall risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/23,53,54\">",
"     23,53,54",
"    </a>",
"    ]. However, among 22 women with osteoporosis, there was no association between kyphosis and balance measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/55\">",
"     55",
"    </a>",
"    ]. Similarly, in 151 older men and women there was no association between kyphosis and postural sway [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/24\">",
"     24",
"    </a>",
"    ]. The association between kyphosis and falls, if present, appears to be minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/56-59\">",
"     56-59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Increased fractures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkyphosis is associated with thoracic vertebral fractures, and it is presumed that the fracture leads to hyperkyphosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/7,60-62\">",
"     7,60-62",
"    </a>",
"    ]. However, with forward bent posture, changes in gravitational loads may increase the risk of sustaining a spinal or other osteoporotic fracture (through gait instability and falls).",
"   </p>",
"   <p>",
"    In prospective cohort and case-control studies in older women, hyperkyphosis was associated with increased risk of fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. As an example, in a study of 596 older women followed prospectively over four years, women with hyperkyphosis were at increased risk for future fracture (OR 1.7, 95% CI 1.0 -3.0 compared to those without hyperkyphosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/65\">",
"     65",
"    </a>",
"    ]. As this association was adjusted for age, bone mineral density, and prior fracture, the increased fracture risk was likely independent of osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other health-related consequences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Age-related hyperkyphosis may be associated with other adverse health effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain symptoms, particularly back pain, is associated with hyperkyphosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/7,45,66\">",
"       7,45,66",
"      </a>",
"      ]. In addition, there are many case reports of associations between hyperkyphosis and insufficiency fractures of the sternum where patients tend to present with chest pain that is at first confused with that of acute myocardial infarction or pulmonary embolism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/67,68\">",
"       67,68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multiple gastrointestinal problems including dysphagia, reflux esophagitis, hiatal hernia, Barrett&rsquo;s esophagus, and intrathoracic stomach have been associated with hyperkyphosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/69-73\">",
"       69-73",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The risk of pelvic prolapse may increase with greater kyphosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/74,75\">",
"       74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In one study examining osteoporosis and quality of life, patients with osteoporosis and self-reported postural changes had increased physical difficulty, made more adaptations to daily life, and had more fears about their future [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/76\">",
"       76",
"      </a>",
"      ]. Women with postural changes and no osteoporosis had significantly more physical difficulty and lifestyle adaptations than those with a prior fracture and no postural changes, demonstrating that the ill effects of hyperkyphosis are not necessarily due to underlying fractures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Increased mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperkyphosis is associated with increased mortality in older men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/2,9,60,77\">",
"     2,9,60,77",
"    </a>",
"    ]. Until recently, most have assumed that the degree of hyperkyphosis simply represents the severity of underlying vertebral fractures. However, in a prospective cohort of 610 women, each standard deviation increase in kyphosis was associated with an increased risk of all-cause mortality (RR 1.15, 95% CI 1.01-1.30) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/77\">",
"     77",
"    </a>",
"    ]. This association was adjusted for age, bone mineral density, and prior vertebral fracture, suggesting that low bone density and underlying vertebral fractures were not the only causes for the increased mortality risk. However, this study further showed that women with both hyperkyphosis and vertebral fracture were at the greatest risk of earlier mortality compared to women with either hyperkyphosis or vertebral fracture alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike other geriatric syndromes, such as osteoporosis and incontinence, the hyperkyphotic phenotype is immediately obvious from appearance, making observation an important clinical tool (",
"    <a class=\"graphic graphic_picture graphicRef53742 \" href=\"mobipreview.htm?29/39/30323\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most primary care clinicians do not have experience assessing the clinical and radiologic tests described in this section. Thus, it is reasonable to refer patients to a clinician with experience in treating hyperkyphosis (eg, physiatrist, rheumatologist, orthopedic surgeon) once hyperkyphosis is suspected on history",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    physical examination. As kyphosis is clinically apparent early in the disease process and likely takes years to progress, early recognition and treatment may help improve the health and quality of life of a substantial portion of the older population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Measuring kyphosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If hyperkyphosis is suspected, objective measurement of kyphosis should be performed to diagnose and determine severity of hyperkyphosis.",
"   </p>",
"   <p>",
"    In the sagittal plane, the normal spine contains three curves: the cervical region that is convex anteriorly, or lordotic; the thoracic region that is concave anteriorly, or kyphotic; and the lumbar region that is convex anteriorly, also lordotic (",
"    <a class=\"graphic graphic_figure graphicRef65574 \" href=\"mobipreview.htm?15/29/15826\">",
"     figure 1",
"    </a>",
"    ). The degree of kyphosis can be measured clinically or radiographically.",
"   </p>",
"   <p>",
"    Clinical methods use devices such as the flexicurve ruler [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/1\">",
"     1",
"    </a>",
"    ], goniometer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/20\">",
"     20",
"    </a>",
"    ], inclinometer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/57\">",
"     57",
"    </a>",
"    ], or Debrunner kyphometer (in which a protractor is applied to the upper back) (",
"    <a class=\"graphic graphic_picture graphicRef63165 \" href=\"mobipreview.htm?8/61/9168\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/78\">",
"     78",
"    </a>",
"    ]. Other clinical measures of kyphosis include: the distance from the occiput-to-wall [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/79\">",
"     79",
"    </a>",
"    ], the number of 1.7 cm blocks between the head and exam table while lying flat with the neck in a neutral position (",
"    <a class=\"graphic graphic_figure graphicRef66018 \" href=\"mobipreview.htm?0/42/675\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/2\">",
"     2",
"    </a>",
"    ], and qualitative visual measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The radiologic methods generally use lateral spine radiographs with either manual or computer-assisted calculation of an angle of curvature, termed the Cobb angle. The Cobb angle is measured by drawing perpendicular lines from two lines: (1) a line from the upper border of the vertebral body marking the beginning of the thoracic curve (commonly T4); and (2) a line from the inferior border of the vertebral body representing the interface between the thoracic-lumbar curves (commonly T12). The Cobb angle is then calculated as the angle of intersection of these perpendicular lines (",
"    <a class=\"graphic graphic_figure graphicRef61923 \" href=\"mobipreview.htm?2/35/2611\">",
"     figure 3",
"    </a>",
"    ). Although the Cobb angle was first developed to assess scoliosis angles on spinal radiographs, it was later modified to measure kyphosis and is currently considered by some to be the gold standard of kyphosis measurement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have evaluated some of the more commonly used kyphosis measurements and report similar reliability and validity (intra- and inter-rater reliabilities range from 0.90 to 0.98 between the Debrunner kyphometer, flexicurve kyphosis index, and radiographic Cobb angle measurements) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/10,78,81\">",
"     10,78,81",
"    </a>",
"    ]. The Spinal Mouse, a skin-surface device for measuring spinal curvature, has been gaining usage in clinical research studies because of its non-invasive nature. It has demonstrated acceptable intra- and inter-rater reliability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/82\">",
"     82",
"    </a>",
"    ]. However, measurement validity in assessing thoracic kyphosis has not been established, and there was poor validity in assessing frontal curvatures when compared to standard radiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Defining hyperkyphosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Defining hyperkyphosis is challenging as there are no standardized, age-adjusted reference ranges to distinguish between hyperkyphosis and normal age-related kyphosis.",
"   </p>",
"   <p>",
"    Defining hyperkyphosis is further complicated by the fact that the degree of kyphosis progression varies based upon comorbidities. For example, in a longitudinal study of healthy men and women age &ge;50 years, the mean age-related increase in the thoracic angle was 2.8 degrees after 12 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/84\">",
"     84",
"    </a>",
"    ]. In contrast, in a longitudinal study of postmenopausal women following vertebral fracture, there was a mean increase of 5.6 degrees after only three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In younger persons, normal kyphosis angles range between 20 and 50 degrees [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. In older adults, the mean kyphotic angle is 48 to 50 degrees in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/6,7,61\">",
"     6,7,61",
"    </a>",
"    ], 44 degrees in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/6\">",
"     6",
"    </a>",
"    ], and continues to increase with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/1,6,17,62,85,87-95\">",
"     1,6,17,62,85,87-95",
"    </a>",
"    ]. While there are no widely accepted thresholds for defining hyperkyphosis and many studies use different measurement techniques, several studies have used the cut-off of &ge;40 degrees in older adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/44,96,97\">",
"     44,96,97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are ongoing large prospective cohort studies that may provide important longitudinal data to better define hyperkyphosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Assessing other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;If clinical parameters are used to measure kyphosis, a plain spine radiograph should be performed to rule out underlying osteoporotic vertebral fractures.",
"   </p>",
"   <p>",
"    Ideally, a musculoskeletal radiologist should read the film since the interrater reading of vertebral fractures is rather poor, even among skilled radiologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/98\">",
"     98",
"    </a>",
"    ]. The radiologist should also assess for previously undiagnosed Scheuermann's disease, anterior wedge compression of the intervertebral discs, or other spinal pathologies.",
"   </p>",
"   <p>",
"    All patients with hyperkyphosis require an evaluation for osteoporosis. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=see_link\">",
"     \"Screening for osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=see_link\">",
"     \"Diagnosis and evaluation of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no standardized therapies or management guidelines for age-related hyperkyphosis. Most available treatments focus on the rehabilitation of postural abnormalities using exercise therapy. Other less commonly used treatments include spinal orthoses, postural taping, and pharmacologic therapy, as well as surgical approaches. Although randomized trial data are limited for the management of hyperkyphosis, we suggest exercise-based interventions as first-line treatment for hyperkyphosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Exercise-based interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the last several years, there have been many exercise intervention studies assessing effects on thoracic curvature.",
"   </p>",
"   <p>",
"    In some randomized trials, exercise improved spine extensor muscle strength [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/99\">",
"     99",
"    </a>",
"    ] and physical functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/100\">",
"     100",
"    </a>",
"    ], but other trials have not found benefit in kyphotic angle measurement. Representative studies include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a two-year randomized trial that evaluated the effect of back-strengthening exercises on posture in 60 postmenopausal women, there were no overall differences in either back strength or kyphosis between those randomly assigned to the exercise intervention and those randomly assigned to usual care [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/101\">",
"       101",
"      </a>",
"      ]. However, in a post-hoc pooled analysis, women with substantial kyphosis and the greatest increases in back extensor strength demonstrated a 2.8 degree decrease in kyphotic angle. While the exercise intervention was of adequate duration (two years), major limitations included its small size, non-blinded measurements, and post-hoc subgroup analyses.",
"     </li>",
"     <li>",
"      In the Yoga for Kyphosis Trial of 118 patients age 60 and older with a kyphosis angle of &ge;40 degrees, those randomly assigned to six months of yoga had no improvement in primary outcomes of Debrunner kyphometer-assessed kyphosis angle, physical performance, or quality of life scores compared to the control group [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In prospective cohort studies, exercise improved kyphosis angle measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/5,97,103,104\">",
"     5,97,103,104",
"    </a>",
"    ]. However, the degree of improvement is modest and may be measurement dependent. As an example, in a prospective cohort study of 21 women age 65 years or older with thoracic kyphosis &ge;50 degrees, participants in a 12 week multidimensional group exercise program had significant improvements in kyphosis (6 &plusmn; 3 degrees) and spinal extensor muscle strength (21 &plusmn; 13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/97\">",
"     97",
"    </a>",
"    ]. In addition to twice weekly flexibility, strengthening, and postural alignment exercises with a physical therapist, patients were also provided motivational interviewing and educational handouts.",
"   </p>",
"   <p>",
"    In a follow-up study of 19 of the original 21 participants re-evaluated after one year, these women maintained the improvement in kyphosis, suggesting that educational awareness and exercise training may have long-term beneficial effects in motivated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/103\">",
"     103",
"    </a>",
"    ]. Although this study was not randomized and did not include blinded assessments, it was a well-designed, pre- and post-intervention study with clearly reported outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Spinal orthosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a wide variety of flexible spinal orthoses (back braces) designed to improve posture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/105-107\">",
"     105-107",
"    </a>",
"    ]. In addition, spinal orthoses may facilitate stimulation of proprioception to improve unconscious muscle strengthening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a randomized trial of 62 patients with osteoporosis and an angle of kyphosis &ge;60 degrees, those randomly assigned to wearing a spinal orthosis for six months were found to have significantly improved back extensor strength (+189 versus +7 newtons), angle of kyphosis (-7.9 versus -1.6 degrees), and quality of life score (+10.4 versus -2.3 points) compared to those randomly assigned to not wearing the orthosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/105\">",
"     105",
"    </a>",
"    ]. The main limitation of this study was lack of blinding that could have biased the study results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Postural taping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal postural taping may also improve kyphosis. In a study of therapeutic postural taping, control taping, or no taping in 15 women over the age of 50 with vertebral fractures, kyphosis was measured before and after each of three testing conditions done in random order [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/109\">",
"     109",
"    </a>",
"    ]. Therapeutic tape significantly decreased kyphosis compared to control taping (5.2 versus 2.1, respectively). While 73 percent of the participants enjoyed immediate reduction in kyphosis, they did not demonstrate any significant changes in trunk muscle activity or balance parameters. It is unclear whether the immediate effects of therapeutic taping lead to longer-term beneficial effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Pharmacologic therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few data are available showing benefit of pharmacologic therapies in treating hyperkyphosis.",
"   </p>",
"   <p>",
"    In the Fracture Intervention Trial of 4432 postmenopausal women with low bone density, those randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    had reduced height loss compared to those randomly assigned to placebo (7.0 versus 8.5 mm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/110\">",
"     110",
"    </a>",
"    ]. However, in a secondary analysis of the Fracture Intervention Trial, there was no benefit of alendronate in delaying kyphosis progression over an average of 4.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study that combined results from two randomized trials reported that treatment with strontium ranelate decreased progression in kyphosis index over three years compared to placebo (3.7 versus 4.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/112\">",
"     112",
"    </a>",
"    ]. Kyphosis index was defined as the percentage ratio between the maximum depth of thoracic curvature and the height measured from the T4 to the T12 vertebrae. As the difference in kyphosis index progression was only 1 percent, the beneficial effect of strontium on delaying kyphosis progression, if present, is likely of minimal consequence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Surgical interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive surgical interventions for correcting hyperkyphosis are associated with high rates of perioperative complications (33 percent) and are not recommended unless patients develop intractable pain or disabling function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/113,114\">",
"     113,114",
"    </a>",
"    ]. Vertebroplasty and kyphoplasty, less invasive interventions, have also not demonstrated long-term benefits in relieving pain from VCF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/115-117\">",
"     115-117",
"    </a>",
"    ]. The clinical diagnosis and management of VCF are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=see_link\">",
"     \"Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Osteoporosis treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to treatment for hyperkyphosis, patients should also be offered treatment for osteoporosis, when present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=see_link\">",
"     \"Treatment of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise and maintaining good posture have been suggested as measures to prevent hyperkyphosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35769/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. However, there are no prospective studies or randomized trials evaluating the effects of preventive measures on kyphosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/62/29665?source=see_link\">",
"       \"Patient information: Kyphosis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperkyphosis is excessive curvature of the thoracic spine that tends to worsen with age. Since there is no widely-accepted definition of hyperkyphosis, the prevalence of hyperkyphosis in older persons is not precisely known. However, current estimates range between 20 to 40 percent among community-dwelling elders. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperkyphosis is associated with several adverse health conditions including thoracic pain, decreased pulmonary function, limited physical functioning, increased fractures, and increased mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Associated health consequences'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The degree of kyphosis can be measured clinically with devices such as a kyphometer or radiographically with plain film (",
"      <a class=\"graphic graphic_figure graphicRef65574 \" href=\"mobipreview.htm?15/29/15826\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63165 \" href=\"mobipreview.htm?8/61/9168\">",
"       picture 2",
"      </a>",
"      ). While there are no widely accepted thresholds for assessing hyperkyphosis, many clinicians consider &ge;40 degrees the defining cut-off for hyperkyphosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hyperkyphosis, we suggest using an exercise-based treatment program (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). There are few data showing consistent benefit of other treatment options, including spinal orthosis, postural taping, pharmacologic therapies, and surgery. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Management'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The exercise program should focus on postural alignment, as well as flexibility and strengthening of back extensor muscles. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Exercise-based interventions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/1\">",
"      Milne JS, Lauder IJ. Age effects in kyphosis and lordosis in adults. Ann Hum Biol 1974; 1:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/2\">",
"      Kado DM, Huang MH, Karlamangla AS, et al. Hyperkyphotic posture predicts mortality in older community-dwelling men and women: a prospective study. J Am Geriatr Soc 2004; 52:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/3\">",
"      Ryan SD, Fried LP. The impact of kyphosis on daily functioning. J Am Geriatr Soc 1997; 45:1479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/4\">",
"      Takahashi T, Ishida K, Hirose D, et al. Trunk deformity is associated with a reduction in outdoor activities of daily living and life satisfaction in community-dwelling older people. Osteoporos Int 2005; 16:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/5\">",
"      Ball JM, Cagle P, Johnson BE, et al. Spinal extension exercises prevent natural progression of kyphosis. Osteoporos Int 2009; 20:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/6\">",
"      Schneider DL, von M&uuml;hlen D, Barrett-Connor E, Sartoris DJ. Kyphosis does not equal vertebral fractures: the Rancho Bernardo study. J Rheumatol 2004; 31:747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/7\">",
"      Ensrud KE, Black DM, Harris F, et al. Correlates of kyphosis in older women. The Fracture Intervention Trial Research Group. J Am Geriatr Soc 1997; 45:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/8\">",
"      Lyles KW, Gold DT, Shipp KM, et al. Association of osteoporotic vertebral compression fractures with impaired functional status. Am J Med 1993; 94:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/9\">",
"      Kado DM, Browner WS, Palermo L, et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/10\">",
"      Siminoski K, Warshawski RS, Jen H, Lee KC. The accuracy of clinical kyphosis examination for detection of thoracic vertebral fractures: comparison of direct and indirect kyphosis measures. J Musculoskelet Neuronal Interact 2011; 11:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/11\">",
"      Kado DM, Huang MH, Karlamangla AS, et al. Factors associated with kyphosis progression in older women: 15 years' experience in the study of osteoporotic fractures. J Bone Miner Res 2013; 28:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/12\">",
"      McKenzie L, Sillence D. Familial Scheuermann disease: a genetic and linkage study. J Med Genet 1992; 29:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/13\">",
"      Axenovich TI, Zaidman AM, Zorkoltseva IV, et al. Segregation analysis of Scheuermann disease in ninety families from Siberia. Am J Med Genet 2001; 100:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/14\">",
"      Graat HC, van Rhijn LW, Schrander-Stumpel CT, van Ooij A. Classical Scheuermann disease in male monozygotic twins: further support for the genetic etiology hypothesis. Spine (Phila Pa 1976) 2002; 27:E485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/15\">",
"      Findlay A, Conner AN, Connor JM. Dominant inheritance of Scheuermann's juvenile kyphosis. J Med Genet 1989; 26:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/16\">",
"      Goh S, Price RI, Leedman PJ, Singer KP. The relative influence of vertebral body and intervertebral disc shape on thoracic kyphosis. Clin Biomech (Bristol, Avon) 1999; 14:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/17\">",
"      Boyle JJ, Milne N, Singer KP. Influence of age on cervicothoracic spinal curvature: an ex vivo radiographic survey. Clin Biomech (Bristol, Avon) 2002; 17:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/18\">",
"      Vialle R, Levassor N, Rillardon L, et al. Radiographic analysis of the sagittal alignment and balance of the spine in asymptomatic subjects. J Bone Joint Surg Am 2005; 87:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/19\">",
"      Hinman MR. Comparison of thoracic kyphosis and postural stiffness in younger and older women. Spine J 2004; 4:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/20\">",
"      Mika A, Unnithan VB, Mika P. Differences in thoracic kyphosis and in back muscle strength in women with bone loss due to osteoporosis. Spine (Phila Pa 1976) 2005; 30:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/21\">",
"      Sinaki M, Itoi E, Rogers JW, et al. Correlation of back extensor strength with thoracic kyphosis and lumbar lordosis in estrogen-deficient women. Am J Phys Med Rehabil 1996; 75:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/22\">",
"      Sinaki M, Wollan PC, Scott RW, Gelczer RK. Can strong back extensors prevent vertebral fractures in women with osteoporosis? Mayo Clin Proc 1996; 71:951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/23\">",
"      Sinaki M, Brey RH, Hughes CA, et al. Balance disorder and increased risk of falls in osteoporosis and kyphosis: significance of kyphotic posture and muscle strength. Osteoporos Int 2005; 16:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/24\">",
"      Brocklehurst JC, Robertson D, James-Groom P. Skeletal deformities in the elderly and their effect on postural sway. J Am Geriatr Soc 1982; 30:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/25\">",
"      Chow RK, Harrison JE. Relationship of kyphosis to physical fitness and bone mass on post-menopausal women. Am J Phys Med 1987; 66:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/26\">",
"      Granito RN, Aveiro MC, Renno AC, et al. Comparison of thoracic kyphosis degree, trunk muscle strength and joint position sense among healthy and osteoporotic elderly women: a cross-sectional preliminary study. Arch Gerontol Geriatr 2012; 54:e199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/27\">",
"      Miyakoshi N, Hongo M, Maekawa S, et al. Factors related to spinal mobility in patients with postmenopausal osteoporosis. Osteoporos Int 2005; 16:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/28\">",
"      Eagan MS, Sedlock DA. Kyphosis in active and sedentary postmenopausal women. Med Sci Sports Exerc 2001; 33:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/29\">",
"      Hongo M, Miyakoshi N, Shimada Y, Sinaki M. Association of spinal curve deformity and back extensor strength in elderly women with osteoporosis in Japan and the United States. Osteoporos Int 2012; 23:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/30\">",
"      Katzman W, Cawthon P, Hicks GE, et al. Association of spinal muscle composition and prevalence of hyperkyphosis in healthy community-dwelling older men and women. J Gerontol A Biol Sci Med Sci 2012; 67:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/31\">",
"      Resnick D. Degenerative diseases of the vertebral column. Radiology 1985; 156:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/32\">",
"      Birnbaum K, Siebert CH, Hinkelmann J, et al. Correction of kyphotic deformity before and after transection of the anterior longitudinal ligament--a cadaver study. Arch Orthop Trauma Surg 2001; 121:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/33\">",
"      Kado, DM, Palermo, L. Is there evidence of heritability of hyperkyphosis in older women?. J Bone Miner Res 2005; 20:S231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/34\">",
"      Kuro-o M, Matsumura Y, Aizawa H, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature 1997; 390:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/35\">",
"      Vogel H, Lim DS, Karsenty G, et al. Deletion of Ku86 causes early onset of senescence in mice. Proc Natl Acad Sci U S A 1999; 96:10770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/36\">",
"      Tyner SD, Venkatachalam S, Choi J, et al. p53 mutant mice that display early ageing-associated phenotypes. Nature 2002; 415:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/37\">",
"      de Boer J, Andressoo JO, de Wit J, et al. Premature aging in mice deficient in DNA repair and transcription. Science 2002; 296:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/38\">",
"      Harrison RA, Siminoski K, Vethanayagam D, Majumdar SR. Osteoporosis-related kyphosis and impairments in pulmonary function: a systematic review. J Bone Miner Res 2007; 22:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/39\">",
"      Leech JA, Dulberg C, Kellie S, et al. Relationship of lung function to severity of osteoporosis in women. Am Rev Respir Dis 1990; 141:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/40\">",
"      Schlaich C, Minne HW, Bruckner T, et al. Reduced pulmonary function in patients with spinal osteoporotic fractures. Osteoporos Int 1998; 8:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/41\">",
"      Culham EG, Jimenez HA, King CE. Thoracic kyphosis, rib mobility, and lung volumes in normal women and women with osteoporosis. Spine (Phila Pa 1976) 1994; 19:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/42\">",
"      Lombardi I Jr, Oliveira LM, Mayer AF, et al. Evaluation of pulmonary function and quality of life in women with osteoporosis. Osteoporos Int 2005; 16:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/43\">",
"      Di Bari M, Chiarlone M, Matteuzzi D, et al. Thoracic kyphosis and ventilatory dysfunction in unselected older persons: an epidemiological study in Dicomano, Italy. J Am Geriatr Soc 2004; 52:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/44\">",
"      Ordu Gokkaya NK, Koseoglu F, Albayrak N. Reduced aerobic capacity in patients with severe osteoporosis: a cross sectional study. Eur J Phys Rehabil Med 2008; 44:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/45\">",
"      Ryan PJ, Blake G, Herd R, Fogelman I. A clinical profile of back pain and disability in patients with spinal osteoporosis. Bone 1994; 15:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/46\">",
"      Cortet B, Houvenagel E, Puisieux F, et al. Spinal curvatures and quality of life in women with vertebral fractures secondary to osteoporosis. Spine (Phila Pa 1976) 1999; 24:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/47\">",
"      Lombardi I Jr, Oliveira LM, Monteiro CR, et al. Evaluation of physical capacity and quality of life in osteoporotic women. Osteoporos Int 2004; 15:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/48\">",
"      Hirose D, Ishida K, Nagano Y, et al. Posture of the trunk in the sagittal plane is associated with gait in community-dwelling elderly population. Clin Biomech (Bristol, Avon) 2004; 19:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/49\">",
"      Kado DM, Huang MH, Barrett-Connor E, Greendale GA. Hyperkyphotic posture and poor physical functional ability in older community-dwelling men and women: the Rancho Bernardo study. J Gerontol A Biol Sci Med Sci 2005; 60:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/50\">",
"      Antonelli-Incalzi R, Pedone C, Cesari M, et al. Relationship between the occiput-wall distance and physical performance in the elderly: a cross sectional study. Aging Clin Exp Res 2007; 19:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/51\">",
"      Katzman WB, Vittinghoff E, Kado DM. Age-related hyperkyphosis, independent of spinal osteoporosis, is associated with impaired mobility in older community-dwelling women. Osteoporos Int 2011; 22:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/52\">",
"      Katzman WB, Vittinghoff E, Ensrud K, et al. Increasing kyphosis predicts worsening mobility in older community-dwelling women: a prospective cohort study. J Am Geriatr Soc 2011; 59:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/53\">",
"      Lynn SG, Sinaki M, Westerlind KC. Balance characteristics of persons with osteoporosis. Arch Phys Med Rehabil 1997; 78:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/54\">",
"      de Groot MH, van der Jagt-Willems HC, van Campen JP, et al. Testing postural control among various osteoporotic patient groups: a literature review. Geriatr Gerontol Int 2012; 12:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/55\">",
"      Greig AM, Bennell KL, Briggs AM, et al. Balance impairment is related to vertebral fracture rather than thoracic kyphosis in individuals with osteoporosis. Osteoporos Int 2007; 18:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/56\">",
"      Woodhull-McNeal AP. Changes in posture and balance with age. Aging (Milano) 1992; 4:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/57\">",
"      O'Brien K, Culham E, Pickles B. Balance and skeletal alignment in a group of elderly female fallers and nonfallers. J Gerontol A Biol Sci Med Sci 1997; 52:B221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/58\">",
"      Arnold CM, Busch AJ, Schachter CL, et al. The relationship of intrinsic fall risk factors to a recent history of falling in older women with osteoporosis. J Orthop Sports Phys Ther 2005; 35:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/59\">",
"      Kado DM, Huang MH, Nguyen CB, et al. Hyperkyphotic posture and risk of injurious falls in older persons: the Rancho Bernardo Study. J Gerontol A Biol Sci Med Sci 2007; 62:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/60\">",
"      Milne JS, Williamson J. A longitudinal study of kyphosis in older people. Age Ageing 1983; 12:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/61\">",
"      De Smet AA, Robinson RG, Johnson BE, Lukert BP. Spinal compression fractures in osteoporotic women: patterns and relationship to hyperkyphosis. Radiology 1988; 166:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/62\">",
"      Puche RC, Morosano M, Masoni A, et al. The natural history of kyphosis in postmenopausal women. Bone 1995; 17:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/63\">",
"      McGrother CW, Donaldson MM, Clayton D, et al. Evaluation of a hip fracture risk score for assessing elderly women: the Melton Osteoporotic Fracture (MOF) study. Osteoporos Int 2002; 13:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/64\">",
"      Porter RW, Johnson K, McCutchan JD. Wrist fracture, heel bone density and thoracic kyphosis: a case control study. Bone 1990; 11:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/65\">",
"      Huang MH, Barrett-Connor E, Greendale GA, Kado DM. Hyperkyphotic posture and risk of future osteoporotic fractures: the Rancho Bernardo study. J Bone Miner Res 2006; 21:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/66\">",
"      Ettinger B, Black DM, Palermo L, et al. Kyphosis in older women and its relation to back pain, disability and osteopenia: the study of osteoporotic fractures. Osteoporos Int 1994; 4:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/67\">",
"      Cooper KL. Insufficiency fractures of the sternum: a consequence of thoracic kyphosis? Radiology 1988; 167:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/68\">",
"      Klaase JM, Zimmerman KW, Veldhuis EF. Increased kyphosis by a combination of fractures of the sternum and thoracic spine. Eur Spine J 1998; 7:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/69\">",
"      Blechacz B, Gajic O. Images in clinical medicine. Severe kyphosis. N Engl J Med 2008; 358:e28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/70\">",
"      Kusano M, Hashizume K, Ehara Y, et al. Size of hiatus hernia correlates with severity of kyphosis, not with obesity, in elderly Japanese women. J Clin Gastroenterol 2008; 42:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/71\">",
"      Furukawa N, Iwakiri R, Koyama T, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol 1999; 34:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/72\">",
"      Polomsky M, Siddall KA, Salvador R, et al. Association of kyphosis and spinal skeletal abnormalities with intrathoracic stomach: a link toward understanding its pathogenesis. J Am Coll Surg 2009; 208:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/73\">",
"      Uno G, Amano Y, Yuki T, et al. Relationship between kyphosis and Barrett's esophagus in Japanese patients. Intern Med 2011; 50:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/74\">",
"      Lind LR, Lucente V, Kohn N. Thoracic kyphosis and the prevalence of advanced uterine prolapse. Obstet Gynecol 1996; 87:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/75\">",
"      Mattox TF, Lucente V, McIntyre P, et al. Abnormal spinal curvature and its relationship to pelvic organ prolapse. Am J Obstet Gynecol 2000; 183:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/76\">",
"      Martin AR, Sornay-Rendu E, Chandler JM, et al. The impact of osteoporosis on quality-of-life: the OFELY cohort. Bone 2002; 31:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/77\">",
"      Kado DM, Lui LY, Ensrud KE, et al. Hyperkyphosis predicts mortality independent of vertebral osteoporosis in older women. Ann Intern Med 2009; 150:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/78\">",
"      Lundon KM, Li AM, Bibershtein S. Interrater and intrarater reliability in the measurement of kyphosis in postmenopausal women with osteoporosis. Spine (Phila Pa 1976) 1998; 23:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/79\">",
"      Leidig-Bruckner G, Minne HW, Schlaich C, et al. Clinical grading of spinal osteoporosis: quality of life components and spinal deformity in women with chronic low back pain and women with vertebral osteoporosis. J Bone Miner Res 1997; 12:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/80\">",
"      Kado DM, Prenovost K, Crandall C. Narrative review: hyperkyphosis in older persons. Ann Intern Med 2007; 147:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/81\">",
"      Greendale GA, Nili NS, Huang MH, et al. The reliability and validity of three non-radiological measures of thoracic kyphosis and their relations to the standing radiological Cobb angle. Osteoporos Int 2011; 22:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/82\">",
"      Mannion AF, Knecht K, Balaban G, et al. A new skin-surface device for measuring the curvature and global and segmental ranges of motion of the spine: reliability of measurements and comparison with data reviewed from the literature. Eur Spine J 2004; 13:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/83\">",
"      Ripani M, Di Cesare A, Giombini A, et al. Spinal curvature: comparison of frontal measurements with the Spinal Mouse and radiographic assessment. J Sports Med Phys Fitness 2008; 48:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/84\">",
"      Kobayashi T, Atsuta Y, Matsuno T, Takeda N. A longitudinal study of congruent sagittal spinal alignment in an adult cohort. Spine (Phila Pa 1976) 2004; 29:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/85\">",
"      Cortet B, Roches E, Logier R, et al. Evaluation of spinal curvatures after a recent osteoporotic vertebral fracture. Joint Bone Spine 2002; 69:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/86\">",
"      Fon GT, Pitt MJ, Thies AC Jr. Thoracic kyphosis: range in normal subjects. AJR Am J Roentgenol 1980; 134:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/87\">",
"      Boseker EH, Moe JH, Winter RB, Koop SE. Determination of \"normal\" thoracic kyphosis: a roentgenographic study of 121 \"normal\" children. J Pediatr Orthop 2000; 20:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/88\">",
"      Manns RA, Haddaway MJ, McCall IW, et al. The relative contribution of disc and vertebral morphometry to the angle of kyphosis in asymptomatic subjects. Clin Radiol 1996; 51:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/89\">",
"      Sidhu LS, Singal P. Age changes in kyphosis and lordosis of Jat-Sikh and Bania females of Punjab (India) from 20 to 80 years. Anthropol Anz 1983; 41:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/90\">",
"      Singer KP, Jones TJ, Breidahl PD. A comparison of radiographic and computer-assisted measurements of thoracic and thoracolumbar sagittal curvature. Skeletal Radiol 1990; 19:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/91\">",
"      Schenkman M, Shipp KM, Chandler J, et al. Relationships between mobility of axial structures and physical performance. Phys Ther 1996; 76:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/92\">",
"      Korovessis PG, Stamatakis MV, Baikousis AG. Reciprocal angulation of vertebral bodies in the sagittal plane in an asymptomatic Greek population. Spine (Phila Pa 1976) 1998; 23:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/93\">",
"      T&uuml;z&uuml;n C, Yorulmaz I, Cinda�� A, Vatan S. Low back pain and posture. Clin Rheumatol 1999; 18:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/94\">",
"      Bartynski WS, Heller MT, Grahovac SZ, et al. Severe thoracic kyphosis in the older patient in the absence of vertebral fracture: association of extreme curve with age. AJNR Am J Neuroradiol 2005; 26:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/95\">",
"      Ostrowska B, Rozek-Mr&oacute;z K, Giemza C. Body posture in elderly, physically active males. Aging Male 2003; 6:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/96\">",
"      Greendale GA, McDivit A, Carpenter A, et al. Yoga for women with hyperkyphosis: results of a pilot study. Am J Public Health 2002; 92:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/97\">",
"      Katzman WB, Sellmeyer DE, Stewart AL, et al. Changes in flexed posture, musculoskeletal impairments, and physical performance after group exercise in community-dwelling older women. Arch Phys Med Rehabil 2007; 88:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/98\">",
"      Hedlund LR, Gallagher JC. Vertebral morphometry in diagnosis of spinal fractures. Bone Miner 1988; 5:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/99\">",
"      Benedetti MG, Berti L, Presti C, et al. Effects of an adapted physical activity program in a group of elderly subjects with flexed posture: clinical and instrumental assessment. J Neuroeng Rehabil 2008; 5:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/100\">",
"      Morey MC, Schenkman M, Studenski SA, et al. Spinal-flexibility-plus-aerobic versus aerobic-only training: effect of a randomized clinical trial on function in at-risk older adults. J Gerontol A Biol Sci Med Sci 1999; 54:M335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/101\">",
"      Itoi E, Sinaki M. Effect of back-strengthening exercise on posture in healthy women 49 to 65 years of age. Mayo Clin Proc 1994; 69:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/102\">",
"      Greendale GA, Huang MH, Karlamangla AS, et al. Yoga decreases kyphosis in senior women and men with adult-onset hyperkyphosis: results of a randomized controlled trial. J Am Geriatr Soc 2009; 57:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/103\">",
"      Pawlowsky SB, Hamel KA, Katzman WB. Stability of kyphosis, strength, and physical performance gains 1 year after a group exercise program in community-dwelling hyperkyphotic older women. Arch Phys Med Rehabil 2009; 90:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/104\">",
"      Renno, ACM GR, Driusso, P, Costa, D, Oishi, J. Effects of an exercise program on respiratory function, posture and on quality of life in osteoporotic women: a pilot study. Physiotherapy 2005; 91:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/105\">",
"      Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil 2004; 83:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/106\">",
"      Vogt L, H&uuml;bscher M, Brettmann K, et al. Postural correction by osteoporosis orthosis (Osteo-med): a randomized, placebo-controlled trial. Prosthet Orthot Int 2008; 32:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/107\">",
"      Pfeifer M, Kohlwey L, Begerow B, Minne HW. Effects of two newly developed spinal orthoses on trunk muscle strength, posture, and quality-of-life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil 2011; 90:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/108\">",
"      Sinaki M, Brey RH, Hughes CA, et al. Significant reduction in risk of falls and back pain in osteoporotic-kyphotic women through a Spinal Proprioceptive Extension Exercise Dynamic (SPEED) program. Mayo Clin Proc 2005; 80:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/109\">",
"      Greig AM, Bennell KL, Briggs AM, Hodges PW. Postural taping decreases thoracic kyphosis but does not influence trunk muscle electromyographic activity or balance in women with osteoporosis. Man Ther 2008; 13:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/110\">",
"      Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/111\">",
"      Kado, DM, Huan, MH, Barrett-Conner, E, et al. Does Alendronate Use Prevent Kyphosis Progression in Older Women? J Bone Miner Res 2008; 23:S209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/112\">",
"      Roux C, Fechtenbaum J, Kolta S, et al. Prospective assessment of thoracic kyphosis in postmenopausal women with osteoporosis. J Bone Miner Res 2010; 25:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/113\">",
"      Heary RF. Evaluation and treatment of adult spinal deformity. Invited submission from the Joint Section Meeting on Disorders of the Spine and Peripheral Nerves, March 2004. J Neurosurg Spine 2004; 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/114\">",
"      Finocchiaro FM, Nena U, Lo Scalzo V, Monterumici DA. Treatment of kyphotic deformities in adults: our experience. Eur Spine J 2012; 21 Suppl 1:S100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/115\">",
"      Buchbinder R, Osborne RH, Ebeling PR, et al. A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 2009; 361:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/116\">",
"      Kallmes DF, Comstock BA, Heagerty PJ, et al. A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 2009; 361:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/117\">",
"      Staples MP, Kallmes DF, Comstock BA, et al. Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis. BMJ 2011; 343:d3952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/118\">",
"      Preventing kyphosis. Reducing your risk of getting a hunched back. Mayo Clin Health Lett 2008; 26:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35769/abstract/119\">",
"      Standing tall. Exercises can help with the bad posture and osteoporosis that cause us to stoop and lose height as we get older. Harv Health Lett 2005; 31:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3008 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-57BF54AE18-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35769=[""].join("\n");
var outline_f34_59_35769=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ASSOCIATED HEALTH CONSEQUENCES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Impaired pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diminished physical function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Falls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Increased fractures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other health-related consequences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Increased mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Measuring kyphosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Defining hyperkyphosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Assessing other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Exercise-based interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Spinal orthosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Postural taping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Pharmacologic therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Surgical interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Osteoporosis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/3008\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3008|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/29/15826\" title=\"figure 1\">",
"      Vertebral column",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/42/675\" title=\"figure 2\">",
"      Blocks measurement kyphosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/35/2611\" title=\"figure 3\">",
"      Cobb angle measurement 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/3008|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/39/30323\" title=\"picture 1\">",
"      Hyperkyphosis patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/61/9168\" title=\"picture 2\">",
"      Debrunner kyphometer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/45/19162?source=related_link\">",
"      Back pain in children and adolescents: Overview of causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/7/14458?source=related_link\">",
"      Clinical manifestations and treatment of osteoporotic thoracolumbar vertebral compression fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/55/11128?source=related_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/62/29665?source=related_link\">",
"      Patient information: Kyphosis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/28/40393?source=related_link\">",
"      Screening for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/58/31657?source=related_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_59_35770="Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease";
var content_f34_59_35770=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hereditary primary motor sensory neuropathies, including Charcot-Marie-Tooth disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Robert P Cruse, DO",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Jeremy M Shefner, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/59/35770/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/59/35770/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hereditary peripheral neuropathies have been classified based upon clinical characteristics, mode of inheritance, electrophysiologic features, metabolic defect, and specific genetic markers. The primary hereditary neuropathies predominantly affect peripheral nerves and produce symptoms of peripheral nerve dysfunction.",
"   </p>",
"   <p>",
"    Historically, the primary hereditary neuropathies were designated by eponyms that had the connotation of specific clinical features (eg, Charcot-Marie-Tooth disease or Dejerine-Sottas disease). However, phenotypic variability resulted in substantial diagnostic confusion.",
"   </p>",
"   <p>",
"    The Dyck classification developed in the 1970s helped to define specific types based upon clinical and electrophysiologic features [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/1\">",
"     1",
"    </a>",
"    ]. Many of the primary hereditary neuropathies were divided into motor-sensory and sensory&ndash;autonomic neuropathies.",
"   </p>",
"   <p>",
"    The primary hereditary motor sensory neuropathies (HMSN) are reviewed here. The primary hereditary sensory autonomic neuropathies (HSAN), the neuropathies not included in this classification, and the disorders affecting both the central and peripheral nervous systems are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21895?source=see_link\">",
"     \"Overview of hereditary neuropathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary motor sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth (CMT) disease, is really a spectrum of disorders caused by a specific mutation in one of several myelin genes that result in defects in myelin structure, maintenance, and formation. Each gene locus serves a specific function in maintaining myelin integrity. Gene expression can be altered by intragenic mutation but also by \"gene dosage imbalance\" caused by DNA duplications or deletions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Duplication of the PMP22 gene causes CMT1A, the most common type of hereditary motor sensory neuropathy (~40 percent overall).",
"   </p>",
"   <p>",
"    The association of different mutations within the same gene with various clinical phenotypes is a common finding in this group of peripheral neuropathies. This variability suggests that these disorders represent a spectrum of related phenotypes caused by an underlying defect in peripheral nervous system myelination.",
"   </p>",
"   <p>",
"    Hereditary motor sensory neuropathy (Charcot-Marie-Tooth disease) has been classified as CMT types 1 through 7 and is genetically heterogeneous with more than 40",
"    <span class=\"nowrap\">",
"     genes/loci",
"    </span>",
"    identified to date. The major division comprises type 1 and type 2, which together are the most common hereditary peripheral neuropathies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/4\">",
"     4",
"    </a>",
"    ], with an estimated prevalence of 40 per 100,000. Common features include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits (",
"    <a class=\"graphic graphic_table graphicRef72688 graphicRef52711 \" href=\"mobipreview.htm?37/12/38094\">",
"     table 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HMSN/CMT 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMSN type 1, also known as Charcot-Marie-Tooth type 1 (CMT1) disease, is a demyelinating disorder of peripheral nerves. It has been subdivided on the basis of genetic markers into types 1A, 1B, and 1C, although the clinical manifestations are similar. Type 1A, due to duplication of the PMP22 gene, is the most common and accounts for approximately 70 to 80 percent of CMT1 cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/4\">",
"     4",
"    </a>",
"    ]. Affected patients typically present in the first or early second decade, but infants may be symptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early complaints may include frequent sprained ankles caused by distal muscle weakness or difficulty running and keeping up with peers. The only obvious physical findings may be loss of reflexes, pes cavus foot deformity, and hammer toes.",
"     </li>",
"     <li>",
"      Distal calf muscle atrophy often occurs, causing the classic \"stork leg deformity.\" Walking is clumsy because of both muscle weakness and sensory loss. Sensory loss is gradual and mainly involves proprioception and vibration.",
"     </li>",
"     <li>",
"      Later changes include atrophy of the intrinsic hand and foot muscles. Palpable enlargement of the peripheral nerves may occur secondary to nerve hypertrophy. In addition, kyphosis or scoliosis often develops.",
"     </li>",
"     <li>",
"      Ambulation is variable but usually is maintained through life. Life expectancy is not affected.",
"     </li>",
"     <li>",
"      Disease exacerbation can occur in pregnancy, an effect that may be mediated by increased plasma progesterone&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H781703\">",
"       'Management'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the typical findings discussed above, patients with type 1A HMSN may have associated sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. In one report, 13 asymptomatic family members of an index patient with CMT and sleep apnea were investigated for these disorders. Eleven of the 14 (including the index patient) had PMP22 duplication on chromosome 17; all 11 also had sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nerve conduction studies (NCS) show severe slowing of conduction velocity in both the motor and sensory nerves to less than 60 percent of normal. Slowing is present even in infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/9\">",
"     9",
"    </a>",
"    ]. Frequently, little correlation exists between the electromyographic and clinical findings, as the latter are probably produced primarily by axonal degeneration or loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sural nerve biopsy shows demyelination that affects primarily the large nerve fibers. Onion bulbs are a characteristic feature; they reflect repeated demyelination and remyelination and represent redundant Schwann cells, collagen, and fibroblasts. Secondary axonal changes are present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Genetics of CMT1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 disease is caused by mutations in genes that are expressed in Schwann cells, the myelinating cells of the peripheral nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/3\">",
"     3",
"    </a>",
"    ]. The most common types exhibit autosomal dominant inheritance and have been subdivided into types 1A, 1B, and 1C, etc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/12\">",
"     12",
"    </a>",
"    ]. However, autosomal recessive and X-linked forms also occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'X-linked CMT'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4307678\">",
"    <span class=\"h3\">",
"     CMT1A",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMT1A (MIM 118220) is associated with a 1.5 Mb duplication or, less commonly, a point mutation of the peripheral myelin protein 22 (PMP22) gene on chromosome 17p11.2-p1; duplication leads to overexpression of PMP22, while point mutations alter distribution of the protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/2,17,18\">",
"     2,17,18",
"    </a>",
"    ]. Interestingly, patients with a 1.5 Mb deletion at this site develop hereditary neuropathy with pressure palsy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=see_link\">",
"     \"Hereditary sensory and autonomic neuropathies\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    Patients with point mutations usually have more prominent clinical manifestations. In these patients, PMP22 partially accumulates in the Schwann cells rather than being inserted in the myelin sheath, as occurs with gene duplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4307685\">",
"    <span class=\"h3\">",
"     CMT1B",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMT1B (MIM 118200), originally known as peroneal muscular atrophy, is most often caused by point mutations in the myelin protein zero (MPZ) gene on chromosome 1q22, which cause overexpression of the major myelin structural protein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Normal peripheral nerve myelination depends upon strict dosage of MPZ, and overexpression may be deleterious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Transgenic mice containing extra copies of the Mpz gene manifest a dose-dependent, dysmyelinating neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/21\">",
"     21",
"    </a>",
"    ]. In six individuals with CMT1 from one family, comparative genome hybridization analysis revealed an increased gene dosage, estimated to be five copies, of the entire MPZ gene and flanking genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/23\">",
"     23",
"    </a>",
"    ]. Mutations of MPZ gene introns that disrupt normal protein splicing have also been identified in a small number of families with CMT1B [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Myelin protein-zero is normally expressed on the cell membrane of Schwann cells, and plays a major role in myelin membrane adhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. In one family with CMT1B, in vitro fluorescence analysis demonstrated that mutant protein-zero was localized in the endoplasmic reticulum and Golgi apparatus rather than on the cell membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/27\">",
"     27",
"    </a>",
"    ]. In addition, the adhesiveness of cells expressing mutant protein-zero was diminished compared with controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4307635\">",
"    <span class=\"h3\">",
"     Additional CMT1 subtypes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CMT1C",
"      </strong>",
"      (MIM 601098) is caused by mutations in the LITAF (lipopolysaccharide-induced tumor necrosis factor-alpha factor) gene, which is mapped to chromosome 16p.13.1-p12.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. LITAF, which is also known as SIMPLE, is widely expressed and encodes a protein that may play a role in protein degradation pathways. The clustering of mutations associated with CMT1C suggests that a domain of LITAF may be important in peripheral nerve function. In contrast to other known genes that cause CMT1, the level of expression of the LITAF transcript did not change during development or in response to lung injury, suggesting a potential new mechanism of peripheral nerve perturbation resulting in demyelinating neuropathy.",
"     </li>",
"     <li>",
"      <strong>",
"       CMT1D",
"      </strong>",
"      (MIM 607678) is caused by mutations in the early growth response 2 gene (EGR2) on chromosome 10q21.1-q22.1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT1E",
"      </strong>",
"      (MIM 118300) is characterized by a classic CMT phenotype and sensorineural hearing loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/31\">",
"       31",
"      </a>",
"      ]. The cause is point mutations in the PMP22 gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT1F",
"      </strong>",
"      (MIM 607734) is caused by mutations in the NEFL gene on chromosome 8p21 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/33\">",
"       33",
"      </a>",
"      ]. Mutations in the same gene can cause an axonal form classified as CMT2E. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HMSN/CMT 2'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Roussy-Levy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Roussy-Levy syndrome, first described in 1926, is a CMT type 1 phenotype with manifestations that include postural tremor, gait ataxia, distal muscle atrophy, pes cavus, areflexia, and mild distal sensory loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Genetic testing of members of the original family identified a heterozygous missense mutation in the extracellular domain of the MPZ gene, indicating type 1B disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/34\">",
"     34",
"    </a>",
"    ]. However, testing in another large family with the same phenotype found a partial duplication at chromosome 17p11.2, indicating type 1A disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HMSN/CMT 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;HMSN type 2 (CMT2, also called axonal CMT) is a more heterogeneous disorder than is CMT1. It is characterized by normal or mildly reduced nerve conduction velocity with decreased amplitude and axonal degenerative loss without hypertrophic features; demyelination with onion bulb formation does not occur or is minimal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/36\">",
"     36",
"    </a>",
"    ]. These features distinguish CMT2 from CMT1, which is characterized by moderately to severely reduced nerve conduction velocity and onion bulb formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic features of CMT2 include distal weakness, atrophy, sensory loss, decreased deep tendon reflexes and variable foot deformity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/37\">",
"     37",
"    </a>",
"    ]. The onset of symptoms usually is in the second or third decade of life. The clinical course is similar to that of CMT1, but sensory symptoms, with loss of vibration and proprioception, typically predominate over motor symptoms, and peripheral nerves are not palpably enlarged. Distal trophic ulcerations in the feet may occur.",
"   </p>",
"   <p>",
"    An early-onset form of CMT2 becomes clinically apparent before the child reaches five years of age. Weakness progresses rapidly, with loss of strength below the knees by the second decade. Sensory symptoms are present but overshadowed by the motor weakness. Ambulation often is lost by the time the child reaches mid-teens.",
"   </p>",
"   <p>",
"    Possible late-onset forms of CMT2 presenting from 35 to 85 years of age (median age 57) have been described in six families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/38\">",
"     38",
"    </a>",
"    ]. The electrophysiologic findings were primarily those of axonal involvement. The late-onset forms are likely to be genetically heterogeneous. Autosomal dominant inheritance was demonstrated in two of the families, while inheritance patterns were unclear in the remaining four families.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Genetics of CMT2",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of cases are autosomal dominant, but, as with CMT1, the genetic basis of CMT2 is heterogeneous.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mitochondrial fusion protein mitofusin 2 (MFN2) gene mutations appear to be the most common cause of the CMT2 phenotype, accounting for approximately one-third of autosomal dominantly inherited CMT2 cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In addition, some MFN2 mutations cause a form of early onset CMT2 with apparent autosomal recessive inheritance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      MPZ gene mutations, as seen in CMT1B, have been reported in some patients with CMT2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HMSN/CMT 1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NEFL gene mutations, both autosomal dominant and recessive, have been identified as the cause of CMT2E [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. Other mutations in the NEFL gene cause a predominantly demyelinating neuropathy classified as CMT1F. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HMSN/CMT 1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dynamin 2 (DNM2) gene mutations, as seen in dominant-intermediate CMT, have been observed in families with CMT2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dominant intermediate CMT'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a cohort of 270 patients with a clinical phenotype consistent with CMT2, a disease-causing mutation in the mitochondrially encoded ATP synthase 6 (MT-ATP6) gene was identified in 3 (1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      X-linked and autosomal recessive inheritance can occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/14,50-52\">",
"       14,50-52",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'X-linked CMT'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one of the largest series of patients with CMT2, a causative genetic mutation was found in only 3 of 18 families (17 percent), indicating that the genetic basis of CMT2 is incompletely described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several different types of CMT2 have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/37\">",
"     37",
"    </a>",
"    ], as discussed in the sections that follow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4307628\">",
"    <span class=\"h3\">",
"     CMT2A",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMT2A is the most common CMT2 phenotype and maps to chromosome 1p35-36 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/54\">",
"     54",
"    </a>",
"    ]. The gene most commonly implicated in CMT2A is mitochondrial fusion protein mitofusin 2 (MFN2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/37,40,55-57\">",
"     37,40,55-57",
"    </a>",
"    ]. An early report identified a mutation in the kinesin family member 1B gene (KIF1B) in a single Japanese family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/58\">",
"     58",
"    </a>",
"    ], but this mutation has not been confirmed in other CMT2A families and may represent a benign rare polymorphism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4307590\">",
"    <span class=\"h3\">",
"     Other CMT2 subtypes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMT2B is characterized by predominant sensory involvement; it maps to chromosome 3q21.3 and is associated with RAS associated protein 7 (RAB7) gene mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/60,61\">",
"       60,61",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2C is characterized by distal muscle weakness, vocal cord paralysis, mild sensory impairment, and axonal neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/62,63\">",
"       62,63",
"      </a>",
"      ]. It maps to chromosome 12q24.1 and is associated with mutations in the TRPV4 gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. TRPV4 mutations also cause congenital distal spinal muscular atrophy and scapuloperoneal spinal muscular atrophy.",
"     </li>",
"     <li>",
"      CMT2D is characterized by predominant hand weakness and atrophy with a locus on chromosome 7p15 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/66\">",
"       66",
"      </a>",
"      ]. Associated mutations have been identified in the glycyl tRNA synthetase (GARS) gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2E is caused by mutations in the neurofilament light polypeptide (NEFL) gene linked to chromosome 8p [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/44-46\">",
"       44-46",
"      </a>",
"      ]. In several families with CMT2E, electrophysiological studies showed features consistent with a mixed axonal and demyelinating neuropathy, while pathological studies revealed an axonopathy with giant axons, accumulation of disorganized neurofilaments, and significant secondary demyelination [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2F is characterized by a classic CMT phenotype with a locus on chromosome 7q11.23 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/69\">",
"       69",
"      </a>",
"      ], and is associated with missense mutations in the heat shock 27kDa protein 1 (HSPB1) gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2G is characterized by a classic CMT phenotype and maps to chromosome 12q12-q13 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2I is a clinically distinct late onset CMT phenotype associated with mutations in the MPZ gene and characterized by axonal polyneuropathy, prominent sensory involvement, pupillary abnormalities, and hearing loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/43,72-75\">",
"       43,72-75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2K is a form of axonal CMT with autosomal dominant or recessive inheritance caused by mutations in the GDAP1 gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/76-78\">",
"       76-78",
"      </a>",
"      ]. Mutations in GDAP1 have also been identified in patients with CMT4A, a demyelinating form. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'CMT 4'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      CMT2L is characterized by a classic CMT phenotype and maps to chromosome 12q24.23 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/79\">",
"       79",
"      </a>",
"      ] and is associated with mutations in the heat shock protein 8 (HSPB8) gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      CMT2 caused by an MT-ATP6 mutation, which does not yet have a subtype letter designation, is characterized by onset in the first to second decade, variable severity, an initial pure motor neuropathy that evolves to a motor-predominant axonal neuropathy in the third to fourth decades, and early proximal leg weakness despite distal weakness [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/49\">",
"       49",
"      </a>",
"      ]. Rapid clinical deterioration may occur in the setting of a febrile infectious illness.",
"     </li>",
"     <li>",
"      Novel forms of CMT2 continue to be reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     X-LINKED CMT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are X-linked dominant and X-linked recessive forms of CMT type 1 and type 2 involving different loci [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/52\">",
"     52",
"    </a>",
"    ]. Together, the X-linked forms account for approximately 10 to 15 percent of all CMT cases. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'HMSN/CMT 1'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'HMSN/CMT 2'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4308332\">",
"    <span class=\"h2\">",
"     CMTX1",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMTX1, the X-linked dominant form of CMT type 1, is the second most common form of CMT after CMT1A, accounting for 7 to 12 percent of all CMT cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/52,82,83\">",
"     52,82,83",
"    </a>",
"    ]. It is the most common X-linked form of CMT. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'HMSN/CMT 1'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    CMTX1 is caused by mutations in the gap junction protein beta 1 (GJB1) gene, also known as the connexin 32 gene, on chromosome Xq13.1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/14-16,36\">",
"     14-16,36",
"    </a>",
"    ]. The gene is expressed in myelinating Schwann cells but not incorporated into the myelin sheath [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/84\">",
"     84",
"    </a>",
"    ]. Most GJB1 mutations are thought to cause disability by a loss of function of the gap junction protein connexin 32 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/85\">",
"     85",
"    </a>",
"    ]. Both sexes are affected, but symptoms are more prominent in boys who generally present in infancy or later in childhood with gait problems (eg, toe walking, flat footed walking, falls, difficulty running,); some present in infancy with foot deformities (pes planus or pes cavus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/86\">",
"     86",
"    </a>",
"    ]. Less common features include tremor, hand weakness, and sensorineural deafness. However, all remain ambulatory. Reflexes are lost at the ankles in all cases, whereas patellar reflexes are retained in approximately one-half of girls. Nerve conduction velocities are moderately slowed, but not to the same degree as in autosomal dominant CMT1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/87\">",
"     87",
"    </a>",
"    ]. Demyelination and axonal loss is observed histologically, but onion bulb formation is minimal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4308339\">",
"    <span class=\"h2\">",
"     Additional CMTX subtypes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CMTX2",
"      </strong>",
"      is X-linked recessive form that maps to Xp22 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. In the one described family, carrier females were unaffected. In males, the phenotype was notable for infantile onset, atrophy and weakness of lower leg muscles, areflexia, and pes cavus. Mental retardation was present in some. Electrophysiologic studies demonstrated both demyelination and axonal involvement.",
"     </li>",
"     <li>",
"      <strong>",
"       CMTX3",
"      </strong>",
"      is also X-linked recessive and maps to Xq26.3-q27.1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]. In two described families, the phenotype was notable for juvenile onset, distal atrophy with weakness, and normal intelligence, with both demyelination and axonal features by electrophysiologic studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. In a third family, disease severity was variable between affected males, with widely ranging nerve conduction velocities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/90\">",
"       90",
"      </a>",
"      ]. Symptoms began in the legs during the first decade of life, and arm involvement followed approximately ten years later in two-thirds of patients. Pain and paresthesia were frequently the first sensory symptoms. Pyramidal signs, tremor, and hearing loss were not observed. Female carriers were usually asymptomatic.",
"     </li>",
"     <li>",
"      <strong>",
"       Cowchock syndrome",
"      </strong>",
"      (CMT with deafness and mental retardation) is a rare form of infantile onset CMT type 2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/91\">",
"       91",
"      </a>",
"      ]. Affected males demonstrated severe muscle weakness associated with deafness and mental retardation. Females demonstrated only minor abnormalities involving sensory nerve conduction, electromyography, and hearing. The locus for this disorder links to Xq24-q26 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMTX5",
"      </strong>",
"      is an X-linked recessive disorder with deafness and optic neuropathy that has been reported in a Korean family; the disease locus maps to Xq21.32-q24 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DOMINANT INTERMEDIATE CMT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dominant intermediate Charcot-Marie-Tooth (DI-CMT) is an uncommon CMT variant. There has been controversy among experts regarding the existence and classification of this form of CMT, although most now accept it as a distinct entity.",
"   </p>",
"   <p>",
"    DI-CMT is characterized by intermediate nerve conduction velocities and both axonal and demyelinating features on histology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/12,94-96\">",
"     12,94-96",
"    </a>",
"    ]. Thus, it is considered an \"intermediate\" phenotype between CMT type 1 (predominate demyelination) and CMT type 2 (predominate axonal degeneration). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'HMSN/CMT 1'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7\">",
"     'HMSN/CMT 2'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    This intermediate group is further distinguished from CMT type I by the absence of clinically observed nerve hypertrophy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/95\">",
"     95",
"    </a>",
"    ]. Nerve conduction studies (NCS) generally reveal median nerve motor conduction velocities of 25 to 45",
"    <span class=\"nowrap\">",
"     m/s,",
"    </span>",
"    although values may vary between different laboratories.",
"   </p>",
"   <p>",
"    DI-CMT appears to be genetically heterogeneous, with autosomal dominant inheritance linked to several different loci:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DI-CMTA on chromosome 10q24.1-q25.1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/97\">",
"       97",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DI-CMTB on chromosome 19p12-p13.2, caused by mutations in the dynamin 2 gene (DNM2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/98,99\">",
"       98,99",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DI-CMTC on chromosome 1p34-p35, caused by mutations in the tyrosyl-tRNA synthetase gene (YARS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/100,101\">",
"       100,101",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      DI-CMTD, caused by mutations in the MPZ gene on chromosome locus 1q22 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/102,103\">",
"       102,103",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HMSN/CMT 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two disorders, Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy, are classified as HMSN 3. These are severe, early-onset peripheral neuropathies that are thought to be caused by an inability of the Schwann cells to produce normal myelin, resulting in thin, poorly formed myelin. On histologic examination, patients with Dejerine-Sottas syndrome have thin myelin sheaths and large onion bulb formation, whereas those with congenital hypomyelinating neuropathy show essentially absent myelin without evidence of inflammation, myelin breakdown, or onion bulbs.",
"   </p>",
"   <p>",
"    Historically, Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy were considered to be distinct clinical and genetic entities. However, they are now recognized to be genetically heterogeneous.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dejerine-Sottas syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dejerine-Sottas syndrome is a severe demyelinating neuropathy clinically evident in early infancy because of hypotonia. The phenotype is characterized by delayed motor development, prominent sensory loss, distal followed by proximal weakness, absent reflexes, ataxia, and profound slowing of nerve conduction velocities to &le;10",
"    <span class=\"nowrap\">",
"     m/sec.",
"    </span>",
"    Scoliosis appears early and progresses with time, and contractures develop. Progression is slow, often with ambulation maintained through adult life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/104\">",
"     104",
"    </a>",
"    ]. Although the term Dejerine-Sottas syndrome is still used to describe this clinical phenotype, the condition is genetically heterogeneous, and the term does not imply a specific inheritance pattern or a genetic defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Autosomal recessive and several dominant heterozygous forms of Dejerine-Sottas syndrome have been described, affecting genes that are also involved in CMT1 and CMT4. They include mutations in the PMP22 gene (as in CMT1A) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/22,36,106,107\">",
"     22,36,106,107",
"    </a>",
"    ], the MPZ gene (as in CMT1B) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/22,36\">",
"     22,36",
"    </a>",
"    ], and the EGR2 gene (as perhaps occurs in CMT1C) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/108,109\">",
"     108,109",
"    </a>",
"    ]. In one series of nine patients, for example, four novel point mutations occurred in the PMP22 gene and two in the MPZ gene; two cases were autosomal dominant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/22\">",
"     22",
"    </a>",
"    ]. Recessive inheritance involving the periaxin gene was described in three unrelated patients with Dejerine-Sottas neuropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/110\">",
"     110",
"    </a>",
"    ]. The defective gene mapped to 19q13.13-13.2, a region associated with CMT4F. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'CMT 4'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Congenital hypomyelinating neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital hypomyelinating neuropathy presents at birth with profound hypotonia and contractures. Conduction velocities are either absent or extremely slow. Feeding difficulties and respiratory distress often lead to death in infancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/111\">",
"     111",
"    </a>",
"    ]. However, several cases that exhibited spontaneous improvement in motor function with increasing age have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/112-114\">",
"     112-114",
"    </a>",
"    ]; one patient completely recovered by four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Congenital hypomyelinating neuropathy is genetically heterogeneous. Most cases are thought to be the result of peripheral myelin protein mutations caused by either PMP22 gene or MPZ gene mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. Other mutations have been described in the early growth response 2 gene (EGR2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/30\">",
"     30",
"    </a>",
"    ] and the myotubularin related 2 gene (MTMR2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/117\">",
"     117",
"    </a>",
"    ]. Genetic transmission in most cases is autosomal dominant, but rare autosomal recessive cases have been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CMT 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMT type 4 currently is a rapidly expanding heterogeneous group of autosomal recessive demyelinating motor sensory neuropathies (CMT4). These autosomal recessive forms of CMT are rare, clinically more severe, and less likely to result from mutations in structural myelin proteins than the autosomal dominant forms. Individuals with CMT4 have a typical CMT phenotype of distal muscle weakness and atrophy associated with sensory loss and foot deformities (ie, pes cavus) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/118\">",
"     118",
"    </a>",
"    ]. Conduction velocities are typically slow (&lt;40",
"    <span class=\"nowrap\">",
"     m/s)",
"    </span>",
"    on nerve conduction studies.",
"   </p>",
"   <p>",
"    Several subtypes of CMT4 disease are described based upon electrophysiologic, pathologic, and genetic criteria.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CMT4A",
"      </strong>",
"      was identified in Tunisian inbred families. It presents in early childhood with distal weakness and mild sensory loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/119\">",
"       119",
"      </a>",
"      ]. The neuropathy is rapidly progressive. Patients often are incapacitated by the fourth decade. Hypomyelination, loss of myelinated fibers, and basal laminal onion bulbs are present. Conduction velocities are moderately reduced. The disease has been mapped to chromosome 8q13-q21.1. Mutations have been identified in the GDAP1 gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/120,121\">",
"       120,121",
"      </a>",
"      ]. GDAP1 appears to be predominately expressed in neurons but not in Schwann cells, and localized in mitochondrial membranes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/122\">",
"       122",
"      </a>",
"      ]. This finding suggests that mitochondrial abnormalities may cause CMT4A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4B",
"      </strong>",
"      is divided into two subtypes that map to different segments of chromosome 11.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <strong>",
"       CMT4B1",
"      </strong>",
"      was described in a consanguineous Italian family [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/123,124\">",
"       123,124",
"      </a>",
"      ]. The disease presented in patients at age two to four with distal and proximal weakness with moderate sensory loss and frequent involvement of cranial nerves [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/125\">",
"       125",
"      </a>",
"      ]. Loss of myelin fibers, segmental demyelination and remyelination, and numerous onion bulbs occur; focally folded myelin sheaths were present in peripheral nerves. Conduction velocity was slow. The causative MTMR2 gene is on chromosome 11q22-23 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/126\">",
"       126",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4B2",
"      </strong>",
"      shares the same morphological features on nerve biopsy as CMT4B1 but differs in age of onset and clinical presentation. The causative SBF2 gene is on chromosome 11p15 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/127,128\">",
"       127,128",
"      </a>",
"      ]. The age of onset ranges from 4 to 13 years old [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/127-131\">",
"       127-131",
"      </a>",
"      ]. Distal weakness is prominent on presentation, with proximal weakness developing only after several years. Motor nerve conduction velocities are similarly slowed. Early onset glaucoma is a feature in some families [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/128,130,131\">",
"       128,130,131",
"      </a>",
"      ]. An Italian family has also been reported with CMT4B2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/132,133\">",
"       132,133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       CMT4C",
"      </strong>",
"      was first described in Algerian families with severe spinal deformities and weakness in childhood and adolescence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/134-136\">",
"       134-136",
"      </a>",
"      ]. Scoliosis often requires operative correction at an early age. Loss of myelinated fibers and some classic onion bulbs are present on nerve pathology. Motor nerve conduction velocity is slowed. CMT4C appears to account for approximately 20 percent of cases of autosomal recessive demyelinating CMT, and is associated with mutations in the SH3TC2 gene on chromosome 5q32 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/137,138\">",
"       137,138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4D",
"      </strong>",
"      is also known as hereditary motor and sensory neuropathy-Lom (HMSNL) and is one of the more common autosomal recessive forms. It occurs in divergent Romani (Gypsy) groups descended from a small founder population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/139\">",
"       139",
"      </a>",
"      ]. CMT4D is an early onset neuropathy that presents with muscle weakness and wasting, skeletal deformities, sensory loss, and severe reduction in nerve conduction velocities. Neural deafness develops during the second or third decade of life. Slow motor nerve conduction velocity occurs and onion bulbs are present in peripheral nerves. The founder mutation involves the NDRG1 gene on chromosome 8q24.3 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/140\">",
"       140",
"      </a>",
"      ]. NDRG1 is ubiquitously expressed, with particularly high levels in Schwann cells, and may play a role in growth arrest and cell differentiation.",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4E",
"      </strong>",
"      corresponds to a congenital hypomyelinating neuropathy caused by a homozygous missense mutation in the early growth response 2 gene (EGR2) on chromosome 10q21-22 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/30\">",
"       30",
"      </a>",
"      ]. Distal weakness is present at birth. Myelin sheaths are thin or absent and onion bulbs are present.",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4F",
"      </strong>",
"      was found in a large inbred Lebanese family [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/141\">",
"       141",
"      </a>",
"      ]. Onset is in early childhood, with distal muscle weakness and severe sensory loss. Nerve conduction studies revealed the total absence of any sensory or motor evoked response in the upper and lower limbs. Nerve pathology showed severe depletion of myelinated fibers and multiple small onion bulbs. The locus for this subtype has been mapped to chromosome 19q13.1-13.3. The defective gene (PRX) appears to encode for periaxin, a protein of myelinating Schwann cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/110,141\">",
"       110,141",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4H",
"      </strong>",
"      was described in Lebanese and Algerian families as a severe form of CMT with onset in the first two years of life [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/142\">",
"       142",
"      </a>",
"      ]. Major features include unsteady gait, loss of reflexes, scoliosis, and severe demyelinating neuropathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/142\">",
"       142",
"      </a>",
"      ]. It is caused by mutations in the FGD4 gene on chromosome 12p11.2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/143,144\">",
"       143,144",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       CMT4J",
"      </strong>",
"      was first identified in four unrelated patients as a severe form of childhood-onset CMT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/145\">",
"       145",
"      </a>",
"      ]. Nerve pathology from one patient showed axonal loss and evidence of demyelination and remyelination. In a subsequent report, two siblings with adult-onset CMT4J developed a progressive asymmetric paralysis that clinically resembled motor neuron disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/146\">",
"       146",
"      </a>",
"      ]. Neurophysiologic testing showed severe and widespread denervation, while nerve pathology from one sibling revealed severe loss of myelinated nerve fibers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/146\">",
"       146",
"      </a>",
"      ]. In these families, CMT4J was caused by mutations in the FIG4 gene on chromosome 6q21 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/145\">",
"       145",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HMSN/CMT 5, 6, AND 7",
"    </span>",
"    &nbsp;&mdash;&nbsp;Types 5, 6, and 7 were used in the 1975 Dyck classification but these disorders are referred to more commonly by the associated symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HMSN 5 refers to patients with autosomal dominant spastic paraparesis with sensory neuropathy",
"     </li>",
"     <li>",
"      HMSN 6 refers to patients with dominant or recessive optic atrophy and motor sensory neuropathy",
"     </li>",
"     <li>",
"      HMSN 7 refers to patients with retinitis pigmentosa and motor sensory neuropathy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     GENETIC TESTING AND COUNSELING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic testing can simplify the diagnosis of CMT by avoiding uncomfortable and invasive procedures such as electromyography and nerve biopsy. In addition, early diagnosis can facilitate early interventions such as physical therapy. However, genetic testing often will",
"    <strong>",
"     not",
"    </strong>",
"    affect the management for individual patients with CMT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/147\">",
"     147",
"    </a>",
"    ]. In addition, genetic testing is currently expensive. Thus, insurance reimbursement should be clarified if it is pursued. However, the costs of sequencing are falling rapidly. The introduction of next-generation sequencing technologies to clinical practice will soon enable cost-efficient sequencing of multiple genes. Consequently, opportunities to obtain a precise genetic diagnosis for those affected by CMT should greatly improve.",
"   </p>",
"   <p>",
"    Genetic testing for CMT is complicated by the extensive underlying genetic heterogeneity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/148\">",
"     148",
"    </a>",
"    ]. The CMT spectrum of disorders can be inherited in an autosomal dominant, autosomal recessive, or X-linked manner. In addition, more than 35 genes have been implicated as causes of the various forms of CMT. At one expert CMT center that evaluated over 787 patients with a clinical diagnosis of CMT between 1997 and 2009, a specific genetic mutation was identified in 527 (67 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/148\">",
"     148",
"    </a>",
"    ]. The most commonly identified CMT subtypes were CMT1A (PMP22 duplication), CMTX1 (GJB1 mutation), hereditary neuropathy with liability to pressure palsies (PMP22 deletion), CMT1B (MPZ mutation), and CMT2A (MFN2 mutation). Together, these five subtypes accounted for 92 percent of genetically defined CMT cases. All other CMT subtypes and associated mutations each accounted for &lt;1 percent of genetically defined CMT.",
"   </p>",
"   <p>",
"    Based upon these results, the investigators proposed a strategy of focused genetic testing for CMT directed by age at onset, electrodiagnostic findings, and inheritance pattern as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with slow upper extremity (ulnar) motor nerve conduction velocities (&gt;15 to &le;35",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      and a classic CMT phenotype (ie, walking before age 15 months), test first for the PMP22 duplication (CMT1A). If negative and if no male to male transmission in the pedigree, test next for GJB1 (CMTX1) followed by MPZ (CMT1B), or test only for MPZ if there is male to male transmission. If these are negative, test for point mutations in",
"      <span class=\"nowrap\">",
"       LITAF/SIMPLE",
"      </span>",
"      (CMT1C), PMP22 (CMT1E), and EGR2 (CMT1D). If these are all negative and if there is no affected parent or child, test for recessive forms of CMT.",
"     </li>",
"     <li>",
"      For patients with very slow motor nerve conduction velocities (&le;15",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      and delayed walking (age 15 months or later), test for both the PMP22 duplication (CMT1A) and MPZ mutations (CMT1B). For patients who walked before age 15 months, test first for the PMP22 duplication, followed by the MPZ mutation. If PMP22 duplication and MPZ mutation testing are negative, test next for PMP22 sequencing (CMT1E). If that is negative, proceed to testing for point mutations in",
"      <span class=\"nowrap\">",
"       LITAF/SIMPLE",
"      </span>",
"      (CMT1C), PMP22 and EGR2 (CMT1D). If these all negative and if there is no affected parent or child, test for recessive forms of CMT.",
"     </li>",
"     <li>",
"      For patients who have intermediate slowing of motor nerve conduction velocities (&gt;35 to &le;45",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      with a classic CMT phenotype of childhood onset and no male to male transmission, test for GJB1 (CMTX1) followed if negative by MPZ (CMT1B); if there is male to male transmission, test only for MPZ. If these are all negative and there is no affected parent or child, test for recessive forms of CMT.",
"     </li>",
"     <li>",
"      For patients with intermediate slowing of motor nerve conduction velocities (&gt;35 to &le;45",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      and adult-onset CMT, test first for MPZ mutations (CMT1B). If negative and no male to male transmission, test next for GJB1 (CMTX1); if there is male to male transmission and no affected parent or child, test for recessive forms of CMT.",
"     </li>",
"     <li>",
"      For patients with either normal upper extremity motor nerve conduction velocities (&gt;45",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      or unobtainable motor nerve conduction velocities and compound muscle action potentials who have symptom onset in infancy or severe symptoms in childhood, first test for MFN2 (CMT2A). For patients with a classic phenotype or adult onset and no male to male transmission, first test for GJB1 (CMTX1) followed if negative by MPZ (CMT1B); if there is male to male transmission, test only for MPZ. If testing for GJB1",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      MPZ is negative, test next for MFN2. Regardless of age of onset or severity, testing for other forms of CMT2 may be appropriate if testing for CMT2A, CTMX1, and CMT1B is negative. For patients with pure motor upper of lower limb onset, test next for GARS (CMT2D); for other presentations, test for both NEFL (CMT2E) and GDAP1 (CMT2K). If these are all negative and there is no affected parent or child, test for recessive forms of axonal CMT.",
"     </li>",
"     <li>",
"      Hereditary neuropathy with liability to pressure palsies (HNPP) is distinguished from other forms of CMT by a distinct phenotype that includes focal episodes of weakness or sensory loss and focal slowing of motor never conduction velocities. When these features are present, test for PMP22 deletion and point mutations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic screening for relatives of a patient diagnosed with CMT is an option, but risk assessment depends on several factors, including accuracy of the diagnosis, determination of the mode of inheritance for the individual family, and results of molecular genetic testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic counseling should be made available to the family if a specific genetic abnormality is identified, particularly with regard to prenatal testing. Prenatal testing for pregnancies at increased risk is possible for some types of CMT only if the disease-causing mutation in the family is already known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H781703\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of CMT is supportive. Specific disease-modifying therapy is not available. Daily stretching exercises early in the course of the disease may help delay ankle contractures. Orthotics are often used to help stabilize the ankles. Orthopedic foot surgery often is required by the time the patient reaches adolescence to treat the pes cavus deformity and hammer toes.",
"   </p>",
"   <p>",
"    Animal models of CMT1A have been produced by introducing extra copies of the PMP22 gene, resulting in overexpression of the protein; these models were then used to test different therapies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progesterone can increase PMP22 expression and studies in humans have suggested disease exacerbation in pregnancy, a setting in which plasma progesterone increases up to 10-fold [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/6\">",
"       6",
"      </a>",
"      ]. Observations in an animal model were consistent with these findings as the administration of progesterone resulted in a more progressive neuropathy, while a progesterone antagonist reduced overexpression of PMP22 and slowed disease progression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Ascorbic acid (vitamin C), which is known to promote myelination, appeared promising in an animal model of CMT1A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/150\">",
"       150",
"      </a>",
"      ]. Ascorbic acid therapy reduced the expression of PMP22 to a level below that required to induce the disease. This change was associated with remyelination, amelioration of the CMT1A phenotype, and prolonged lifespan. However, there was no clear benefit of ascorbic acid in a 12 month randomized controlled trial of 81 children with CMT1A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/151\">",
"       151",
"      </a>",
"      ] or in a similar trial of 179 adults with CMT1A [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/152\">",
"       152",
"      </a>",
"      ]. Since disease progression in CMT1A is typically slow, trials with longer treatment periods may be necessary to detect benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/153\">",
"       153",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurotrophin-3 (NT3) improved axonal regeneration and associated myelination in both a xenograft model of Schwann cells with a PMP22 duplication and in a mouse model with a PMP22 point mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/154\">",
"       154",
"      </a>",
"      ]. In the same report, a single-blinded pilot clinical trial involving eight patients with CMT1A found that NT3 treatment for six months was associated with improved sural nerve myelinated fiber regeneration compared with placebo treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the clinical applicability of these observations remains to be proven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H782027\">",
"    <span class=\"h2\">",
"     Drugs that may exacerbate CMT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because patients with CMT have an existing peripheral neuropathy, they are considered to be more susceptible to injury when treated with standard &ldquo;non-toxic&rdquo; dosages of neurotoxic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/155\">",
"     155",
"    </a>",
"    ]. A systematic review published in 2006 identified 26 publications, mainly case reports or small case series, describing CMT exacerbation associated with toxic medications, of which 22 involved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/156\">",
"     156",
"    </a>",
"    ]. Acute worsening or onset of weakness in patients with CMT was observed after vincristine administration of 2 to 4 mg for adults or 1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per dose in children. Most of the patients had undiagnosed demyelinating forms of CMT (eg, CMT1A). Thus, vincristine is considered to be of definite high risk for patients with CMT, including those who are asymptomatic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    undiagnosed. Vincristine has long been labeled as contraindicated for patients with demyelinating forms of CMT.",
"   </p>",
"   <p>",
"    Data for other drugs is quite limited, but a list of medications considered to have moderate to significant risk for patients with CMT is as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/156\">",
"     156",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"       Amiodarone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/63/11257?source=see_link\">",
"       Bortezomib",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"       oxaliplatin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/13/32983?source=see_link\">",
"       Colchicine",
"      </a>",
"      (extended use)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/59/32688?source=see_link\">",
"       Dapsone",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/38/14952?source=see_link\">",
"       Didanosine",
"      </a>",
"     </li>",
"     <li>",
"      Dichloroacetate",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"       Disulfiram",
"      </a>",
"     </li>",
"     <li>",
"      Gold salts",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       Leflunomide",
"      </a>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"        Metronidazole",
"       </a>",
"       /Misonidazole",
"      </span>",
"      (extended use)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/22/25958?source=see_link\">",
"       Nitrofurantoin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"       Nitrous oxide",
"      </a>",
"      (inhalation abuse or vitamin B12 deficiency)",
"     </li>",
"     <li>",
"      Perhexiline (not used in the United States)",
"     </li>",
"     <li>",
"      Pyridoxine (high dose)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/45/43734?source=see_link\">",
"       Stavudine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/50/30498?source=see_link\">",
"       Suramin",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"     </li>",
"     <li>",
"      Taxols (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"     </li>",
"     <li>",
"      Zalcitabine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A longer list of drugs of concern for patients with CMT, including drugs of uncertain or minor risk, and negligible or doubtful risk, can be found online at the",
"    <a class=\"external\" href=\"file://www.cmtausa.org/\">",
"     Charcot-Marie-Tooth Association",
"    </a>",
"    website.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1431397\">",
"    <span class=\"h3\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regional anesthesia has been controversial due to theoretical concerns that patients with CMT may have an increased susceptibility to further nerve damage with the use of local anesthetic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/157\">",
"     157",
"    </a>",
"    ]. However, the available limited clinical data suggest otherwise. A number of small case series and case reports have described uneventful outcomes with regional anesthesia, including both peripheral nerve and neuraxial blocks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/59/35770/abstract/158-160\">",
"     158-160",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/59/24497?source=see_link\">",
"       \"Patient information: Charcot-Marie-Tooth disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19900458\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hereditary motor sensory neuropathy (HMSN), also known as Charcot-Marie-Tooth (CMT) disease, is really a spectrum of disorders caused by specific mutations in one of several myelin genes that lead to defects in myelin structure, maintenance, and formation. CMT has been classified as types one through seven and consists of at least 30 different disorders. The major division comprises type 1 and type 2, which together are the most common hereditary peripheral neuropathies. Common features include both motor and sensory nerve manifestations with distal leg weakness, foot deformities (pes cavus, hammer toes), and sensory deficits (",
"      <a class=\"graphic graphic_table graphicRef72688 graphicRef52711 \" href=\"mobipreview.htm?37/12/38094\">",
"       table 1A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HMSN type 1, also known as Charcot-Marie-Tooth type 1 (CMT1) disease, is a demyelinating disorder of peripheral nerves. It has been subdivided on the basis of genetic markers into several subtypes, of which CMT1A and CMT1B are the most common. However, the clinical manifestations are similar. Affected patients typically present in the first or early second decade, but infants may be symptomatic. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HMSN/CMT 1'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Early complaints may include frequent sprained ankles caused by distal muscle weakness or difficulty running and keeping up with peers. The only obvious physical findings may be loss of reflexes, pes cavus foot deformity, and hammer toes. Distal calf muscle atrophy often occurs, causing the classic \"stork leg deformity.\" Walking is clumsy because of both muscle weakness and sensory loss. Sensory loss is gradual and mainly involves proprioception and vibration. Later changes include atrophy of the intrinsic hand and foot muscles. Palpable enlargement of the peripheral nerves may occur secondary to nerve hypertrophy. In addition, kyphosis or scoliosis often develops. Ambulation is variable but usually is maintained through life. Life expectancy is not affected. Disease exacerbation can occur in pregnancy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HMSN/CMT 1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nerve conduction studies show severe slowing of conduction velocity in both the motor and sensory nerves to less than 60 percent of normal. Frequently, little correlation exists between the electromyographic and clinical findings. Sural nerve biopsy shows demyelination that affects primarily the large nerve fibers. Onion bulbs are a characteristic feature; they reflect repeated demyelination and remyelination. Secondary axonal changes are present. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'HMSN/CMT 1'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common type of CMT1 is caused by duplication of the PMP22 gene (CMT1A), which accounts for 70 to 80 percent of CMT1 cases. CMT1 can also be caused by mutations in genes (particularly PMP22 and MPZ, but also LITAF, ERG2, and NEFL) that are expressed in Schwann cells, the myelinating cells of the peripheral nervous system. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Genetics of CMT1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HMSN type 2 (CMT2, also called axonal CMT) is a more heterogeneous disorder than CMT1. It is characterized by normal or mildly reduced nerve conduction velocities with decreased amplitude and axonal degenerative loss without hypertrophic features; demyelination with onion bulb formation does not occur or is minimal. The classic features of CMT2 include distal weakness, atrophy, sensory loss, decreased deep tendon reflexes and variable foot deformity. The onset of symptoms usually is in the second or third decade of life. Sensory symptoms, with loss of vibration and proprioception, typically predominate over motor symptoms, and peripheral nerves are not palpably enlarged. Distal trophic ulcerations in the feet may occur. An early-onset form of CMT2 becomes clinically apparent before age five years. Possible late-onset forms of CMT2 have also been described. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'HMSN/CMT 2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The genetic basis of CMT2 is heterogeneous, though MFN2 gene mutations appear to be the most common cause of the CMT2 phenotype (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Genetics of CMT2'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are X-linked dominant and X-linked recessive forms of CMT type 1 and type 2. CMTX1 is the second most common form of CMT after CMT1A, accounting for 7 to 12 percent of all CMT cases. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'X-linked CMT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dominant intermediate Charcot-Marie-Tooth (DI-CMT) is an uncommon CMT variant that is characterized by intermediate nerve conduction velocities and both axonal and demyelinating features on histology. Thus, it is considered an \"intermediate\" phenotype between CMT1 (predominate demyelination) and CMT2 (predominate axonal degeneration). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Dominant intermediate CMT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy are classified as",
"      <span class=\"nowrap\">",
"       HMSN/CMT",
"      </span>",
"      type 3. These are severe, early-onset peripheral neuropathies. Historically, Dejerine-Sottas syndrome and congenital hypomyelinating neuropathy were considered to be distinct clinical and genetic entities. However, they are now recognized to be genetically heterogeneous. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'HMSN/CMT 3'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMT type 4 (CMT4) is a heterogeneous group of autosomal recessive demyelinating motor sensory neuropathies. These autosomal recessive forms of CMT are rare, clinically more severe, and less likely to result from mutations in structural myelin proteins than the autosomal dominant forms. Individuals with CMT4 have a typical CMT phenotype of distal muscle weakness and atrophy associated with sensory loss and foot deformities (eg, pes cavus). Conduction velocities are typically slow (&lt;40",
"      <span class=\"nowrap\">",
"       m/s)",
"      </span>",
"      on nerve conduction studies. Several subtypes of CMT4 disease are described based upon electrophysiologic, pathologic, and genetic criteria. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'CMT 4'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific therapy for CMT is not yet available. Management is supportive. Daily stretching exercises early in the course of the disease may help delay ankle contractures. Orthotics are often used to help stabilize the ankles. Orthopedic foot surgery often is required by the time the patient reaches adolescence. (See",
"      <a class=\"local\" href=\"#H781703\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dyck PJ. Neuronal atrophy and degeneration predominantly affecting peripheral sensory and autonomic neurons. In: Peripheral Neuropathy, Dyck PJ, Thomas PK, Lambert EH, et al (Eds), WB Saunders, Philadelphia 1984. Vol 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/2\">",
"      Lupski JR. Charcot-Marie-Tooth polyneuropathy: duplication, gene dosage, and genetic heterogeneity. Pediatr Res 1999; 45:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/3\">",
"      Kamholz J, Menichella D, Jani A, et al. Charcot-Marie-Tooth disease type 1: molecular pathogenesis to gene therapy. Brain 2000; 123 ( Pt 2):222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/4\">",
"      Mersiyanova IV, Ismailov SM, Polyakov AV, et al. Screening for mutations in the peripheral myelin genes PMP22, MPZ and Cx32 (GJB1) in Russian Charcot-Marie-Tooth neuropathy patients. Hum Mutat 2000; 15:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/5\">",
"      Roy EP 3rd, Gutmann L, Riggs JE. Longitudinal conduction studies in hereditary motor and sensory neuropathy type 1. Muscle Nerve 1989; 12:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/6\">",
"      Rudnik-Sch&ouml;neborn S, R&ouml;hrig D, Nicholson G, Zerres K. Pregnancy and delivery in Charcot-Marie-Tooth disease type 1. Neurology 1993; 43:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/7\">",
"      Dematteis M, P&eacute;pin JL, Jeanmart M, et al. Charcot-Marie-Tooth disease and sleep apnoea syndrome: a family study. Lancet 2001; 357:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/8\">",
"      Dziewas R, Waldmann N, B&ouml;ntert M, et al. Increased prevalence of obstructive sleep apnoea in patients with Charcot-Marie-Tooth disease: a case control study. J Neurol Neurosurg Psychiatry 2008; 79:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/9\">",
"      Hagberg B, Lyon G. Pooled European series of hereditary peripheral neuropathies in infancy and childhood. A \"correspondence work shop\" report of the European Federation of Child Neurology Societies (EFCNS). Neuropediatrics 1981; 12:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/10\">",
"      Krajewski KM, Lewis RA, Fuerst DR, et al. Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A. Brain 2000; 123 ( Pt 7):1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/11\">",
"      Videler AJ, van Dijk JP, Beelen A, et al. Motor axon loss is associated with hand dysfunction in Charcot-Marie-Tooth disease 1a. Neurology 2008; 71:1254.",
"     </a>",
"    </li>",
"    <li>",
"     Bird, TD. Charcot-Marie-Tooth hereditary neuropathy overview. GeneReviews.  www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=cmt#cmt (Accessed on November 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/13\">",
"      Gabre&euml;ls-Festen AA, Gabre&euml;ls FJ, Jennekens FG, et al. Autosomal recessive form of hereditary motor and sensory neuropathy type I. Neurology 1992; 42:1755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/14\">",
"      Hahn AF, Brown WF, Koopman WJ, Feasby TE. X-linked dominant hereditary motor and sensory neuropathy. Brain 1990; 113 ( Pt 5):1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/15\">",
"      Bergoffen J, Trofatter J, Pericak-Vance MA, et al. Linkage localization of X-linked Charcot-Marie-Tooth disease. Am J Hum Genet 1993; 52:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/16\">",
"      Bergoffen J, Scherer SS, Wang S, et al. Connexin mutations in X-linked Charcot-Marie-Tooth disease. Science 1993; 262:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/17\">",
"      Shaffer LG, Kennedy GM, Spikes AS, Lupski JR. Diagnosis of CMT1A duplications and HNPP deletions by interphase FISH: implications for testing in the cytogenetics laboratory. Am J Med Genet 1997; 69:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/18\">",
"      Hanemann CO, D'Urso D, Gabre&euml;ls-Festen AA, M&uuml;ller HW. Mutation-dependent alteration in cellular distribution of peripheral myelin protein 22 in nerve biopsies from Charcot-Marie-Tooth type 1A. Brain 2000; 123 ( Pt 5):1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/19\">",
"      Bird TD. Historical perspective of defining Charcot-Marie-Tooth type 1B. Ann N Y Acad Sci 1999; 883:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/20\">",
"      Hayasaka K, Himoro M, Sato W, et al. Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet 1993; 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/21\">",
"      Wrabetz L, Feltri ML, Quattrini A, et al. P(0) glycoprotein overexpression causes congenital hypomyelination of peripheral nerves. J Cell Biol 2000; 148:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/22\">",
"      Tyson J, Ellis D, Fairbrother U, et al. Hereditary demyelinating neuropathy of infancy. A genetically complex syndrome. Brain 1997; 120 ( Pt 1):47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/23\">",
"      Maeda MH, Mitsui J, Soong BW, et al. Increased gene dosage of myelin protein zero causes Charcot-Marie-Tooth disease. Ann Neurol 2012; 71:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/24\">",
"      Sabet A, Li J, Ghandour K, et al. Skin biopsies demonstrate MPZ splicing abnormalities in Charcot-Marie-Tooth neuropathy 1B. Neurology 2006; 67:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/25\">",
"      Spiryda LB. Myelin protein zero and membrane adhesion. J Neurosci Res 1998; 54:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/26\">",
"      Matsuyama W, Nakagawa M, Takashima H, Osame M. Altered trafficking and adhesion function of MPZ mutations and phenotypes of Charcot-Marie-Tooth disease 1B. Acta Neuropathol 2002; 103:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/27\">",
"      Lee YC, Yu CT, Lin KP, et al. MPZ mutation G123S characterization: evidence for a complex pathogenesis in CMT disease. Neurology 2008; 70:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/28\">",
"      Street VA, Goldy JD, Golden AS, et al. Mapping of Charcot-Marie-Tooth disease type 1C to chromosome 16p identifies a novel locus for demyelinating neuropathies. Am J Hum Genet 2002; 70:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/29\">",
"      Street VA, Bennett CL, Goldy JD, et al. Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot-Marie-Tooth disease 1C. Neurology 2003; 60:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/30\">",
"      Warner LE, Mancias P, Butler IJ, et al. Mutations in the early growth response 2 (EGR2) gene are associated with hereditary myelinopathies. Nat Genet 1998; 18:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/31\">",
"      Kousseff BG, Hadro TA, Treiber DL, et al. Charcot-Marie-Tooth disease with sensorineural hearing loss--an autosomal dominant trait. Birth Defects Orig Artic Ser 1982; 18:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/32\">",
"      Kovach MJ, Lin JP, Boyadjiev S, et al. A unique point mutation in the PMP22 gene is associated with Charcot-Marie-Tooth disease and deafness. Am J Hum Genet 1999; 64:1580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/33\">",
"      Jordanova A, De Jonghe P, Boerkoel CF, et al. Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot-Marie-Tooth disease. Brain 2003; 126:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/34\">",
"      Plant&eacute;-Bordeneuve V, Guiochon-Mantel A, Lacroix C, et al. The Roussy-L&eacute;vy family: from the original description to the gene. Ann Neurol 1999; 46:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/35\">",
"      Auer-Grumbach M, Strasser-Fuchs S, Wagner K, et al. Roussy-L&eacute;vy syndrome is a phenotypic variant of Charcot-Marie-Tooth syndrome IA associated with a duplication on chromosome 17p11.2. J Neurol Sci 1998; 154:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/36\">",
"      Keller MP, Chance PF. Inherited peripheral neuropathy. Semin Neurol 1999; 19:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/37\">",
"      Reilly MM. Axonal Charcot-Marie-Tooth disease: the fog is slowly lifting! Neurology 2005; 65:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/38\">",
"      Bennett CL, Lawson VH, Brickell KL, et al. Late-onset hereditary axonal neuropathies. Neurology 2008; 71:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/39\">",
"      Calvo J, Funalot B, Ouvrier RA, et al. Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations. Arch Neurol 2009; 66:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/40\">",
"      Ouvrier R, Grew S. Mechanisms of disease and clinical features of mutations of the gene for mitofusin 2: an important cause of hereditary peripheral neuropathy with striking clinical variability in children and adults. Dev Med Child Neurol 2010; 52:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/41\">",
"      Polke JM, Laur&aacute; M, Pareyson D, et al. Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations. Neurology 2011; 77:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/42\">",
"      Marrosu MG, Vaccargiu S, Marrosu G, et al. Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology 1998; 50:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/43\">",
"      Senderek J, Hermanns B, Lehmann U, et al. Charcot-Marie-Tooth neuropathy type 2 and P0 point mutations: two novel amino acid substitutions (Asp61Gly; Tyr119Cys) and a possible \"hotspot\" on Thr124Met. Brain Pathol 2000; 10:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/44\">",
"      Mersiyanova IV, Perepelov AV, Polyakov AV, et al. A new variant of Charcot-Marie-Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet 2000; 67:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/45\">",
"      De Jonghe P, Mersivanova I, Nelis E, et al. Further evidence that neurofilament light chain gene mutations can cause Charcot-Marie-Tooth disease type 2E. Ann Neurol 2001; 49:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/46\">",
"      Yum SW, Zhang J, Mo K, et al. A novel recessive Nefl mutation causes a severe, early-onset axonal neuropathy. Ann Neurol 2009; 66:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/47\">",
"      Fabrizi GM, Ferrarini M, Cavallaro T, et al. Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease. Neurology 2007; 69:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/48\">",
"      Claeys KG, Z&uuml;chner S, Kennerson M, et al. Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy. Brain 2009; 132:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/49\">",
"      Pitceathly RD, Murphy SM, Cottenie E, et al. Genetic dysfunction of MT-ATP6 causes axonal Charcot-Marie-Tooth disease. Neurology 2012; 79:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/50\">",
"      Bouhouche A, Benomar A, Birouk N, et al. A locus for an axonal form of autosomal recessive Charcot-Marie-Tooth disease maps to chromosome 1q21.2-q21.3. Am J Hum Genet 1999; 65:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/51\">",
"      Bouhouche A, Birouk N, Azzedine H, et al. Autosomal recessive axonal Charcot-Marie-Tooth disease (ARCMT2): phenotype-genotype correlations in 13 Moroccan families. Brain 2007; 130:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/52\">",
"      Ouvrier R, Geevasingha N, Ryan MM. Autosomal-recessive and X-linked forms of hereditary motor and sensory neuropathy in childhood. Muscle Nerve 2007; 36:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/53\">",
"      Bienfait HM, Baas F, Koelman JH, et al. Phenotype of Charcot-Marie-Tooth disease Type 2. Neurology 2007; 68:1658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/54\">",
"      Ben Othmane K, Middleton LT, Loprest LJ, et al. Localization of a gene (CMT2A) for autosomal dominant Charcot-Marie-Tooth disease type 2 to chromosome 1p and evidence of genetic heterogeneity. Genomics 1993; 17:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/55\">",
"      Z&uuml;chner S, Mersiyanova IV, Muglia M, et al. Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A. Nat Genet 2004; 36:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/56\">",
"      Lawson VH, Graham BV, Flanigan KM. Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene. Neurology 2005; 65:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/57\">",
"      Feely SM, Laura M, Siskind CE, et al. MFN2 mutations cause severe phenotypes in most patients with CMT2A. Neurology 2011; 76:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/58\">",
"      Zhao C, Takita J, Tanaka Y, et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bbeta. Cell 2001; 105:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/59\">",
"      Bissar-Tadmouri N, Nelis E, Z&uuml;chner S, et al. Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene. Neurology 2004; 62:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/60\">",
"      Elliott JL, Kwon JM, Goodfellow PJ, Yee WC. Hereditary motor and sensory neuropathy IIB: clinical and electrodiagnostic characteristics. Neurology 1997; 48:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/61\">",
"      Verhoeven K, De Jonghe P, Coen K, et al. Mutations in the small GTP-ase late endosomal protein RAB7 cause Charcot-Marie-Tooth type 2B neuropathy. Am J Hum Genet 2003; 72:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/62\">",
"      Klein CJ, Cunningham JM, Atkinson EJ, et al. The gene for HMSN2C maps to 12q23-24: a region of neuromuscular disorders. Neurology 2003; 60:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/63\">",
"      McEntagart ME, Reid SL, Irrthum A, et al. Confirmation of a hereditary motor and sensory neuropathy IIC locus at chromosome 12q23-q24. Ann Neurol 2005; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/64\">",
"      Auer-Grumbach M, Olschewski A, Papi�� L, et al. Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C. Nat Genet 2010; 42:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/65\">",
"      Chen DH, Sul Y, Weiss M, et al. CMT2C with vocal cord paresis associated with short stature and mutations in the TRPV4 gene. Neurology 2010; 75:1968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/66\">",
"      Ionasescu V, Searby C, Sheffield VC, et al. Autosomal dominant Charcot-Marie-Tooth axonal neuropathy mapped on chromosome 7p (CMT2D). Hum Mol Genet 1996; 5:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/67\">",
"      Antonellis A, Ellsworth RE, Sambuughin N, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am J Hum Genet 2003; 72:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/68\">",
"      Fabrizi GM, Cavallaro T, Angiari C, et al. Charcot-Marie-Tooth disease type 2E, a disorder of the cytoskeleton. Brain 2007; 130:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/69\">",
"      Ismailov SM, Fedotov VP, Dadali EL, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2F) maps to chromosome 7q11-q21. Eur J Hum Genet 2001; 9:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/70\">",
"      Evgrafov OV, Mersiyanova I, Irobi J, et al. Mutant small heat-shock protein 27 causes axonal Charcot-Marie-Tooth disease and distal hereditary motor neuropathy. Nat Genet 2004; 36:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/71\">",
"      Nelis E, Berciano J, Verpoorten N, et al. Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13.3. J Med Genet 2004; 41:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/72\">",
"      Chapon F, Latour P, Diraison P, et al. Axonal phenotype of Charcot-Marie-Tooth disease associated with a mutation in the myelin protein zero gene. J Neurol Neurosurg Psychiatry 1999; 66:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/73\">",
"      De Jonghe P, Timmerman V, Ceuterick C, et al. The Thr124Met mutation in the peripheral myelin protein zero (MPZ) gene is associated with a clinically distinct Charcot-Marie-Tooth phenotype. Brain 1999; 122 ( Pt 2):281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/74\">",
"      Misu K, Yoshihara T, Shikama Y, et al. An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val). J Neurol Neurosurg Psychiatry 2000; 69:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/75\">",
"      Hattori N, Yamamoto M, Yoshihara T, et al. Demyelinating and axonal features of Charcot-Marie-Tooth disease with mutations of myelin-related proteins (PMP22, MPZ and Cx32): a clinicopathological study of 205 Japanese patients. Brain 2003; 126:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/76\">",
"      Birouk N, Azzedine H, Dubourg O, et al. Phenotypical features of a Moroccan family with autosomal recessive Charcot-Marie-Tooth disease associated with the S194X mutation in the GDAP1 gene. Arch Neurol 2003; 60:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/77\">",
"      Chung KW, Kim SM, Sunwoo IN, et al. A novel GDAP1 Q218E mutation in autosomal dominant Charcot-Marie-Tooth disease. J Hum Genet 2008; 53:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/78\">",
"      Crimella C, Tonelli A, Airoldi G, et al. The GST domain of GDAP1 is a frequent target of mutations in the dominant form of axonal Charcot Marie Tooth type 2K. J Med Genet 2010; 47:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/79\">",
"      Tang BS, Luo W, Xia K, et al. A new locus for autosomal dominant Charcot-Marie-Tooth disease type 2 (CMT2L) maps to chromosome 12q24. Hum Genet 2004; 114:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/80\">",
"      Irobi J, Van Impe K, Seeman P, et al. Hot-spot residue in small heat-shock protein 22 causes distal motor neuropathy. Nat Genet 2004; 36:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/81\">",
"      Kochanski A, Kennerson M, Kawulak M, et al. Mild early onset axonal Charcot-Marie-Tooth disease not linked to other axonal Charcot-Marie-Tooth loci. Neurology 2005; 64:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/82\">",
"      Pareyson D, Marchesi C. Diagnosis, natural history, and management of Charcot-Marie-Tooth disease. Lancet Neurol 2009; 8:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/83\">",
"      Boerkoel CF, Takashima H, Lupski JR. The genetic convergence of Charcot-Marie-Tooth disease types 1 and 2 and the role of genetics in sporadic neuropathy. Curr Neurol Neurosci Rep 2002; 2:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/84\">",
"      Latour P, L&eacute;vy N, Paret M, et al. Mutations in the X-linked form of Charcot-Marie-Tooth disease in the French population. Neurogenetics 1997; 1:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/85\">",
"      Shy ME, Siskind C, Swan ER, et al. CMT1X phenotypes represent loss of GJB1 gene function. Neurology 2007; 68:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/86\">",
"      Yiu EM, Geevasinga N, Nicholson GA, et al. A retrospective review of X-linked Charcot-Marie-Tooth disease in childhood. Neurology 2011; 76:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/87\">",
"      Nicholson G, Nash J. Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families. Neurology 1993; 43:2558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/88\">",
"      Ionasescu VV, Trofatter J, Haines JL, et al. Heterogeneity in X-linked recessive Charcot-Marie-Tooth neuropathy. Am J Hum Genet 1991; 48:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/89\">",
"      Ionasescu VV, Trofatter J, Haines JL, et al. X-linked recessive Charcot-Marie-Tooth neuropathy: clinical and genetic study. Muscle Nerve 1992; 15:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/90\">",
"      Huttner IG, Kennerson ML, Reddel SW, et al. Proof of genetic heterogeneity in X-linked Charcot-Marie-Tooth disease. Neurology 2006; 67:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/91\">",
"      Cowchock FS, Duckett SW, Streletz LJ, et al. X-linked motor-sensory neuropathy type-II with deafness and mental retardation: a new disorder. Am J Med Genet 1985; 20:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/92\">",
"      Priest JM, Fischbeck KH, Nouri N, Keats BJ. A locus for axonal motor-sensory neuropathy with deafness and mental retardation maps to Xq24-q26. Genomics 1995; 29:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/93\">",
"      Kim HJ, Hong SH, Ki CS, et al. A novel locus for X-linked recessive CMT with deafness and optic neuropathy maps to Xq21.32-q24. Neurology 2005; 64:1964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/94\">",
"      Salisachs P. Wide spectrum of motor conduction velocity in Charcot-Marie-Tooth disease. An anatomico-physiological interpretation. J Neurol Sci 1974; 23:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/95\">",
"      Davis CJ, Bradley WG, Madrid R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J Genet Hum 1978; 26:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/96\">",
"      Rossi A, Paradiso C, Cioni R, et al. Charcot-Marie-Tooth disease: study of a large kinship with an intermediate form. J Neurol 1985; 232:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/97\">",
"      Verhoeven K, Villanova M, Rossi A, et al. Localization of the gene for the intermediate form of Charcot-Marie-Tooth to chromosome 10q24.1-q25.1. Am J Hum Genet 2001; 69:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/98\">",
"      Kennerson ML, Zhu D, Gardner RJ, et al. Dominant intermediate Charcot-Marie-Tooth neuropathy maps to chromosome 19p12-p13.2. Am J Hum Genet 2001; 69:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/99\">",
"      Z&uuml;chner S, Noureddine M, Kennerson M, et al. Mutations in the pleckstrin homology domain of dynamin 2 cause dominant intermediate Charcot-Marie-Tooth disease. Nat Genet 2005; 37:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/100\">",
"      Jordanova A, Thomas FP, Guergueltcheva V, et al. Dominant intermediate Charcot-Marie-Tooth type C maps to chromosome 1p34-p35. Am J Hum Genet 2003; 73:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/101\">",
"      Jordanova A, Irobi J, Thomas FP, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat Genet 2006; 38:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/102\">",
"      Mastaglia FL, Nowak KJ, Stell R, et al. Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 1999; 67:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/103\">",
"      Banchs I, Casasnovas C, Montero J, et al. Charcot-Marie-Tooth disease with intermediate conduction velocities caused by a novel mutation in the MPZ gene. Muscle Nerve 2010; 42:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/104\">",
"      Ouvrier RA, McLeod JG, Conchin TE. The hypertrophic forms of hereditary motor and sensory neuropathy. A study of hypertrophic Charcot-Marie-Tooth disease (HMSN type I) and Dejerine-Sottas disease (HMSN type III) in childhood. Brain 1987; 110 ( Pt 1):121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/105\">",
"      Parman Y, Battaloglu E, Baris I, et al. Clinicopathological and genetic study of early-onset demyelinating neuropathy. Brain 2004; 127:2540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/106\">",
"      Parman Y, Plant&eacute;-Bordeneuve V, Guiochon-Mantel A, et al. Recessive inheritance of a new point mutation of the PMP22 gene in Dejerine-Sottas disease. Ann Neurol 1999; 45:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/107\">",
"      Ikegami T, Ikeda H, Aoyama M, et al. Novel mutations of the peripheral myelin protein 22 gene in two pedigrees with Dejerine-Sottas disease. Hum Genet 1998; 102:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/108\">",
"      Timmerman V, De Jonghe P, Ceuterick C, et al. Novel missense mutation in the early growth response 2 gene associated with Dejerine-Sottas syndrome phenotype. Neurology 1999; 52:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/109\">",
"      Boerkoel CF, Takashima H, Bacino CA, et al. EGR2 mutation R359W causes a spectrum of Dejerine-Sottas neuropathy. Neurogenetics 2001; 3:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/110\">",
"      Boerkoel CF, Takashima H, Stankiewicz P, et al. Periaxin mutations cause recessive Dejerine-Sottas neuropathy. Am J Hum Genet 2001; 68:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/111\">",
"      Charnas L, Trapp B, Griffin J. Congenital absence of peripheral myelin: abnormal Schwann cell development causes lethal arthrogryposis multiplex congenita. Neurology 1988; 38:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/112\">",
"      Ghamdi M, Armstrong DL, Miller G. Congenital hypomyelinating neuropathy: a reversible case. Pediatr Neurol 1997; 16:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/113\">",
"      Levy BK, Fenton GA, Loaiza S, Hayat GR. Unexpected recovery in a newborn with severe hypomyelinating neuropathy. Pediatr Neurol 1997; 16:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/114\">",
"      Phillips JP, Warner LE, Lupski JR, Garg BP. Congenital hypomyelinating neuropathy: two patients with long-term follow-up. Pediatr Neurol 1999; 20:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/115\">",
"      Mandich P, Mancardi GL, Varese A, et al. Congenital hypomyelination due to myelin protein zero Q215X mutation. Ann Neurol 1999; 45:676.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/116\">",
"      Kochanski A, Drac H, Kabzi��ska D, et al. A novel MPZ gene mutation in congenital neuropathy with hypomyelination. Neurology 2004; 62:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/117\">",
"      Bolino A, Lonie LJ, Zimmer M, et al. Denaturing high-performance liquid chromatography of the myotubularin-related 2 gene (MTMR2) in unrelated patients with Charcot-Marie-Tooth disease suggests a low frequency of mutation in inherited neuropathy. Neurogenetics 2001; 3:107.",
"     </a>",
"    </li>",
"    <li>",
"     Bird, TD. Charcot-Marie-Tooth neuropathy type 4. Gene Reviews.  www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=cmt4 (Accessed on November 03, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/119\">",
"      Ben Othmane K, Hentati F, Lennon F, et al. Linkage of a locus (CMT4A) for autosomal recessive Charcot-Marie-Tooth disease to chromosome 8q. Hum Mol Genet 1993; 2:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/120\">",
"      Baxter RV, Ben Othmane K, Rochelle JM, et al. Ganglioside-induced differentiation-associated protein-1 is mutant in Charcot-Marie-Tooth disease type 4A/8q21. Nat Genet 2002; 30:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/121\">",
"      Cuesta A, Pedrola L, Sevilla T, et al. The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet 2002; 30:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/122\">",
"      Pedrola L, Espert A, Wu X, et al. GDAP1, the protein causing Charcot-Marie-Tooth disease type 4A, is expressed in neurons and is associated with mitochondria. Hum Mol Genet 2005; 14:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/123\">",
"      Bolino A, Brancolini V, Bono F, et al. Localization of a gene responsible for autosomal recessive demyelinating neuropathy with focally folded myelin sheaths to chromosome 11q23 by homozygosity mapping and haplotype sharing. Hum Mol Genet 1996; 5:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/124\">",
"      Bolino A, Levy ER, Muglia M, et al. Genetic refinement and physical mapping of the CMT4B gene on chromosome 11q22. Genomics 2000; 63:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/125\">",
"      Quattrone A, Gambardella A, Bono F, et al. Autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths: clinical, electrophysiologic, and genetic aspects of a large family. Neurology 1996; 46:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/126\">",
"      Bolino A, Muglia M, Conforti FL, et al. Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2. Nat Genet 2000; 25:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/127\">",
"      Othmane KB, Johnson E, Menold M, et al. Identification of a new locus for autosomal recessive Charcot-Marie-Tooth disease with focally folded myelin on chromosome 11p15. Genomics 1999; 62:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/128\">",
"      Hirano R, Takashima H, Umehara F, et al. SET binding factor 2 (SBF2) mutation causes CMT4B with juvenile onset glaucoma. Neurology 2004; 63:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/129\">",
"      Senderek J, Bergmann C, Weber S, et al. Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15. Hum Mol Genet 2003; 12:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/130\">",
"      Azzedine H, Bolino A, Ta&iuml;eb T, et al. Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma. Am J Hum Genet 2003; 72:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/131\">",
"      Kiwaki T, Umehara F, Takashima H, et al. Hereditary motor and sensory neuropathy with myelin folding and juvenile onset glaucoma. Neurology 2000; 55:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/132\">",
"      Gambardella A, Bolino A, Muglia M, et al. Genetic heterogeneity in autosomal recessive hereditary motor and sensory neuropathy with focally folded myelin sheaths (CMT4B). Neurology 1998; 50:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/133\">",
"      Conforti FL, Muglia M, Mazzei R, et al. A new SBF2 mutation in a family with recessive demyelinating Charcot-Marie-Tooth (CMT4B2). Neurology 2004; 63:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/134\">",
"      LeGuern E, Guilbot A, Kessali M, et al. Homozygosity mapping of an autosomal recessive form of demyelinating Charcot-Marie-Tooth disease to chromosome 5q23-q33. Hum Mol Genet 1996; 5:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/135\">",
"      Gabre&euml;ls-Festen A, van Beersum S, Eshuis L, et al. Study on the gene and phenotypic characterisation of autosomal recessive demyelinating motor and sensory neuropathy (Charcot-Marie-Tooth disease) with a gene locus on chromosome 5q23-q33. J Neurol Neurosurg Psychiatry 1999; 66:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/136\">",
"      Guilbot A, Ravis&eacute; N, Bouhouche A, et al. Genetic, cytogenetic and physical refinement of the autosomal recessive CMT linked to 5q31-q33: exclusion of candidate genes including EGR1. Eur J Hum Genet 1999; 7:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/137\">",
"      Senderek J, Bergmann C, Stendel C, et al. Mutations in a gene encoding a novel SH3/TPR domain protein cause autosomal recessive Charcot-Marie-Tooth type 4C neuropathy. Am J Hum Genet 2003; 73:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/138\">",
"      Azzedine H, Ravis&eacute; N, Verny C, et al. Spine deformities in Charcot-Marie-Tooth 4C caused by SH3TC2 gene mutations. Neurology 2006; 67:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/139\">",
"      Kalaydjieva L, Hallmayer J, Chandler D, et al. Gene mapping in Gypsies identifies a novel demyelinating neuropathy on chromosome 8q24. Nat Genet 1996; 14:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/140\">",
"      Kalaydjieva L, Gresham D, Gooding R, et al. N-myc downstream-regulated gene 1 is mutated in hereditary motor and sensory neuropathy-Lom. Am J Hum Genet 2000; 67:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/141\">",
"      Guilbot A, Williams A, Ravis&eacute; N, et al. A mutation in periaxin is responsible for CMT4F, an autosomal recessive form of Charcot-Marie-Tooth disease. Hum Mol Genet 2001; 10:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/142\">",
"      De Sandre-Giovannoli A, Delague V, Hamadouche T, et al. Homozygosity mapping of autosomal recessive demyelinating Charcot-Marie-Tooth neuropathy (CMT4H) to a novel locus on chromosome 12p11.21-q13.11. J Med Genet 2005; 42:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/143\">",
"      Stendel C, Roos A, Deconinck T, et al. Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am J Hum Genet 2007; 81:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/144\">",
"      Fabrizi GM, Taioli F, Cavallaro T, et al. Further evidence that mutations in FGD4/frabin cause Charcot-Marie-Tooth disease type 4H. Neurology 2009; 72:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/145\">",
"      Chow CY, Zhang Y, Dowling JJ, et al. Mutation of FIG4 causes neurodegeneration in the pale tremor mouse and patients with CMT4J. Nature 2007; 448:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/146\">",
"      Zhang X, Chow CY, Sahenk Z, et al. Mutation of FIG4 causes a rapidly progressive, asymmetric neuronal degeneration. Brain 2008; 131:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/147\">",
"      Amato AA, Reilly MM. The death panel for Charcot-Marie-Tooth panels. Ann Neurol 2011; 69:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/148\">",
"      Saporta AS, Sottile SL, Miller LJ, et al. Charcot-Marie-Tooth disease subtypes and genetic testing strategies. Ann Neurol 2011; 69:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/149\">",
"      Sereda MW, Meyer zu H&ouml;rste G, Suter U, et al. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 2003; 9:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/150\">",
"      Passage E, Norreel JC, Noack-Fraissignes P, et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 2004; 10:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/151\">",
"      Burns J, Ouvrier RA, Yiu EM, et al. Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol 2009; 8:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/152\">",
"      Micallef J, Attarian S, Dubourg O, et al. Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2009; 8:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/153\">",
"      Pareyson D, Solari A. Charcot-Marie-Tooth disease type 1A: is ascorbic acid effective? Lancet Neurol 2009; 8:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/154\">",
"      Sahenk Z, Nagaraja HN, McCracken BS, et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005; 65:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/155\">",
"      Chaudhry V, Chaudhry M, Crawford TO, et al. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/156\">",
"      Weimer LH, Podwall D. Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease. J Neurol Sci 2006; 242:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/157\">",
"      Guay J. First, do no harm: balancing the risks and benefits of regional anesthesia in patients with underlying neurological disease. Can J Anaesth 2008; 55:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/158\">",
"      Greenwood JJ, Scott WE. Charcot-Marie-Tooth disease: peripartum management of two contrasting clinical cases. Int J Obstet Anesth 2007; 16:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/159\">",
"      Dhir S, Balasubramanian S, Ross D. Ultrasound-guided peripheral regional blockade in patients with Charcot-Marie-Tooth disease: a review of three cases. Can J Anaesth 2008; 55:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/59/35770/abstract/160\">",
"      Brock M, Guinn C, Jones M. Anesthetic management of an obstetric patient with Charcot-Marie-Tooth disease: a case study. AANA J 2009; 77:335.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6220 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-B1A854215F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35770=[""].join("\n");
var outline_f34_59_35770=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19900458\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HMSN/CMT 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Genetics of CMT1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4307678\">",
"      - CMT1A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4307685\">",
"      - CMT1B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4307635\">",
"      - Additional CMT1 subtypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Roussy-Levy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HMSN/CMT 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Genetics of CMT2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4307628\">",
"      - CMT2A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4307590\">",
"      - Other CMT2 subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      X-LINKED CMT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4308332\">",
"      CMTX1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4308339\">",
"      Additional CMTX subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DOMINANT INTERMEDIATE CMT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HMSN/CMT 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dejerine-Sottas syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Congenital hypomyelinating neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CMT 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HMSN/CMT 5, 6, AND 7",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      GENETIC TESTING AND COUNSELING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H781703\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H782027\">",
"      Drugs that may exacerbate CMT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1431397\">",
"      - Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19900458\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6220\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6220|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/37/39517\" title=\"table 1A\">",
"      CMT types 1 through 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/3/16445\" title=\"table 1B\">",
"      CMT types 4 through 7",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/16/43272?source=related_link\">",
"      Hereditary sensory and autonomic neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21895?source=related_link\">",
"      Overview of hereditary neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/59/24497?source=related_link\">",
"      Patient information: Charcot-Marie-Tooth disease (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_59_35771="Products of carcinoid tumors";
var content_f34_59_35771=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F79329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F79329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Products of carcinoid tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Amines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5-Hydroxytryptophan",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Norepinephrine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dopamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Histamine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Polypeptides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Kallikrein",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic polypeptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bradykinin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Motilin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Somatostatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasoactive intestinal peptide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuropeptide K",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substance P",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurokinin A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurokinin B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Corticotropin (ACTH)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastrin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Growth hormone",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptide YY",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucagon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta-endorphin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurotensin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chromogranin A",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Prostaglandins",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35771=[""].join("\n");
var outline_f34_59_35771=null;
var title_f34_59_35772="Polygenic risk in JIA";
var content_f34_59_35772=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F72340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F72340&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Polygenic risk in early-onset pauciarticular juvenile idiopathic arthritis*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number",
"       </td>",
"       <td class=\"subtitle1\">",
"        Percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        x",
"        <sup>",
"         2",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        p",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative odds ratio",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        DRB1*0801 study (n = 98)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female sex",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        90.8",
"       </td>",
"       <td>",
"        14.12",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        4.51",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female+HLA-A2",
"       </td>",
"       <td>",
"        67",
"       </td>",
"       <td>",
"        68.4",
"       </td>",
"       <td>",
"        29.71",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        8.74",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female+HLA-A2, DRB1*0801",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        21.4",
"       </td>",
"       <td>",
"        17.21",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        63.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female+HLA-A2, DRB1*0801, DPBI*0201",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10.2",
"       </td>",
"       <td>",
"        8.96",
"       </td>",
"       <td>",
"        &lt;0.010",
"       </td>",
"       <td>",
"        119.00",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        DRB1*1301 study (n = 102)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female sex",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        91.2",
"       </td>",
"       <td>",
"        14.44",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        4.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female+HLA-A2",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        72.5",
"       </td>",
"       <td>",
"        7.28",
"       </td>",
"       <td>",
"        &lt;0.010",
"       </td>",
"       <td>",
"        5.55",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female+HLA-A2, DRB1*1301",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        20.6",
"       </td>",
"       <td>",
"        9.78",
"       </td>",
"       <td>",
"        &lt;0.010",
"       </td>",
"       <td>",
"        10.50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female+HLA-A2, DRB1*1301, DPB1*0201",
"       </td>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"       <td>",
"        13.21",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"       <td>",
"        52.00",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on homogenous population of 98 patients studied for DRB1*0801 and of 102 patients studied for DRB1*1301, from Cincinnati/Indianapolis area.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Calculated based on risk of 1.00 for individuals negative for all risk factors.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35772=[""].join("\n");
var outline_f34_59_35772=null;
var title_f34_59_35773="1996 1999 2007 recs ACIP";
var content_f34_59_35773=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72958&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of recommendations of the Advisory Committee on Immunization Practices (ACIP) for prevention of varicella-United States, 1996, 1999, and 2007",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category",
"       </td>",
"       <td class=\"subtitle1\">",
"        1996 recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        1999 recommendations",
"       </td>",
"       <td class=\"subtitle1\">",
"        2007 recommendations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Routine childhood schedules",
"        </strong>",
"       </td>",
"       <td>",
"        1 dose recommended at age 12-18 months",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          2 doses recommended:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          1st dose at age 12-15 months",
"         </li>",
"         <li>",
"          2nd dose at age 4-6 years",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Adults and adolescents aged &ge;13 years",
"        </strong>",
"       </td>",
"       <td>",
"        2 doses, 4-8 weeks apart",
"       </td>",
"       <td>",
"        2 doses, 4-8 weeks apart",
"       </td>",
"       <td>",
"        2 doses, 4-8 weeks apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Recommended for susceptible persons who have close contact with persons at high risk for serious complications:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Health-care workers",
"         </li>",
"         <li>",
"          Family contacts of immunocompromised persons",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td rowspan=\"3\">",
"        Recommended for all adolescents and adults without evidence of immunity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Should be considered for susceptible persons at high risk for exposure:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Persons who live or work in environments in which transmission of VZV is likely (eg, teachers of young children, child care employees, and residents and staff members in institutional settings)",
"         </li>",
"         <li>",
"          Persons who live and work in environments in which transmission can occur (eg, college students, inmates and staff members of correctional institutions, and military personnel)",
"         </li>",
"         <li>",
"          Nonpregnant women of childbearing age",
"         </li>",
"         <li>",
"          International travelers",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         <strong>",
"          Recommended for susceptible persons at high risk for exposure or transmission:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Persons who live or work in environments in which transmission of VZV is likely (eg, teachers of young children, day care employees, and residents and staff members in institutional settings)",
"         </li>",
"         <li>",
"          Persons who live and work in environments in which transmission can occur (eg, college students, inmates and staff members of correctional institutions, and military personnel)",
"         </li>",
"         <li>",
"          Nonpregnant women of childbearing age",
"         </li>",
"         <li>",
"          International travelers",
"         </li>",
"         <li>",
"          Adolescents and adults living in households with children",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Is desirable for other susceptible adolescents",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Catch-up vaccination",
"        </strong>",
"       </td>",
"       <td>",
"        1 dose recommended for all susceptible children aged 19 months-12 years (ie, those with no history of varicella or vaccination)",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"       <td>",
"        2nd dose recommended for all persons who received 1 dose previously",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         HIV*-infected persons",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Contraindicated",
"       </td>",
"       <td>",
"        2 doses, 3 months apart",
"       </td>",
"       <td>",
"        2 doses, 3 months apart",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Should be considered for asymptomatic or mildly symptomatic HIV-infected children in CDC immunologic and clinical categories N1 or A1 with age-specific CD4+ T-lymphocyte percentages &ge;25 percent",
"       </td>",
"       <td>",
"        Should be considered for HIV-infected children with age-specific CD4+ T-lymphocyte, lymphocyte percentages &ge;15 percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May be considered for adolescents and adults with CD4 counts &ge;200/microL",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Antenatal screening",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Recommended prenatal assessment and postpartum vaccination",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Outbreak control vaccination",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Should be considered",
"       </td>",
"       <td>",
"        Recommended 2-dose vaccination policy",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Postexposure vaccination",
"        </strong>",
"       </td>",
"       <td>",
"        None",
"       </td>",
"       <td>",
"        Recommended within 3-5 days",
"       </td>",
"       <td>",
"        No change",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        <strong>",
"         Vaccination requirements",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        None",
"       </td>",
"       <td>",
"        Recommended for children without evidence of immunity attending child care centers and entering elementary school",
"       </td>",
"       <td rowspan=\"2\">",
"        Recommended for children attending child care centers, students in all grade levels, and persons attending college or other postsecondary educational institutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should be considered for middle school and junior high school students without other evidence of immunity",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Human immunodeficiency virus.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Marin M, Guris DG, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56(RR-4):1-40.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35773=[""].join("\n");
var outline_f34_59_35773=null;
var title_f34_59_35774="Dieulafoys lesion Endosc";
var content_f34_59_35774=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dieulafoy's lesion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 323px; height: 317px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE9AUMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5bNApDQKLFC0UUDnpRcLCEZpyqxIAp6RkHkGrKqAOOtJyNIwuV1gdj81WVtht5qRAT1FSjpzWMpG8aHUjjjCLxU0QYc9qVEyOKmiQ7aycjqpxHRhqdIWVDUyjC1XnbgipT1NHEoysxzTN7BRT+SDUTcVomYVES5YilgnaJ+e9Qhz0p+QOT1qmTFF24lDpnvVFiS/Hamlzn2pwXJzQhyZHLv8AWoiHJ5qaY49ajVuelWjCQ5Ay81Ytw0khz0NQGTI4p9tKY3Unlc0mJFqWyOCQKzpInVyp7VtXN8hiAQYOKy5XLZJ60RCWxXcELxSIzYFP5A5pgPNWZMV2am4OKVz70ckU0SN5FKGY9qCDS7vSmFhOcUqswFJzQMkUmCQAMzZpzpk0RkjipAaRaREIyBmmOD1NWQ3PTihlBHSgbhzaldelIakaIjnBqM9aLmUlYXtQvWjtQvWqWxKFooooAioooHJwK0Y46jlGTg1ZSNUXPenQW2OWPNWNgPbNYSZvGJDnLLmpo0Bc08oNy8VIiDcT0rFyOlQsNCkHjpUu0bfelGKliiBbJP4Vk5GyfQjiQk4zVuOLHekhjUP0OKskAHiobOinEjIAFZ9yuT+NaJFVJkGaSepcolIpxUZj61c8vjNMZAelapnNOJR24NJ0Bq2Ivao5IwKtMzcdCu3QVOuPK3ZxUci4XimbgQFNWjGQ1m3HrSx4ZuTTXRR0qM/JypqkYsl2EMQO9Lgx4VhSJLjBIqaSZZccc0MaI5TkDFRk4ODTnj6EGmEfMaIhLYa4zSBRilakGaszaBlFKvSlPTrSLTQkhGoUcUOKVelMLDQOadk7aTIBpc8UmMRCc0/vTUznpUnepLQ5ac54GKQDjFKy4xSbNI7CljgVDLFkZHWp2YBRjrSxgYyaVyZQuUcEdetIOtWriMbNw6+lVe9aRehzzjyscKKB0opkEJOBirFrDn5jUEKb5AK1lQRoADUyZpRjqIo3GplUjpTF4PFWogCMmueTO5IjUc805lJ4FShMnmnhemOlQ5GyRCsRxU8MZHNSqmenNWI4jWMpG8YDI1OKlCbjipUQDrUqpnpWfMdcEVDFiqs8fWtJozVSZdvLdKFIJRuUMfKRSpCSOKm2jBxTo/ukVomZuBB5eOpqCVFzzVwoSeahlhyRjmq5iHTuUJEHaoGiPWtQQjvTZIQRxWkZGFSjcytvbNNaMA1aliweDURBAraMjjnRcdSLbxTcbTTwcHk0uATnNVzGXKxUYGgoCaaQB900gYihsNgdKj2H14qUnNMK+9CZLG4xQqgfxU6k2g9Kq5FwZQf4qQCnbAOtAouGo0haGGFpSo9akxlaGxqFxVXKChR83NSIOABT9ozzUORrGnYY4HbrSoPWnlFJ4OTShT3FRc1URpUY4pNuKft54pDkUXHyibcjFUpk2tmrmTRKisnFXEicShketFBXk0Vdjm5SWxjy2TVsnc5FQ2wJ5TpViJcNk1MmaUYksK+tWtygYqBBnpUiqD1PNc8mdyRKgyanC8U2KIAc1Oic57VjKRvCAQoatopxRBHk8CriR4+8OKxlI64xViOOLcOakMe0cVLjHQUFWI6Vnc2giqMc5qncHcxXqKnuiyNikjQbd2MmmmVy6lUxfJ6VH5ZVMirc+dvFMCjyhVpicCkpJzmoyGLcHAFTS/KeKbj5TnqatXJ5CNjg8daR2xjjrTlQ4JxUbuf4hjHFXFmcokEwGOlVSMmrbEt0FRMK2izCdO6K5hpPKPUDirKg96f/AAjaKvmMJUfIpmMjtSkpsGRzV1lzHyBmqhHzEFRQmYSovsVSATwcUhTnrVhkAPA5pFhyevNWmZOk+xBnFIvFWzBgc0woKfMQ6RA2TT1HFSBB6U4IMUXLjSI9op6qMU7bnpUqJUykbwpW6CRIMU9kqeKPjpTmj9qzci+QqqnNOYYqbYBTWQk8UlIlxIcc5pjnmpmBxjvUJRjTuKw3GRQPSnrweaTgHNNSaJlG6GGDJzRUu4UVXOzHkG29u3lnFTJCUHNWovljyO9LJyMHrRJjpRIcY6VPCueagBz1q1bgkHFYtnWok8WS2MVZ24IGKbCMD3qUZzzXPJnYoli3T0q0FNR2qk1bAArmkzZRIwtOI+XApw4NOA5qUzaMShew5Ge9JAu2Js+lSXG4vt4qB3aP5T1NaJmqiQBHkJ44pSMKQRVy3DgdBzTJwB9/rRzBymO6kPzSsmFz61POB1NV/N6g/hXRGWgnEjZtoNVWy2anlbPSoguee1UjOUSPGKaVNSN14pGPpVpmElYZg4poBp5c4pFz+NVczaYMDtqApyDVtgdtRYPFCkRKLK7IS4p4hZCSalX74yKkOT97pT5hKlcrMC3FMETGre0H7oqVNp470cw/q1yh5RFORDjmrMi5OBimMMDijmE6PKQhOeKnjTmiABs+tWIVzScgUSSOP2pzKfSp0AC0cntWbkJxKbKfSoWVs1fcgDpVOVmDdBRFkOJGeuCKgH3jVhuQT3qJMA4bqa0TM3EaseQajZCDVrocUxwatMXLoRCPiinfNRRcy5S7CB5IqO4OHAFKhxEBnpSnDEHFEtApRGRRhnxV+3h21FbRYfJORWnFEG5HFYOSOxQYxBip0XJFKIj14qaJQpBNYSkdaiSwjbVgCoR6gVYT7ucVzyNkgC1JtGKYvJxSyHYpOc1KZrGxQvuJRioJkYbWPelJMtxu6AetWJ5kKYCkmqNoomiwlvu71U8sysWYcUtvKxBRhkVaMixx4xSvqXymZdQqFNZMigHitW7mLZxWbISzfSuiD0Ja0ICKYwxU5FNZM81qmYyiQgGkIyeRU2PQUgznpVXMvZtkexfSgR5bI6VMQSOMURg5wRzSuUqIwJniklhZBkCrEaHzKtsvy4YcUcxTomSq5HTmniPjmpZ0KnK8CoySQMU+Yl07DThelAUClVSetOeM9e1FyUmRlRnNRsP3gFWMDHSmYBfNNMiUe4mzaeKt2q461Chy2MVehAXqDUtmLSHLHk5pzLgU9QcjHApJCelZtkuJVfOelU7jrV6VWCk1nyZLVUGQ4jNpZeKe0W0A96ljAC4IOaVlJPTitVJEODINpY4HWkKEVbWPJBAps8ZVcmmpIXI7FXiimlufumiquZcrLEMRKVZW3+WnW6/uwfWrBQjAp1ZE0VqRwx7OtX4FyKZEnHIqzECBwK5HI7ooeE4pyx1JGpIx0qZUwMZrC50pEaJgVMp+XFKABx1pTtA4ODU76GyVxjOsYyaqXF4m0461HfPnIBqiFGPmFPlsaKFhXmzkrUkEmQc8mnQQKwxileIRc02lY1irD7fmSn3UTkjbTIkZzuU4rQQFlGecVlsy2YcttJgnBqi6PGTuFdadpUjbWbeWytzwMV0QkQzAzmhztGB3qWZNrHFQsT0IrVMhguTShG7CmgkdKlhkKnnkVTehMdxFRgfmFWEi3j5asFo2izjmqqzFJMj7vpWd2zVWFEUkbZxmnSTnHI5q9DcxunzCoJxE2SCKlPUbsUJDvFQ8jippMDgUwMK0RlKwzJFOaTI6UFsngUwkjtVpGMpWGsxpcDdxTWJboKeE54o2MW7ixZ8zitGHcx6VWtom3ZrTgiJXPSolJE8jY5YzimNHnmplVmzip1hLJ6Vm5IpU2ZrR5yKqy253ZArUaMq2MVJ5OQOKXtLD9k2ZUduSOlW0tgE5FX0tsEcU8xdqPaB7Iy2h54FU72NgvWuh8gFKoX9sCvFCqaidPQ5zZ70Vo/Yj60Vt7RGHsx9t/q1q4R8wqC2T90tXimCDWlW5x0FfUbGmB1q3Ag656VGgBHIxViBc9BXG2d0ddiQc9BUqr3p0aAdafjnis+ZHSkKijHK1Tu5ApPHFXxnHWsu/OJMMeDSW50QjqjNuCzOSOlQjczYPStOUKyAIuapyQulXc6lG+xatQAtMvCzDAHQ1YsI9yZJ5p04zwFBrPm1DkZFaEKnNWEO7O04qq0JUZ3Gm5YD5TSeuw/ZyZbkQqhO+sm6lbOC1SSyyAEGqkpJ7ZrWCaMpQklqV35ySahIOeOam281YtoVIJrbmsZuLM8qw5xSBuMGtWdVAxiqDRgnirUkyHGXQRH2r1o8xSMGk8s0bcH7tGgJSHKQelByCeeKVUPXHFTeUXXgVLdiuSb2KjEU0FRVk25B5zQtuSDleKpSRnKnUXQqqcnigqWPBqysOGq3aWYc5GaHNIy9lN9ChFbse9Xbez9a0VtkXh+KswwBj8q1jKqaRpNblSC1UVbWMkYUVcjs2x92r1tabTyK55VTeFK5QtLMnlhVh4Ai8CtdIAo54pkkG7is3UNVSOeMBd8YxmpvsZUDmtxLEAEml+zhjjHHrU84OkzG8kjHel8nPatl7dRgYoSAE8CjnJcLGQYcL05qrJBknIropYAE6fNVG5t+KalqRKNzBNsM9KK1fIPpRWnOZezZzdv8A6patEHcKr2wPkg4q+qZwcV6dZnj4aOgyNM9atQKUIpqoAeatRKCBiuFs7KUdRwBJqxHGByaaDjoOakUEj5uKy2OqMRrp82RWVqluWO4CtxV3AA9KR7dnBCgGkpanTGJztn12nqKfdxFlPpT7iF7Wcnb1q3FiSL5umKvmO2nAx7eQxkgmrcUqgkk5qC6RVY7ahjDdQKT7mypXZamnDDgVTMpzgVbVBsyRzVdlG45GKEzf2NhrjcvNVWXGc1YZiBxUcke5MknPtWkHZnNVXIroptKiHmnR3Csfk4qGa2DZ+9mm2un3EkuIgcV0qMWjyp4qopW5S053Hmk8otyvSrZsZ4APNSpFjIXpUysj0aV6sbNFLyWp6QbhzVtkORU6RZwtc8qljshguYgs7EyuFxxW7b6Om0DHSrWm2oEWe9bthbnGWxXHUxDNXg1E5mbRVH8NZt1YiN9orvLtY0jJ7iueNq91cFimFzxinHEOxDwiZkwaSjEZ71oQ6cqD5FxW/bWYAGF5FTmykJ+6B9KX1hsynhYxOSuLTacsKW1QBwAK6l9NGPnBJotNJVH3MtS61yPYIqW1qSgOKtrBznFa6Ww2gBelDWpL56Vk6gvYpbGd9lMgzjpSrZnrit6K3Hl4NOhgGTxS9oJwsYLW7bSMdaVLbAwRzW40IycjpVd4wDkU1O4KJktb9iKikh8kZArWaMu3IqGWEYweaOch07mOwL845qGaIkVqNb4JIqJ4yRzVxmZSp2ZleQaK0Nhoq+cj2Z5/aDNuKujI21BZKfs659avGP7pr2q2x8/hVdDQMnmpoztpuwMOKmhhJFcDZ3UoO45AS2e1WgDxUtvbDZVhIVANQ5I6oxIFUsMCpkhcL15qeKLByBU5iGMkmsWzpjEytUiUQ5ZcmsJWKgjtXXXEJkiIxkVzF5b+VIeDitIvm2O6ijKmyWJqa1KAHdSyRrztPNMEJA4q2d8aT3JZHXtVVyHqQoRTGFJFODsQOvTFbmiaQ990UkL1rLVASM12/hHURp0cgEYdXxmpnOyOKrGUVzFC68OpG33Oahh0/wCyyiQLwvauyu7yO7YPbxMG75rMv9+BmEqcde1XRxCelzms3q0Y2oSx3EOPLwR7Vzrx7WIxXTTyII9uzB9axbqMb8jmrlJ3NaMpyly20KTLyKsJH0NCpu61PGhA56Vzzke9h4aal20mZBgVq292VQDvWRbRM5xGCTXRaXpbvtaYcVyVY3QV5Rpq7GQRmdvnBwa04LVUAAWtO3sY0ACiphbgEgioVkeXUxSvoU44EHIHNWxB8uSKmgtgGy2cVb8scDtSOSda5kyR5ONtCRksARWwsCYzjmkNuOoFBn7dFHygq1AAd+DWo0OeDTWslJzzmm1carJblfZ8tOVQgqf7OQQO1OMAI5qWR7RMpSgnp3qu0DGtRouOnSkKKF560rjUzL8vavPWq8kZJ6VoyAs2AOKYYsUXNE7lAw/J0qpLH8p4rWlAC471BNCvlkgHNVFiaMbYfSirXlN6UVdybHm9mn+jitBYsgfSqtnGBAu6tNIyVG30r360tD5nBR0I4ogRVyCMdMUyGLHar0KD0rzpSPRpx1HxBFGKlWIZyBzQkJLVowRYA45rJyOmMSvDGSORipDBzVpVYHnpTvK+bpxWbkdUIlMRnGAKpXWnpNkMK2whHQUiwgtkilGpynXC0TjpNHKycDipxpQEZIHNdebYOvC81DNZuEIFaKpdnXCsloef3dqUYjFZ8kRBNdfqNoMnsawJowGIrZM7oRU0ZwjOBWvplyIQd54qoFPSlQhXG78OKymlP3WZSoLm1Oy0+YTKGRwoFLq9xG6L8xZgMbF6ms3w3HPqF2LaE7Sa7FdPTwzfxXd3GskgXv6fSnhaFJT1Z4+KlyT5Y7nnuoWt7axiaRGELdFI5qiFc43DGea7Txz4hTV2T7JbiL1PauSbJAwee9ehXhRgrwd2deFoyqRTasyMIM4FaGn2DzkE9DVZVUMuOtdRo0REaHbxXl1Zq56Un7KBd07SEiUErWzDDtAAGBTrYnaABVxEyeRWHNfQ8GtiJSlqRLEeoqREzndVhEJ4FOaHJ5osckqhXRSTjtVjaOKUR4HFO7jNIhyuOCcUhXP3akz8vFRodvagy5mM8v1pc0ryA9ahJz92lexotdxzGmbhnrS7cg5pqxDqKW5asRyz4OMUBgV5olQE8ikRAKLFqwmQeAKDHuFOIwwB6UH5uEosPmKskOOnWopUOzpWkkGSMjLVP9lUjBWmh+3UdzAEDY+7RXSrYrgfJRVC+txPDLJCYBn1rXjTaoA9Kpaen7iPcetagXg4Ne5iNDw8FHQWGIEVYSPBohXBxVxI8jNeY5Ho01qLbrzyKuxocjFV4gc9K0YQcDisXI64QGiE9amSMbfepD93FSRIdmcZNTzam3w6kHl+1LHHlulXo4y3an/Z8c0S12J9qV44tvUU6SMEcjirAXsRTtuBz0q4vlJ5+pzGsWYKkqtcnd2u09Oa9JlRJMhlBrE1PTEkUlFAIraM0z1MJjFHSRwLRkGkwV4DlT9Otal3ZvCxyM1QCEPzRKPVntxUaiui7pN7Jp96lxB8zDrWpruuTasVkkO0qNuAc5rERCDwcVI8e0ADoeTWGl7nPLB0pTUmtSKY+YRubimIiZ2xjipvJZiNvJrV07TixDuPwpSlbU0cqdCN0JpWneY6s68V1tlZqQoRcCo7C02AY4HpW/YQYxtUYrPVnz+NxUm9GMjt9i4xViKAlQavpAD1UVajhUAZUVoonizxBnwRYPNPeEZJrSMK44UVE8NPlMPbXZmmPFRMADV94qqXEJPKnGKHE3jMQYxSPgCmq46d6HbJwKzehZC3OaIk5qURE4p5Taah6jb7CeXkcU3ZtFWEXijHPPNUtCeexQljJzimRoR1rUMS4ztquVXkkYplxq3KUoyMDrU0UYC8dabEm+Q1eghx1FIcppDIEw2T1qyiZNSJEA2ccVZSLABAqlG+pyVKiGhOBRVoRjA4oq+U5/aHz5YJugj5rTEe0E+9QadGDax4GK0vK+Q5r1sS9C8FHQjh+c8VowocDNRWsBX+EVoxRkkcV5dz0qcdRkac9KvwrwOKYsJ31dSI4FZm8XYhCZNXbdelEcOOtThMDIqSZzvoPVR6UFPShM1Nt4zVIwcrEQQe1NZKtIme1PMWewqifaWMyS3PUVWkgLfStt48LVYqMkVcVYuFaxy+p2AkQ7QM1y0+myxyH5eK9Mktww6Cqc1gGPIFbp82jPSoZg4aHnDwyRjlaYiSTHaBjtXoEulK/wDCtNh0dVPCL+VTKCO9ZnDl1MHTtNCxgtgt71u2dlyMqBWhDp5GPlrQgszkZ4rnmtDyq+O5nuVIbYqRtXiteyhOB0FTW9tjFXFh6ADHvSjE8itiLjFj5qcJgVIIdq+9CqWGOmK1UTidS43iopFzUrfLwahkkAoeg4shKc1C8OTVguSPkXNLjjJrOTuaqdimbVAM8ZqN7cA1fIBqMj8aVi41GVAmOlO2jPNWRHmo/s7BuTSaG6g3y/SnrEueasLHx0pphIPWlYnnuQyKB0qhPEztgVpMMMBikEWTxSZUZ2KUNt5QyetW4kzVlbfcORUiwhR0FNK5Eq1yBUyQKsquBQEwacfvAVpFWMZSuPCHFFTBDiimYcx4PYRbLWOtONMxn61X0yP/AESLPPNa8cBLmvQxcraHpYJXQltETWjEoUdKW3hwKsrHyK856Hox0ERBjNSpR5dLtxUXFccpqUDimRgk1ZVMjnpU2MpsYi81YVQRSJGBzUyAZ4pmEpCxpUhU8bakjHFO25NWnqYORH5W4c1E9su4YrRSPIqTyhjkVpcz9rYyntuOKWO1HcVrBFA5FNWME5qkw9uyktqvdRUgtUA+6KuGPNOEJ7VRjKrK+5nyRCNchRUUKNK+7oOlbiW5I5ANPW2UD7oB9qHHmVhfWVaxnxxYxVhEOOKuLAopWi44pKnYxdW5SIbODUipxkdam8rA5oVapqwnO5UnUEe9VY7YliX6VoSJzkc0oVuM4xWUmWqllYrLEF4QU4wK31qyCo6imOR2rOMrdBc7ZSktgOlQqm3rV2QZFVGU5oeprGQoXd0qRQC3NR5NKX2ip2KabLBUAZqtIcnio3l9zTN+88Gk5FRg0SOBjnrT7dckUxYS/GTVpLcxgEUvi1FKSSsWEUBahK7nqXDMvAqRIW6mtUjm5rMqsuKTbl1q4Yh+NIY8Gr5bg6hKq/KKKcBwKKfKZXPEtOQC1h+tbcCjcay9NOLKL61sxFSa6MY9T3MEtCaNeKmVajBwatRjODXDJnU3YRUzQUxVkc0FakyUyBFJqwisMGmIpD8VdReM0Gc5iBTtHFKqHvUqjIp2zHNBg5BHxxViJNxqG3jw2auwgF6a3MJyJYYuKlEeSeKkQgDipQM1ummccpsqtGc9KcYDgYFXAMCmSE5GK1srEKbIEiYdqegJJyOlSqc0qrzUkykxyClYHfwOKcOKnjGRmmtzFyIdhx0pyrxgjmpSvNDZPAqxcxBLDleKqNGcYwa0yDwKHBUdKAVSxl7Ngy1R8E5ya1HjyMmq8sQ4qXFM2jUuVOewzQEBp7DDUhyOlQ4pGlyPauaY0QNWUQnrQVwDSshqZRMQOartEQOa0gBTNm+k4pmsahjyQFm4zUsFsRWsIgFPrTVjxUOKKda5FHFgCrax5AFNVeRUqnBpJHPKbZIsYQADrTscU6Nd2KeUwOKtI5nJ3KzoOoqMpzVo9eelQyKWPFUtDSMwCcdaKlEXAoqhc54fYc2UWPWtiCPOTXJ+AvPufD0c8s26QE8ZrsokOwAdT1rfGQ6n0GBnzRJF5NWYj0FRLH6VZhQgivOtzHTOxaiXilZMmnKMCgUjlTsEahTzUo5PtUeOacKCZak6U/rxUKdanA+WgykKuQeKnjyOaZGtTotBzyZOjYHNWEkzVXHpUqHC1pHQ55RuWt3FJmmxjK09lwoxWykZbApqaICoIRuODVyGMKOO9MibsGznpUoGFqRRQVO7OcU47nO5EfakGAAT1p7Lk8mkJA71bHccAvBp7AMKqs/oakiO4CsZVHtYTj1HsvGBVeZOauBW7GmPHkc9acZ3Ep2ZmunzdDTWUKc1eZcDFVsDJJpy1OiM7iH7tMxkUpcE4FIW5rFuxSEWEE81KY1XpTQc4qVsLzQpEtu5XZRTae53EClAwaXMaJ6EeOakjTJ6VIiZYVYCgU1oZyqW0GqMClqTGRinLHWiMHMgC72xinhApAxVjYQOKaqEvTs29Bc9wEXHSirYXgUVfIzL2h8g/BC+jnsriCa5XepysZPJr1WEnaH6e1fMXw21xtG8SwuDGkMhAJkGa+oImWcxyQOskbruJHSvSx9G2x72UYjnjYmiersfIziqcajNXYyAuK8LlaZ6lR6jyTjigZxQpqRRk0WMmEaZqTy8U5Fwan2/JmixjKdiuo5qUE4xSqAD0qVQCaLGcpXCI1ZXpUGPSl8wqcGlaxk0WU681Jx61AjZFOByaaZm0XI2+WpgwK4NVIzgVIHyatMwlEmj4bNWUPvVTIoJcsNp4p8xlKNzSWSneZ6iqSvsHWgTknrTU7GTplqRl2nnmqpLMMg/hS7t3NPXFV7VPQaXKQDIPJq3bthRSGHK5A5qEh1PFJq4Saki4shLYBqTPBqrDEw+Y1a24Gc9aFoYPcqTMd2BUe3d2qw4Gc1Ez4+7Q2bRGCJU5HJqGROeKk345NIGyuah6miuIBgc1E8hIpGfLHNQmUZ4qGi4xuSxZPJqwg3DNVFfoPWrkRGMVnqE9CVB6CpFUk4wadCMCpkHOa2ickpCogA96kVfalxmjpWqMm7jwKSNMsfrikDEHhgD6tUWo3kWl6XcXksiRLENzNJ0rSnL3rGbbRFLqumxSNHLfwI6nBUtyDRXyJ4g+Jd/Nrd7JDcac0bSsVPl9RRXoezl2DU8YjdozHKB9w5Br6b+FevLrvhmKKSeOS6iABRPlIFfL+7ndn/gNbfhLxFd+HNWjurWQqufnUdx3r1sXS9ovdHgMZLCzstj68iA/KrKocA44rI8J63a+I9IivrNtxAG9cVvIm4+YPuHtXy9WEoPVH10a6qRUkNAOamjApAop4GCKw0FKRMuKfu4xSRgGnMoAyOtTc53JXI3YVLEwK4qMpnmlQENTYrEycdahlcb+Kdu7VA3381EpaBYtxy8DIqdWBqipzUokxio52S4F/IAqJZfmODUPnDb1qBpQpzmh1GQqbNDzjUqu2OKyku0LYzV6OcYqfbO5MoWLJY96aXbPApnmZHFSwnPWtLqSMmrEkUh6HrVyAZUZ61WXbnirEZOKFFHPPUtqQMDtTSoLmq/mHNSgnGa257Iw5bExOF4oJ+Tk0xWz1psjDBo5riUbsrPMQ+McU0tjrURbLnNRSTZOPSlJnTGn2LG1mPI4ppyBjHFMWfj71NEu/vSuy+Vkcivk4Gc0iRYXnrU+QO9KoyaG2NSa3GQxNu5FXEiYHpxTo1wtCOd3Xip1Mak2y5GoC5qVWGOnNQiTgAd6UdetXFt7nLbuSeaF+9xQzfPs/i9KhkDZ+Xk05VUAjOQf4u9apX2E0TKdxAAyc9K8k/aP8YJonhn+zbW5hF5c8PGRkgGuw+JHjWy8CeHpLu6bfcMuyJMdz3r4l8T+IbzxHqlxqOpu7hmPlqx6CvTweFUo88tzCUrPQzNsp5KoT64oqr5xPIVhRXqchPtGUCMqABz60qnDZz+NNIIo5rril1OZ3fvI774ffEPUvDF4kJnzYs2HXHQV9QaHf22s6dFeWMgmjYZOD0P0r4kA24bbuzXYeB/HOq+GbtBbXLm0z+8iPQivPxWEVTWJ6mAxzj7smfXSMCDz0p/UA9jXNeBfF+k+MIg2lEvdp/rI5BtK/T1rqngZGb5RzwfUV4NbCyhufQQrQqbMWI4qbGelQLwanRx3rmUCZxW45VpzqAuacuDQ44ptEX1KuCzcUrJgcipcBTmgjdWbjcq5XXjrTXbBqz5WaPs+e1R7NjU0tylvJ6VIkTSg1YFtz0qzDBsBOKagOVWNtCimnHduqxs8vAFXC2FxVOQMW5pOlfYxU29yVHParVuxxzVSJDVqIcVEYNMyqWsWgQORUiyjFQr0pSPStVFnO1clDnPNSeaO5qrnmmsxqrWFyXLRmH8J5pu8kHNV05NObpQg5LMik3B8ioh8xwRzU2CasQxAEEimzRz5CsLdiM0eQV+6K0yoI4FLtX0ppGbrsoRwO2CRV6ODA5FPUqO1KzYPFVYylUciN14IWkRQq+9SN93io1U55p2QrksZOeakxznqPakjU8Yxn3qaFcgqhKeqjnNUlfQynKw3aRgq209jWJ4x8SWHhHRLjVNRwjhT5aE8sfpWH8S/idoHgq2a3vmL6iynyYYhuyf9r0r5H8ceNtb8X38j67eSSQgkwRL0UV6WFwj3ZhKRd+IHxG1nxrNJ/aU+dOD5jh24+lcPLI0kmScKOgpsjGUgszErxjHFMJxXsRgktDCUtQM8ufuiimb6KuwrlUnOKQsM9KKYetatXMk2lZEwYDPJB7YqNW6+po7U1etC0EtHc1dD1zUNCu1uNMupbeQdWQ4Jr2bwt8epBJBb+IbNPIXh7iEZkb614K3SnRDccGsK1CFRWkjppYmdJ+6z7e0zxPoWp2kVxbaraASfdieQB/xFbohIiWQcxt0YdK+CIneGYPE7K6ngg8iuu0Px/4j0q7hmXU7i4ij6QTNlD9RXnzy2nZ8p6dPMJtao+zAGQgYNPGXX6V81D49eJFVB9lsDgd460NK+OXiC+v4IJLOwVXYAlU5rilgJJXOqFdydj6EKg8BgT9aeqYqlZXrXFvBIY0VpBk4FXtu3HJrzpR5WbtslVMdaeqjmm54pAxpXM2O28044xikXmh+CKN9CRvljuTQEXPPNOop3sMcFWpEAAx3qKnKTU7ktEnelZ8Cmg8U1+lMSQ3fzSnPU9KjH3qkHNJu6KtYXcQOKRXLGpABim4AJoSJF+lWYnwPmqmCd1TIabJmrlvzAOlODAkDPJqqTgU3JYKSeaNjFxRb8wFiBnIpc/Lkms/WLp7DQ7q7hAMkUZcZ6EgV85z/AB/8SAyAWWn8MR9ytsPSlWvboQ9D6ZDEvtHXrTmJiheeYeXCn3nbgCvltv2gvEzxSJ9j09SyEbgnIrzi88e+KdWkuFudbvBbyZ3Qq/yY9MV208vb+JmE6jWx9meIfH/hfQdLkvLvVba4RRzHbSB3/KvB/F37Q+p3qz2mh2cNrbOMJeAkTKPpXz80hWZgAMseT3pzda76eX0oO+5zSqM0tT1e81O9e5v7iS5nY5M0hyxqiWO4gSMF/vd6jJ+U0wk13xikrIhyb3JN5AOTn39aYTk800nNJT2IH8UUyigLn//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic view of the stomach showing a bleeding Dieulafoy's lesion.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rome Jutabha, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35774=[""].join("\n");
var outline_f34_59_35774=null;
var title_f34_59_35775="Op hip and gonadal steroids";
var content_f34_59_35775=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F68642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F68642&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 593px\">",
"   <div class=\"ttl\">",
"    Op hip and gonadal steroids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 573px; height: 455px; background-image: url(data:image/gif;base64,R0lGODlhPQLHAcQAAP///wAz//8AAAAAAICAgAAZf8DAwEBAQH8AAPDw8NDQ0ODg4KCgoDAwMD8AACAgIAAMP2BgYBAQEJCQkLCwsHBwcFBQUAAmv78AAB8AAAAGHwATX18AAAAAAAAAAAAAACH5BAAAAAAALAAAAAA9AscBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVKwoRBxUJIgeeBwqWojQJDCQJFQemo6xUFKEVESIDrbUvDJ4jCQ8GAJy2wE8GB7PBxicKE8QiExXHz0sRBCIPBw8T0MfDI58N2NngQAwNJbuhJAsG6uvs7e7v8PHy8/T19vf4+fr7/P3vLds69dq1oEQ6fwgTKlzIsKHDh+ukjPtF4kAvErg+WaumsaPHjyBDihxJsqTJkyhT/6pcybKlRlosAgKwQEFgiYyfHnB0ybOnz59AgwrtCfPJxBEKTBmQwILAtHCAiqqQSeFAAgVMVziFGjVKqk++UkU4p2IrVz9SUXwFJaLq2KZPz/JJO8as3D10e9i9mydvmL187/jdAThwncFfChuegziH4sVxGnd5DPmN5BuUK7e5vCWz5jWca3j+nCZ0ltGkz5iegTp1mdVXWrseAzuG7Nlhale5jfuL7he8e3f5PSW48C3EWxg/niV5lOXMrzjXGje6ajTQrVOZXra6djLcnWT/HiU8ivHkn5hnMn5f+h3rTaB/zyS+kvEDIOjfz7+/fvvWATjCfPQpIeAR+AWg4P+CDDao4IHHQUhggUhAWESCDma4oIW9SegdhVxwOASGGmYo4mweggjGiUGQWGKDLKaWoopexPiDiy9uSCMNM+6IHHYfxjBAjg7a+FmPPjYH5A1DEsmgkZohmaR0S9rQpJMPTgmDlFpuV2UNV2IJZWVcdinFmIQFuSWWOprJQpluqhdFKQTUJMICBExAUQo4EonmYnDG2cSfzEwwzDS7UKAMXEyymaWgKQQKqYFUbEOBLAA8sOcJfeZIaGCSTlohFQTIYpZF1DXq6Kd8hVrWALDGKuussaopKqsAKKApAKdexKetLoTpJK5yucpnAY4WACykrOp6zgRPsUUCAbQu+6b/owEQe5ax5yHLprKiovCps0iRk0BW3anKprZcccupt1iCG64Jn1oDFgAVNNDAKulaiS27ULkrH7xOyjsvCeYZsOmF1q4grJ8HI+wCWXTamSoNBBBMpMERAzDdAAxUMMCuSHT6IsDhSKZAKiNMYOgB1kKXcbINu+mcAQMkMMABEvBrhMklogyOZAxkYoJMv4qmcY4cR3zzAAqADHMSQGsodDaXIS1CqYxivPSLTR/snM4PQP1AzWmqK2bHxcS0DFIk98va1yWGPe90EwwQAc5k/Yy2uP+y7TFAb+f6QN8DVqs0zYIPjoPCIkBe8t8nPOyp4Fm/Ta5ylE9Lt4Z2h/vx/0VTT672sJizkK8EbNmby8VzM566DbgM0IAnA3SOme4IB862wCXM/C3vOyZHrawPFGS6v6vO3iLxwsdLPI3TSbtE1SY6D4TMn2cY+q05WDBNVcojOL3HvncMvOey/45D1MqfTfX5lp+s/Y3Qd+/g95M+zc35MsBeke7nA+61T3040JkFDJA3i/ntdBBznxAMOLzGTUdksCLH/CB4OQk+b3EVJCANDEAABiyMCAKEkQh5QEHpWTAHmDjAAmS4Qeata4Vp89oBnZYDCcAqU98wHwft58Ht5W+HYnsc1GhROiHacG1FxB8IXViJ49HqirWawtN0dq4gPvCJqItiAY8YQv9KRK9gAIRPDnQysgGU74tgSh8PJ0hGKppRfw3iXxKmo4AGjMxncOSRHJNIxymi0RJn3FgadXA1F6TwSTjUQQsPWUU8MkiPo6qBAojhEQCy44TTot8g7zaiOlLyjkgclA1w5jFaAZIFCUDVLJxCgDdySpTNE6NeTKlIRFpyQZg8wuh00YC/bVICvgrNI9uEwELqsIyTSCTTFpkD+1TglSyQpcfyBMpQDjFokXQML6fpy1TWJwcMKNsDsOkCbTKAhHG7Uzuk8U2rhRMHk+xlJc25BOcsYACsK5uvYqBNbgwUADjxhPzAGMFmfvCZdozmLxUUTCNs0RcLlYEsKZI82An/MpcONaIh9YlKaMoJBw1Q3gG86AI8PSACptAVAQ6AKbl99Ia6ZOE4wUbNPUiTp1pc5RU7l4B1nKOotjwPLnEaUilC9JQS5SelNPkRdj40jiCd41UDONEAVBQRP61bT5n0pZtCsaljHCk592lSJ1RPI1YVKUM7iNZdqhWobI3oSZkkq7F2DatM1apcY9dWSIQVdH4FEw8WIIGklrKe2ctpDgmr10gc1nuJ5REPdJbZpM2ViHXV6V3FWs7CnhMHORkAS1G41LMK1qmUhaokLru/zsrgY7GySg0B61pCxgCpnBstYktbWVWeYZmPCq0KKFBMTfyVq1JlBG3zaFsh5eAA/xRgwAAscJ/WhlG5KZClZPK51pIW97Q2gJ8EyuZAhkF2gJLlUwPUUTilChezxJWtW5X4T2VUVz7ebehrW6AAC0RAAu0FwEHWQc+nkhSfWIxw7o7b1a8SwZ/bHYABirlbs353wCzoKEFu0pGMQte0sX1wXSr83xdMxwK2+2eCH/tZcMYXBY0VQQMQB+D71pYwLKZwdDP5uASko7slkHCERyk6GaSTAAZ+rm2CLEkql2G6l2xxsMrqMQF4+ctgDrOX62dj8KYAuFKGAZaBSc01U1TLLbIyFBoZXISJ+c5gJrM9b4zPnZK2ykPujJz3OoOiQgEwA8CzovUcWTP32cfUBf9yoLXgZq/C+U1CBYD1kGxnRd+Z0fB19O4gnWVJo9gLlbaww5R8xSQLVWTScMpBWZtkT3+ayeBzZorLi89BiyHV1AS1CiVmAz/O6tK88k6ibR1mYUOSz6N2MK8x4+u/VNvDAnacUA2lDsfqehbMbjau+0fjXePVMddOTLpvO0g6S3nZ4R7zuJlV7hOf19x/vvK6hdRuGPpxnZweAbzj7Wxmgli00j53ryd9mn2vKavarsG5AqphjJElX/t6d7y/XPDkHnyy9tYvqdks5FPzG+IXBQCHY9DHiufKXOjyrMA3Lm+Ik/LbU2Z4UxwuaJ07rN83iFovFnANGsgSWp3gcfD/lE1zAXQ8W/eMNr6HC2iTcwHY8AH6DYwNUG9n8yK9Msg8mU7zp7vbGOsbEM8dufaG+1wFZnd1AsWi9HaCPVoHTag1yL7xuEPbBuRVOLXfvpu2XwvlU5DlpajRza3xneDzFlTat2Z4rVTeClhnpNadUFRvhCJRi/Jol8se+ThNnleXP5Y5Wd3q66UecIiHAp6csgo86UnjpLd5k3W9YHtE4PXvWn3ToZT5am6+BpKTnBNnnvvA+nawBMiAA6ZP/epb3wEZAP7AhF929mg/ycfnEemQjejhl144VmQ9rOLSIwIggOYI+D77TDvwcBNf/gIPfwxqd7sDTHh5zNd359cb/8XXfu+3cfFHeN3CfX3nfQpYOfqnZrPSUQAIbs3XW+RRgOXmfvCHf5THgAQnSeonKx6IPrF3A5vWYaMngLqHfPqQXyRlgB34gNtHf8MnSQcYbwlodS4WgTLADl43WBbIgs7HJP5xhPxxdliggbrGgQhYgsVXa93nGDkYbjt4b+x2gsXWVypYf8zmd5rXgo7AhFflhDoIhdfmhbbGHWZohSUIhm0jVMUka11ofmI4A3A4W1Ymg09Ig8GThjdIhTPIg8Higy/wT7O2fEMIeXeYhUUoBithanbEh2foh/N3XmroaWxYhcx2hSKHbXQVh8VWAesQhLC1iPY3gIXYiMNxAf+u+IqwGIuuGB5kCH2caGueqGKAB4hTiE+36Gm5OG01tmcCV01cWIEryIiPyFsfBh6quHPtQ4luaIlqB4L2h4ODeG/6kIfTQUt0iIyZuGjPeHjLKAO9Zw+m2IOsCBx7uIG/qGjBKHi7aI1fOIKxch7viGfxmG/0cn3+WH3cqAPpYGh1eIHN+F7Dhk8agIRIqAGLlIfzWEbS2IloSI9riGttSJH8FI54FpA4EAGwojMzhnMceWvrqI7lmHOESI4YOALnSA+/F43umI2fOHX4VTl2uIwZiYvpVpJi5pE28E8wpmnk93ipeJKrmJJq5oEQOSDS94/+mH0y2YT5eGf7SHX/6GaRmoiRVSlmV3mTOGmQ2eY/tLByipiMR6mUJ6eWbEeNJliOOwmM7UiVNKmLI/dm4pKTLckrXRlmX/ljeSmWoRhxNNBfqjUAI7lVaPmF4/hzSGl5btmUW9OXYPaXkSaKMXBNfxWX8FiRNiiYoBU8lPlllllqgUmEvXVBsaJB4KiXBzmMjTZ4K+mYcDmaXlaaJIeZL1ABJmZfk1mXwniXlnaayriXnKmPPemaY6kDFFBCjSeEi3mRj8mSr2mTgIkDksmXwHlutVE0o2EXx2mVnomJyjmYA2KbAoCbeEmcaZmaPeQMFOByZ+mT4jadtLmXIWeXeDhu4emVcwkD2/Cd/3HRn345np9In3nGldvJj1KIms2YcmYZSNG5lfYJd425gLNpoWJIoJX5ny/wABRgABEQAbaUfut3nguKlfJhj7DCiw6abSjahyiGoBxniC6AM78Qoe7VaS9qnrAZarKJhQ9XmykKlrBBS56QiN70mzJ6bxxKmi5anNX5pLeZnKBZZro5A+sFZVBTkD0amth5ocGXoZHCn+ipnsOZpY4UMwN6pulGpekZpe05pW66keUJptPBAD6kNwGHioxZoWUKqDUopCiJn3CKpgbzG+qwmXWKYocqp3+qk416bzRac87HHWhWTZ9QdwNilJGKn/spqH8YmWZapNc5kTzJT4+qlf/i2IKrOqN3iqWEySNjpUyeKp1sWajVmZ/BGapE2qSnhKpyqaqTeqCxSoyiaaqXGZZfKqvVU6sGwKlLGoBSCqM/mpBBWpNraajFGoMzCaz6qZ3g2quV6nQKOq7ySK1zupwoxTqeEFcvIA0HwF2iV67Z6augupSkuqHdWl7C2pnEqqymSS/HGpvT0q/p6qe46p7YeYw6MF/Bozg8Wq0+yozWap3LipDPxikIm2//ipwBi64Mqq6fSqcCm5vMSrF4ugU7Vq8FC6Rh2oJ6RxIPcG3eeLM4S0vZ+aqT+K2V6Kgdq6ITu64Vy7M1aa826gLp5EZdegMiSkKsKXMKS6G5mpT/xskBGJC1Wru1XIsBHJCGCBC2Yju2ZBu2Oxu0Ruqz0wi0J7ueBHulyHqwbZumKUu0K3sDZFOWadScJoR7zRq3GmtwciuyQkuyC7urRuutdEm4YCkfaHudDaqyshqjP0upL4uts/qDOcNERRm5dju517qxycq4kDu0JXux4lq5waq2Gsm2pJuxpnu4F5u4vTqhrXqp77NEUQOvaRW7VJuv22qyrzuwnnu6FZu6a9uzi6u64Uq7CYu0rvq4sOu7t8uwKBgrEvCcvWu4v7ur+Cq8zEuulyu6oxu+3Mm6qeq65juyU1u94Ju8Rzu+gjsdqEBT0gqd0Fu1LSCZzsu+ttuR/6U6vCj7seIZsutbuO0LwNE7t9+Tv9Z7Zbfavaj7vbMrvcRLvQr8qwectssLv81rwShbvLJbtCDstm/7twabHLE0MolZb/9rkvpLnRXMwGriwIhbwnRLwP5pwB4svnBrsJTbwwn7wj+ZtCuAQQClvadIxPUZw/f5vq1Lnj8Ms4O7waeKvsOqvkLsvzY8wwJswiIswYOZHPOaK/LZmlOMuYHrcVW8xQjMxAnKrzRcjB0cxTXZv2/cxSQ8x+xpvHdbAzSlDqplAOloVxgMw8A7pMaJw6Gjx2DaxnasuGXIyLaCx417yEW8wF9MtycsuXFLxhI7n/LLxmsMdRzLx538uf+AG8SR7K9YDLBa3MrPO8qm7LionMp+7Kw3sBafwLuGzL3uO8GOuMi3jMlNzK2orMMFysOyzMW07BeWXLrGHMe4e1wRHMzH20oseq5WPL0JjMg3nMyvDLKxnL5SjMJUzKTdfMHTXKNaSAbll8bkG8bY/Mjq7MaXDMwZjMybnKjjXMDlnMXn7MlAfM/N/MZw7M7VbAbxjM5q3M6WSsz9XMPPzCeUTMeTXMyQbM7GKs+Cy8ocHa6OrMvWTM/77L0jvcrIe9D5/M2ZrMH4fMV1HNK1G83enNARDcU0PcQpncJc1tPprM/g7MXrHMIQba5yPNEYbYsaDdIC3dEOPc8GvdP//ovTSL3QEGzSQ53NQP3QK03VeVzR+CjOM/3UH9zUVs2/F93HI/zHWX3U99rVUv3VZu3DUf3RTg3LypvRSj3WfY3LbQ26dK3X8evRbKyEUpvW8ybXeD3Y5DzQqlzQU13X51vWhH3Wf63VLy3RRQ3GcG3EnXHNJz3BjE3Kk33Zdk3QQe3YAL3XTJ3Z5RvTN13atRzbLC3NQr3ZD/rTYs3WYmzPrL3Dn3nXpn3aj726ln3cmN3ZnPzZmszcDdzbagoGDa3aXu3Sx6zTlO3Mhl3btg3WHMzX0F3Jaw3Yvy3YNs3OuZ3d7MrQor3VwI3d1MzZsq3eip3U473UsJXeRr3R/9sd1t0NzeVt3vVM0u6t2ezN1dLt36g9ywFu0WQt3vXd33mt3Kkd2UHN35693vO921dQFRZwv8mG4B1O2gte4a0N1dY918G9zBLJGjSlveA54N/93y1935KK1jj+wFNAdFfxAH674o0t3wpN37c92yeO4sLt2krLXRNQUzKn4c3N4Bbu4MTt3Uru4pb74MRWBSGjY6ZY3Rh+3Tuu3Q3O3Vc+GFLuzzEQATWxC4yq42tO0Vxuy7Dt3FhdHHjnsnVet7ms0nPu2wWu0i3eoVMJA+IV53ee5YY+3EJe3IEu6KM9xrGx5xhRYjuBO1D5j/nBkEe4MyExAJvuj53u6f0B6v8e8QBPOerUlwELaer8oQGZ/hKsbn2lDuv/ERKqXuut/uq4DgGy/gmwkegkphE6kROrXuuu/uv6Eewgseu8jn2+juvO7hGiHu0OcOu4juolluysvuzMXu3Wju3Zzuy5/hJX8OUqZ0svmRAaBhH28O7wLg8jOu/zIO/2Dg/13g8y4OYYZQLt3g/7nu/6vjcE/w74fvAMZvAK3w4J7x5W4OO6UgRoQnzIpt/IOAQM4ORQvsQZb1HscfEYrwYgLuLVtF/XI/KZK6EoFOMu/PEUH/LGJQoVL/P91AQTshsqP+I3n/Izbwk17/M9L/RukPO2ofIW//OVEPR9SmRNvwZGr2b/SG/zQ28JSmoEVz8EC1DIP5D1Ws/1YrD1TSD2S+D1QUD2Zd84ar/2bN/2bv/2cB/3cj/3dF/3dn/3eJ/3ea8AeVI+DEAAvmJ7SrwA0EIWgi8CCQAtjsX3tTQCf+8rJPRKdMIvid/4IvD4KqAAvxD5LslNKHAVjg/4I8D5AO+Nd+L5vqD4tENLF4H5p397ZLAAStwDFaMEkz/2YC+Qpi8JNKGnnFAqGzYQIBp6R8wAFMALGKUoy7BSx78wNHH8BQH8EBv8DdYyhhIBzqBpE9D8vLI3EHsC2tUL1I8ow19fiH87W+P94j9f1T/687WooLf82x9PBMVt0a/+yU/8YJAA/8cPAgYwkqV5ouk5TcZBqLEss0ZUzbleKhK8A1WGhqEYPCKTyl2CgCsdRI0FgIGjREaPxI4Aw2oTiccoQlE1FIBpFVdhABaNFMUCGJfPbCtK0YgCvMXNgQFsnVhUHIzsucHJnbiUFG7hAZjlHMCZAJI0AlByLY0mLRA8iJAmSaoe1bUCJTRE/MDOsNrm6i4pRGiaJEhQDYxIeo10ZsIdA0SxMpvY/BADSHZSmxBYqD3DUOOSKBwkAF4DMCeXMbB+L5pHSxxEUKEXLZ7XxiRMNBBQIf/Z1A4fslS7DpJIhzAFgSwLGW57eIKcAmgSi8Wbd3HjwQMH/pmgNWJgPR0M7v/V69bMI4kFFNgMfBetAg6VAxUdUECxmQhzJUkwyMKumLtUxE7+EgOAH0GeKndQePCDipwzJH8o5Egq60YFh7QWowk2wrJ8F5UyBat2lAELEQyWcQhAQjE7E7CqmcGggai7yBSIG0FggopjdKvZsZDqMApigc8RPtw22gOPEtIoHkHXb7O8yDw2kIBDcuLFMYhxzvl48I6TGksYrrsU71pVXCV69bwW28Z4Bx482KSWd+3iQBZUaHDmklwAFs5UIOznDuMYe0UBmB5MM5c0Jhb8+/U8EOEJV+yUSGWAzNzuasZHVwHIPCg72qunvwe//PkTOqvNcR93a+hWWAMTYFf/DTJn7JfdHNsZt8RtC+W2lnrsqWXRRf8NEaGHsYhgwAAe/eKHR6Ik14Bwp/1xwBMpbrJXA0+UIMcBM45g4jh3gFYgAX94V0UDODp4onwikHNjXjCmwIqOXCQZ5CRALjlkjEPSKMNyJliAZY4tomjlh0eIc1mWF/1GIlg/KlmbhhK91OaYc9JZp5134pmnnnvy2aeffwIaqKCDElqooYcimqiiizLaqKOPQhqppJNSWqmll2Kaqaabctqpp5+CGqqoo5Jaqqmnopqqqquy2qqrr8Iaq6yz0lqrrbfimquuu/Laq6+/AhussMMSW6yxxyKbrLLLMtuss89CG+2eBhCQ/+A5K0orgylwjbJtFWYBZRYD4CLk7QwEwDFutrUN0K675J6gSGs56fnbCSOeMwC8zh7gLirZ/dKKOHD0m0LBUBB3Qr/u4pvEwCmclJeLzSS87kVePDAALUjetVwC406ggBwDGEDVXZ5VRAAFC0QwQMjFDEaVAQmAF8fJOZbMgij7qKyCAjkjCDMFBni2gMskUMsAvgToazHFd+GbQMkjUICuKClPQMXPXGy9wF0EqCE1FQdXbTXFpmxy8LcMJDhuvy9gS8I+Ic8s9h0l2/2z1wgm0PLLRFMcLttOS9RvKj080MAAFYwRT2VMtwu2BIkPAMcEA/yhr7uLtHyABMIwrf+45JQTPIAE7S6CuOJnJmQ66lUMUFnDgQwgitKyL8L0vs32CzUMIsLQ+WVc3NivBPtUbghdp3hOMvCBAzCi4u5gvnrgssSD+Qm6qyDLiBkX0TTwzxuPuoiv41sw9v3OQfhChpcxwNAPSCDiARSIDH3LVAD3NN5Mi8BoimGa70q2P0OQoV8LGAMxWjY//LRugRmby/Gid4+5yIV+XFha0yy2MNP9Tl9Gy4LSHkEtwwlwhHFQwARaRgDyUUMBVZvgwegXOKW90AID8FEHUYDDfIUvhC9smgIZCMSRUA92Odyh+xACP4qRaBEVcFcWDmZFx2TMdBUhWTViR6JxcRF6Bbv/IhTVhAIyNqxhFJAfCdKYux5my3De+5m+ngc87PmCizq8nBpa5pY6EtExk6sADakxRmKEjkQ83BcAgWhHQMKAjI20YOAS6ZECNREWT5wiYT6mALb1gBj9EsMUZ3aZpehkil6QnxgwpzVqhbGUwZgDGTl5BzhQIB1k1KDR9IMh5dGMg2+ZmrTkmDE6VouDQ1vcJbiotNiNZA44hGG+KOC9wPWAlsRYYwS4sLJs9NAtJfhhy8JHBFVSs5KspGTBuOlNkGTSFk8kh7skoACGLSNy3tOic9zFl/MtggGnaxfUUrFPe4qRGPRsF10igB8yPvN0izBaPtbouje+K44Mq0nT/56psTsoznVIOh1hmum6IUZSkAwVZT3VcLApumuRIzBaST3RLvCtoV2iS2fBAMpOasC0XZiMJym2ViMj3G1m4VBqduDys6IRsxpTWwBTcbZUq84UqVIxwc+suoCfcTNf8IzDzABH1SJEFVo/K8I/7HY3kEhNZEw1ajHKusCpdZWsXxXBU+dqEKlVtSXEFKi1qmGKMOItsa/EKlWpALi8JrWwRP3UAiooA8jFro+smyykRMKQMHJ2XUUYamg7RVXJlja1ql0ta1vr2tfCNrayXcjHejbTwaB2tpAqmhfepFta1eAFd3gABSZwwd9GSgHyKgYRkIrcXEkiFM+NVFAuCP+O6eKqIU2ZEHYPhQsDZGSs3Y2VV7jwk/EyChdoaR96yfuAvKSGhwybL33ra9/74je/+t0vf/vr3/8COMACHrB+c3DdkWyPwApeMIMb7OAHQzjCDPtQhb5EnXPtrr0cqVgkLsgh9hYmwxq+CIfBkiaWBEJMlxXxiB9SYhIkJx5qiJOUQtxi47zYT7698UZyTIod81giPuYTkIO8kCEvochGPgiS9aTkJeuiyUl4MpRtIWU8UbnKrbjyEbKsZVJw2U5e/vISwgyEMZM5CWamE5rTfIQ166DNbgYCnMck5znroM4YxjOTEXVnPstAzysGdJT9zGJC0/khf0Z0YwzNaFj/CDoGi350CSJtnElTGsELwXSmLV0cTlPa0ygA9aNFvRZSM9rU2Th0pk/j6FaXWdGshnWjD4VqRKsaNrOmtQlyrZVbE9rXgtk1r9v46mIHQdhNQXaibU1sZCsb2IBW9sWeXexoW5vX1JaItPmMbWYn+9jgzsG3x51ncZvb1ZvONq23Let0k/vd8A40uud9L3nbOwXuXne+VVDuft/b2QCvNUK6jed9F5zdsP73wI0t8IZXGt8Qj169B85wiCP8IAaf88UbnvFdbNzNHbd4xQE+cpOr4n/cOg52euuPQU9c0wmPucyVkAD5GU+8M0hAVAzivMCO2iwB7rTEg4CUKCI9/+kBC7KeRRS9CDygpjswxb9qDvM2CiDrWt8617P+cdaePAcE2MAFym72s6P9AhtQuGubLj+cWzsZI8rM1UfS9btv/eurDfu5ChCAvwM+8IIPQAHY3lpBD7SyUgdCMhz7AJ3rutd4n7zeVcv3y/p98Jr/e+GXLGgXrOMjSciKQjCb0UpPHu+VT+3lJZ35zQ++80b+vCiAvoNO1CwYuR225FPf9dWXtvWFeT3sAy97pqsijMINQplwZCMV7Rn1vuc68EMrfIYQv/icNzzYR3ESzHkEjtXu/fS1Xn3OXn/U2df+8XlcZ9PHDvIzl375vU50fk95/cVv/40FTS83CV39mf8fgM1e0Z2Z/sEe/7UY4l0BaG2EhgyAAHqd9g3e+S1L+m0PAm6eAo6Y24lCP6xJAErgAFCg4FmgsmBgNmig5nGghnkgI3BfF4igAJJgCQLeCSZLCsLGCsZeDFqeKkyONjDRr81g/dWgDQYADiLLkCGH3PRI9CEBAfCg4LVgewmaQLVLczxgEZbfEdqgEh6Lj1VAPJAAfbxC3QWBFCIh4fkg67WCW4Ug+RnhGiZhAd7CBdEdBG1PtqkhElYheglaL3yE6BGhHHYhHYKhsQwZLsiEjeXfGv7heCFeuxjC4nEbF06fF5ZgIhbLIl5QIzIEH06h8bVh8JGCiNxTM5QiGkb/4Agioh3KAC4IAiSA03yJIiSuIvqdYu3UjgRYYtG1Ig2+IvLJAAsRARcMgTRAYZeNIuBFYncJGnDEzgDIn8Zhou9pIgVyIrH42Lh4wT8kjdjdoh/m4mQFouIER4ZcY+plo/Zt47DoIAn0oQ0+I3a9Y5ytI+UNo/sZYBc04/Z5Hi+4A9KVY9AZYibuY//1Y5z9IxsGpBI4XX3FzfxhnSuu4T0GSzwKRkPW43QJGmjJQkGu2kFiY0Iu4EKKHUeKZCapmiBsIUmyo0l2IEr2HS4+pPdlTDrGIf3N4UXCojXKI4CpJCwcndIZ5USGISkYjeM44Pjx5CH6JDFSJAEggAQi/8BQtsLYpd1Wmt3atYJRgiWKfcoLjsFKjuRTImRU8iP+nUNVCuBV2mRWYiWYcWVdYiSJqQIbNMMvsqXdWSQS3uWv/BtVWuVc/phhlplMbgqcnY8t7mRFCqNaKiRbEuZbImaSXaaaKaamwJk4JB1SUqRfRiZg/iTI1UJl1h9ckiMszGMJduQMtGPxBaaLoVsw9iRpSiVQCoZbpmZmPuJqJt9mHgG1uFxxGqcXrFxxfCTDmGXkoWVJSuZJUiZvlp9q0mMMtiYFvmagCWcaQkABgGd4iud4FgAENGe8bQVoSABo6iZk3uYXlqYuQANqVqdvRqF9Jlt3HmBcfoin3Vxy9v9l9EigAMQm7M1mrwwmdU6fdbomduInnemnP/Knh3jaPZ0n7z1nTEbnTE5nYU7oKGQn+3FfgW5epIXo/l0ovYEZPj2maL7nJsZnLsyngvoeg2qng36oEpCo5pnog2qF/5FIti1QS+DWMgroX8JnbpqmPNJo6tmoiLKmj+ZZhDJkjiqnLdheDvBc1Y1BcR1XKMKkPm6oC+IbfS6olFYpcIIZlaaklbJL8llB7OxeClBdKkiXpOWj6rEpciWoh6rpYbrpm+0p5gXqcOzizXkOe8ZAJ5wXmGaomOLmWk5lk07ek6JolBYqhI7pfWbqj+7iPZ1E3KVCoxrko+rppgYK/O3/V4raSZ9aZqdK6J8mJqqmIZri5Sjc3DFtFRJ0QnzVInOG6alGqqGcaAKyap24am/Cappe55YNqust662OwuW8xRAeQScICCsO6I5WYKIU6wYeK50ka31Ga03Kqo4+6/CVK216SPO9iIrhabDeHbeaoLfaKqSM65muK7Seq2bS6n7265s+nHtC5bAWyreyYLjOSb7WqH2qqn7d62mkK/btK0IcqKMSbFoaLKEgbA+OZZlSKt5ZqrEWRsje3ciCq7P+a6w265jAmdR4CARu68SKWcQ6CsM6qcOabNehbMKq7Mb+Zsv25xI43f+dWp7OK83WScdSocK6LMj6qdBuz85y/13PemxwriyzNujCEu3iaExvAWhoHuloJmlWHufZ9pZcVuzSAlgt4Gyl6mzUbi3WAi2nBuxujEJIAWshmmrSZu0ODAB5Cq549ujastlcvq3Ixu2r3m1+/q25Sm2EuF0LsFWLju2LaqOVKa0KGu6cMC0pOtykyu2NluzoQindli2I2qzFvmFacYTMIimMQtrm7mDn2hniQi3jRi5sUO3WWW3T/mzqYqbtWpkqeJQWOmXGQmfd+ivz1irxxizudqjuzu2o9a7W/S7ooq7sAmrjgoWe9VJDJA/fKq+GOq+gPi6hem+ffK4zum3uKuvdmmnDQm/00K48rm6fsQU2LN/rIv/t791vpQXwOeTv4fJn4p7s4sbv7jav8CpB+wLkV4alUfaaUtaRQCmqfP4v9Q3wSAwwBDukrUmv6FIv6TLE9WZd9rpv8HKv6tZv9NQlVxKHoLWMTs2pBssrAKcvbH5wAXvuCLfn/OZsoAox3NYvvQZe4a4v4JpkpFXN4FiubRasA8/q+bJs9R4sEC/pbprupZ5wF5Ps9mauKoDwdnJndF5sqZYvpFIxuu6wui7xnpTx+07vAmNxNqCwAKhwBK/pG1NsHJNbE9fmzPqxv/XwC3+aFuMwF5fw6VovGKesGLuj2gIyD6PxIMfuGLOwJrtwJWOZIsvoaebxHofwIzeyF/f/sRVrrQlLsmxW8CnW3g2Hcg5zcCHr2yF78p3McegG8SgrMLnm8i3bMucGszAb7EemQv++ZN/qsCoz8TDXbjEbsJoiMM/+sr5Kc6/hMgM3cAtT3BJ8X4uI3yXSct51sP1CM/4ispuAsgwAlnM5YltCss9+8SmHcSq3MTO+MBLf4Cs/8Hw9XhQTsjNPaTpv5DqfWjvHwHqk7dUVseISsS8f8TbfcRULr/+RVvK66BR78yjw898pMTcDyi5bnYF9abwysh2z8tTO89Xic0cHbUW78TGrgimArUBn8iTPrkETMEJniEILgVRk8LI9dAJHdEsDLwqg1VIzdVN/dB2SsQ9r//Ml4+pARQ5Oky1Mz3Q+P2823+4BH4FLtAV6oLQ823Mkm7JKO3KvOUBbu/Vbw3VbP3VIy3Q3c/I3d+0wuS45M3MtE3Qg8zRJEytQw2aCOWZKA7NIF7U1u6kUayxXA6xIoy9N42pTku9GP7ZW27VOd69k6xhho4AoLMAvYexiV+0102/AOvbyQvYVr7RHCzIp/MFNX/blcvRd9xqAUfRrD4pgc5lxnUIGzyhSa29aJ3Zdr7b5tvYqrzVsU7VH763/lrP5dWdys7Fmd7Vnsy9oo8BpiSOTEvcK17Nao/J0T2BgS7UAPzfRLnU1bvEaCytXW3d8Y3dk1/VIc3eSiXJ48/8xS581Pd/LQC93m3q1elM2ro6LKciyLcBuVuN2X5szevv0muT3A+/3f7u0f5P3PZs3ge52c1u0NwtaSM3FUDP4Bke488633/41v2o3kVX4lF34hqO1hh83b2M2a9e3a4P4Vot4UbmMKKVog2MuZzeGgGv1w+ZXekcvWNfxjfc4YmMzN694Mw845N73ZF/0LlLcroJob7k3kd+2kQd4TruycU95ln+2k5MwjQO4jac5jtt2Zj+43b54QR+4zUmADulQRtMZWs2pmNM5mXf4XI83lJc3x8Z4FM44onM4HvN3KRf6hyd6iN/1FVLRlsngpNNqlft1G5u27zJ5hPg2/Dr/eo1DOoYndZk7OKHHtJwjgaFHnCrAIZgdAN2VdY4rN3Z7eoqDukQXeJNTs6nHeZSbtZtnOIRTt4QHuwevtxKIBihYNhI4Xpij+LKrOJLXeahj76gPHSULbTWf9lGrenFzeovD8Z0Ddp6vQu3AoDxxi6pe+3lnu5kb6KEXe6Vv9plHNZv3cqRXIbensG/2OrZfufqquyWzOxKIyAeyXe5ZVjzr+nXX+cTT97YDe8JLLE/39LA/eb4/Ou8CPLwUPL0fvIuruaYuPBIEYZ8rJZAI97x7eKdru6sf+6m/uaXbvJ1Xr7iLOrkj+6qf+8mne8o/88ofARZ+FFYXOb8fub2X/yi+p7bGGzLHl/rHT/19C7weE3zNO/04TXDSPcCoozPSBwHR7LVGz7mOV/za7zrGj/wm77w+e3yb43yyi3y5izerN/29jxoHYEDgC/7gEz4GcADZyzov66jCCjrbz33Jz3zdbj0pm3HVo3vRs7LPdzvQ373QK7vJJ3nGGz2ebzkpiAUADj2ve73fw3nWw7rjXv4fhzuxu76xT37XQz2PSv0QN3vZlz50n550f37ky/fqRz2a176+x3oHX73dgzyq533Qm/vwJ36qS//ev/Sl20YUmThrynz18/2Yfz14631/6/z4P/Cid1mjP3/OR3/nTz98s/ivx73cf30a72Hqt/895IM/CAAigQjmiaYCUgTuC8dBQYj2jef5IPfwoAsKbYSWr0ezAYfMJoBQG5VUVBPriIzqSNXqFRtL6gbdKg8cW+a45dQX7RI7m2e4Sy3Cz3WMx2AxoLA3OASFQ9aWUmend5ioaPfSKPV48gYnR7gTeacpVMQpN+n5qcVWeYmWiXP6mAq2qlR5sgg32pr4ihVLClCLpjc6mDDgB9Cg1UtoeIM4+wsm7DtrAo11O4VqZMfraX0kvbyNqRWuPGKa7TqumsyqnssO6y5L/e2DTa171O3NGRDsHAADA4gBOEBPIBNm9Z79k+as0r0e+Wbt89GP0EQZ5vaAiiRKYaF0+uT/7UpIyaJJfigjPtqYJgiuNheziPT18JBABYF6Mrg5h2EeagJg/hjiMpFRSTLh0VyJEaWmpZ1EfuRWDugWkipDSZ1ZpqaMbknbUAXYtKTXm2cDCjwwIK6EBFqbCJ1mL6eQsmXapu0KUqpGvQqvklNSlxVXbWv/Mg4chG8Xv1uchoVqUyRlxAITVDgQQVDikY7ycoJIdPM7tZDHxH0NOzZswgINt+M8+snidY0rs8YaOTXtG2C7iA0jePBpnecSGFiQ2647yWaGl3a43Ddg4GOEZy+MeWzW6AyLewmP/JNl4+hhkPUeqeJj7gpV+zqnQELc5LnvUqdi33USWZfSfId1/2dafDfZNg9uo5W33nm9rREhFce51xJ8jDjGW2v1DdfREBEMcIAf0EUn03Qa2oLUisBwGM+EzbgYzYLtvRASebvF6CGFvx24A43XwPiUjMrYF6IQB1QAADEGoJiigC8R2NCA3622HZBSKkWlJwye5GBiEP54G5GXGTlUghtqZ2CZOhwAZ5xyzhknkufACcUAERDwJJTEqagmi3sJCY6Z7KGJF3YKWnVjHOP1t2ORPWLZZoMIKrqmj1m6uQMGnn4Kaqie2qkMXLHxp5V/hOLTYqAvstkhfVua1aUmX7IUZl1jbmoprDzKOqOrNfoqKbDBYiporoQwAEWzfPr556x91f/6nwoBFhirlsdauegWsn0bW6MzPPpgpGdOSlyFKlyIY4bCDknsucZWOeWV90ELqbSTUbsqRYZKiG6ayL4a76EeJknKrpWC+a+F4r73bqEFAzyvwNxmmge++W5bb7eXXpwspdlyyjGX9qZLZq8Ie2muwRU/oa4bD7s78LCaLoxrcBGz2ozG5epb3ckl0yo0zCkzHOTO/ja87szKAqXwyL3eLDXSQANIpXkOI5ooyARn7LOugNYMr85kS0z1r9rSa7LHIqvt5sq2tkzx2kTEjAK7jprttc1vF2u3xR1jfG/YUI/dd9kfDx4yyrxaPfS0RRv9eM6F/4wt3FP/LW/g1UL/UrTWTXP9OQqkGr4g4ox/nfTZPKcNOMlsE+224zhH9XTqdx9tOeydyy5424TvXjnufK/u9+Wo16a68I1fbW3WeFvi9OLOs2571ZbLvQzdWweceeybzy557eH/Pj75+9rL/fJRRr6++eoHLb/oMiNaOi1d2p939cqLTbzbZWZi36tY/qohPd4Zz3q0I1z73LeG5jXwefCj3/DO5zLP9Ysj6lHgAB8YFO+NDnyUE6B4jne95AVQewtsXeLQBjYInkNVSuPgoGoYEwKO0IAbzKEO73cwFEVNc5DLHhF7V0GshW56VvCfC5GnuP/JcG7QA538gjdB7GGwbsDrGhRhyLkM/8ZNiCIE4sv4Rz389fAoP+wf6dbIlJ5NURk0dN3SUJhFFW6xgBrEIRvbmMYg6miFR2xhGLmYPi+mMIqEFF8R56dEt4EwOgsgwAToshAJlu+CkIzeEj14QgZukoJ73CGQJimdRqLvkaU0Yx/taEPfiTGRisxjFFGZmAQ8gAITOEAqk+jJK9ZylFosIQsHWEXT7Y+JK/Af9wxAgJ/80piFROYh+djFAxYlgcWzJjCt6MA54oACERDBAzBZimTqb3LDjB8n0dhENfoxjoCMpyAHYYAGGGBP04RnM7nmT72NC4/E1CM1HYnEbyqTfeKM1kH6lE6FrlOY2rzWQVeZUCwWlP+Rqpwl0uRWgZ8soAH9ZKZA+xFQJ0oUgZ/sZihF6c7G4RKAD82kOllKUThWRZaIZGVFlwnK9MRwDwfokzmGiFBDGjGp3tRoTIuZ0jfOc6dDFecEonAA0dgAms7Ck7MGgICwinWsZA3rAAqA1rSqda1oHYCz3koAsJZ1rmI9K1vvmla3wpUAB3AAXenqAAjgFa8QQMhe5frXstp1sGzV6177mtiyBpaxbC1ss+RW1KoO5K1e5atfIzvWyVJWrZbdq2dBG1rBjjatpYUrYlGLgMWutgCO5exnYSva2bbWtbCt62zz+taZakUBJE2ABHLAVdMqd7lxZa5zn7vc2kJ3usz/7Sx1r2ta6WJ3u82yLnY1YYE+HRcHyeUuZw1r3vR6N73X1S57p7ve907Xvddt6A0q0IAGSBNFwvUG6u6Cr/52T2MTYBIFLEDG5QEYWgL2CKpG02D7Mth9EXbCgv1UYQs/WCQJgFMDtIo5w10YShm2KepKLOHcoJgJK35f2Frs4hTTccM0ffF/aawVGMuYLRS+8YkVjOMdRxDIPxZxkHks5CTnDsM+NpyOh6xklhHZyU2mcpSTfOQFoc4AEPVZlhXC5StrIsxb7rLGvnwOMotYzGxus5vfDOc4y3nOdK6zne+M5zzrec987rOf/wzoQAt60IQutKEPjehEK3rRjG60/6MfDelIS3rSlLYvBU4EAAVY4AAU6Mx+nwAadI4T03IC8R4mcINS48AzoBGNpjmtCQVEYEmYfHWnc9BLC9yaAXFi0nBnXQFMfgZOn3bzpcMma1r7LNkRELXGKGBmKClATpVuAl0WUAEJQPQBCtAlpj3Ba1+KgAEInkA5cYBtbS+ZCfvEgzAU0GkKPMCc3X7At51AAUFU4Nzc9jauE7AACUBnxMPQQb4BsG8RZFbO6Y42lA6e8GcLYgIIDhsDJIBmTxhA3NUWQgIY0IBOO0efIhipCEKqDAX00gYREPm8V51PiD5wAQSRI4sBYHKEF3sPG8c5SXWupCcRfA8jJcC9Rf/Q85rKeeQOh1bSLX5ujU27AhkfM8c7ju7PMEDUC0/60Jvw9IWPYuEAeECJUO1fG5j9AWjngy+9nmV+wj0IAacLXxtwgKNrggKgMTM/AbDpB0QdzmQP2999doAG6J2SDUjA17WSzxI1fdKASEjXxf34IYTdqAAI934L3yRup/0GulTAtJdkAwXYeyCYPzLIkd76g8DJBgkIOQ4oLhKC7Pf1OLBA298Menzx3nB8R7wgMl+X/GD9Btg+wNZT3aeco1wZT2956IMQ/OA7YRLBV71opL/zJoAck+DPQe13/vRe8D0CEB0/lAk/+ei4f3lPln2JHhB+Ji+f9CC/tdLLXm//i8dzHEduAGBu2NcnCvATBjBeU5F6C9iAqSd6aheAy9J4N9Bvq0d6+nUDE7AACeB7ylB03zZ/IwBwEwh/FneBYeOBoFZl0AJtT1Bx+7dqmdZrImBr5zBsWTUCoZYDp4d6rBYamhBuztcknzGEOFCEPJiDhLCD4taENwCERnhgB/B7nuBsJ0dtBngAuhZnQOhr+PKEPlOFwYY6DJB/uZFsZkiDbeiGbwiHcSiHc0iHdWiHd4iHeaiHe8iHfeiHfwiIgSiIg0iIhWiIh4iIiaiIi8iIjeiIjwiJkSiJk0iJlWiJl4iJmaiJm8iJneiJnwiKoSiKo0iKpWiKp4iKqaiK/6vIinEGTQtQSU0XTQpRSabWijj3LCIRi52HEsyihFVHdLm4ED/hi7coELGhA9OWhjIxAAagjJFxdb0QVwJoA3ARf5NoKsXwJM8oEs8IF9inB9/IYrCRckbodqKBeuJojEfiWCV3VQywABOgJ9u4jQmgAFDQgk1yVSNiAM5xIveYjyRCd/04AZdUctGkZmVXcf7ILABHALdmjZ0IF1clkP4oAhQQTbWGj9ChAP2Yaf0Yj1AgCBYpjhiZkQfxB7OIkjbALM/XDO0YBAlQkB2ZABbpjxbZkfF4SQkwIhMgCM64kuN2kuu4B3HBZT8pAWaHceQIFw3QjIkHF3NReyTiB/9c5ladNwAN8AASIAgC6S1ml5WZJgEScAD6YQMUMAC3RhD6kZVs+SQRyYkT2VwDcZUjUpYXCJUDMBfy+BNb+QRK2YwEUQPiSCJO6UtN6ZRM8o21R5Zh+ZJHGZOGWZWCSZd8cpVRGRdF9Rq+JJCL2QCN+XNEuX2b+QTzCIuUiZLQBnDQZI0McJVxZZU18ADzBgjl5JVr0IwAMCKalpvqaAEvR5fl5JQLgJaDmZtx+RoYV5m1iZUixZrNCAgWwJwLoHIjYpnGiYMYaQzi6Jff6Jp8YgGB8JKZGQTfWZqxWZmUCRcfaAywmQeHCQTfaQDhaYui6RqQ2WGvwQCoKY6MOWv/zeiesEmZXimQt8kKuQmb4tifAxCG6gkEDnqNkmiNU9mRbkWZgumfERme8igII2IB1umgYvkAFbCdS/CN3xhXeAcnIGaUQOktQheYVymYIbqS7ukL8FmaKsqD9jmOXPYkFNBprqmZZiiOBMEk/Gie/EiZn+kcDHqjOGeFxNGMU8mTU+qUIiCPmBaiDjoBXJaFlDihflChBEAMvhRX0Oak/IiVxZAHJCWflwkEZzqVK5kfJPWNaNlsAHBsShCYffKhN5CkMapPFWChcKpwcZqWdNGZQICndLGnPLoX5CiPctFtbBmUU6mXuemUmYqe+REXFyiQrglicaWfYikXS2B2/zewpXD6GhHqiNnopJTpmnFRTpiqH09iXAOAdiOSqddJp2xpltnIlUFJqK/BouQICFe4qVV5DJ9aqNi5kgRRoDiKcLBRn5C6VT4afWrmHILQkbTnjDSHSeHajxaJdFoFlLN2oNB2IvbIZbNJl5+Gk7j6HB/po186iR3JZe1ar03Sr/6qAOKKgx6JdP34HPNacs/xrR1JkwMLrgSbrT7aeXOBXJV0nAeLsRyZgNsKHUD5rSLgHBCLrTL2AGZmo0iXnD+xciMrZ4eHm67KsoImsFKYkDHbZzNrszmrszvLsz3rsz8LtEErtENLtEVrtEeLtEmrtEvLtE3rtE8LtVErtQxTS7VVa7VXi7VLGwIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prevalence of hip osteoporosis (T score &lt;-2.5, red bars) and incidence of rapid hip bone loss (&gt;3 percent/year, blue bars) in relation to total testosterone, bioavailable testosterone, total estradiol, and bioavailable estradiol levels in men age 65 or older.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006; 91:3908. file://jcem.endojournals.org/. Copyright &copy; 2006 The Endocrine Society.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_59_35775=[""].join("\n");
var outline_f34_59_35775=null;
